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Abstract 
The generation and execution of adaptive immune responses require fine 
control of the migration of lymphocytes in homeostasis and inflammation. 
Recently it has been shown that certain chemokines and the lipid sphingosine 
1-phosphate interact to regulate egress of resting T cells from lymph nodes. As 
T cells are exposed simultaneously to many chemokines and S1P at other 
points in their life-cycle, other instances of cross-talk are likely. How S1P 
receptor signalling changes following T cell activation, and how S1P may 
modulate cellular responses to chemokines before and after this transition, are 
important questions. 
S1P pre-treatment enhanced the chemotaxis of Jurkat T cells towards CXCL12. 
This was a specific effect as S1P did not affect the amount of cell surface 
CXCR4 or certain signalling responses downstream of chemokine stimulation. 
Unexpectedly, this effect was opposite to that observed with primary resting 
cells, where S1P treatment suppressed migration towards CXCL12. The 
chemokine-induced phosphorylation of Akt was unaffected, suggesting a PI3K-
independent effect. In contrast, S1P enhanced the migration of activated T cells 
towards the inflammatory chemokine CXCL10. 
Using an S1P receptor 1-selective agonist it was shown that receptor signalling 
in T cells was lost transiently after activation. This was demonstrated, using 
siRNA, to be partly dependent on the initial upregulation of CD69. The 
relevance of modulation of S1PR1 signalling was explored further in vivo. The 
S1P receptor super-agonist FTY720 sequestered activated alloreactive cells in 
a peripheral lymph node, suggesting that their egress was dependent on S1P 
receptor signalling. 
These results show that S1P is a key regulator of T cell migration at three 
different stages of their life-cycle: before activation, in their response to 
homeostatic chemokines; following activation, in their ability to egress lymphatic 
tissue; and finally in the responses of differentiated effector cells to 
inflammatory chemokines. 
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Chapter 1. General Introduction  
 2!
1.1 Immune System 
The immune system of mammals evolved to protect the host from disease 
caused by infection with micro-organisms (such as bacteria and viruses) and 
certain larger, multi-cellular ones (for example helminths). In general terms, this 
is achieved by structures and systems that: prevent or inhibit entry of the 
pathogen into the host, inhibit its metabolism and / or replication, effect its 
clearance, or in some cases result in the maintenance of an equilibrium 
between the pathogen and host that allows for their continued survival. 
Two main subsystems are often distinguished: innate and adaptive immunity. 
Whereas the innate system is relatively non-specific to the pathogen, the 
adaptive is highly so. The innate system does not form memory of the 
pathogen; the adaptive can (Medzhitov and Janeway, 2000). 
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1.1.1 Innate Immunity 
Cellular and acellular components are present that function to either prevent 
invasion by pathogens or inhibit their colonisation on outer surfaces of the host. 
The skin and mucosal epithelia form a tight cellular barrier that retards entry of 
micro-organisms. Small proteins called defensins, produced by epithelial cells 
coat these surfaces and have direct anti-microbial function (Ganz and Lehrer, 
1995). In the respiratory tract, motile cilia move mucus, and any associated 
micro-organisms, upwards towards the mouth and therefore inhibit their 
colonisation of the lung (Vareille et al. 2011). 
Innate immune cells are distributed widely in peripheral tissues and act as 
sentinels. They respond to detection of structural components of pathogens 
(pathogen-associated molecular patterns (PAMPs)) that are often very highly 
conserved between classes of microbe. PAMPs are recognised by pattern-
recognition receptors (PRRs) expressed by certain types of immune cell; they 
can be found on the cell surface, on the surface of internal membranes and in 
the cytosol (Matzinger, 1998). A large and important class of PRRs are the Toll-
like receptors (TLRs): there are more than 10 distinct types (O’Neill, 2008). TLR 
3, expressed on the luminal surface of endosomes, binds double-stranded RNA 
(produced during the replication of some viruses) (Gauzzi et al., 2010). TLR 4, 
expressed on the cell surface, acts in concert with other proteins to bind 
lipopolysaccharide (a part of Gram-negative bacteria) (Lu et al., 2008). Innate 
immune cells can be also be activated by endogeneous danger signals 
(Erridge, 2010); these are only available to bind their cognate receptors under 
conditions of cell stress and are therefore indirect markers of infection. 
Signalling of TLRs and other danger receptors on innate immune cells results in 
inflammation, a process characterised by activation of vascular and immune 
cells that signal with each other and coordinate the generation, perpetuation 
and resolution of an immune response to clear the infection (Janeway and 
Medzhitov, 2002).  
The effector cells of innate immunity include neutrophils, eosinophils, basophils, 
mast cells, macrophages and natural killer (NK) cells. Attracted by proteins 
produced early at the acutely inflamed site, neutrophils are usually one of the 
first cells to be recruited (Summers et al., 2010). Once activated through any 
one of a number of different receptors, including those that can bind 
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components of pathogens (such as carbohydrate structures), they can 
phagocytose microbes, generate a cytotoxic respiratory burst, and release 
cytotoxic granules (amongst other roles) (Wright et al., 2010). Macrophages, 
particularly after activation by cytokines such as interferon-!, can ingest and kill 
bacteria within phagolysosomes (Rees, 2010). NK cells provide early protection 
against viral infection. They are sensitive to changes in host cells caused by 
viral infection (specifically, for example, a reduction in the expression of class I 
proteins of the major histocompatibility complex). They can release perforin 
granules on activation and therefore mediate cytolysis of virally-infected cells; 
their production of interferon-! promotes macrophage activity and can influence 
the type of adaptive response that might develop (Lunemann et al., 2009). An 
important acellular component of innate immunity consists of the complement 
proteins. This protein cascade can either be directly activated by pathogens (on 
their surface) or indirectly via other immune-recognition mechanisms. 
Complement proteins can coat pathogens (opsonisation), and thereby signal 
their destruction by complement-receptor bearing immune cells, or in some 
cases they can mediate direct cytolysis (Ricklin et al., 2010).  
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1.1.2 Adaptive Immunity 
The adaptive immune system is distinct from the innate in two important 
respects: a high degree of specificity against the pathogen is developed during 
the course of the response (beyond that provided by the relatively limited range 
of germline-encoded receptors), and the ability to form memory. In the case of a 
primary response to a pathogen, the effector cells of the adaptive system are 
slow to appear when compared with the innate system. This is because of the 
requirement that specialised cells (which are part of the innate immune system) 
must process and present components of pathogens to lymphocytes, in order to 
select those capable of recognising the pathogen. These naïve cells (which 
have not been previously triggered through their specific receptor) then 
proliferate and differentiate to generate large numbers of effector and memory 
cells (Medzhitov and Janeway, 2000).  
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1.1.2.1 Antigen Presentation 
Most mammalian cells ‘present’ antigen, but only specialised cells, professional 
antigen-presenting cells (pAPC), are able to initiate primary adaptive immune 
responses (Banchereau et al., 2000; Lanzavecchia and Sallusto, 2001). 
Dendritic cells are a type of pAPC, and different subsets of DC are widespread 
in the body.  
Activation of pAPC through signalling of innate immune receptors triggers 
enhanced uptake of pathogens, their processing and finally the presentation of 
pathogen components on the cell surface (Mellman and Steinman, 2001). A 
wide range of structures can be presented, including whole proteins, peptides, 
and lipid or carbohydrate-conjugated versions of these. Best understood is the 
presentation of small peptides (typically between 8 and 24 amino acids in 
length) within a pocket of proteins of the major histocompatibility complex 
(MHC). The MHC (the human leukocyte antigens, HLA, in humans; in mice they 
are the H2 proteins) is a large, highly polymorphic and complex gene cluster in 
mammals. The MHC consists of different gene subsets: MHC classes I and II 
consist of three genes each, and the proteins they encode are directly involved 
in the presentation of peptides to T lymphocytes (Kelley et al., 2004). Broadly, 
MHC class I molecules present peptides derived from the cytoplasm (Peaper 
and Cresswell, 2008); MHC class II molecules are loaded with peptides present 
in the lumen of endosomes (Rocha and Neefjes, 2008). Generally, only 
professional antigen-presenting cells express MHC class II, whereas most cells 
express class I. Professional APC can therefore present peptides derived from 
structures that they have phagocytosed (Savina and Amigorena, 2007). 
Once they have been activated and taken up potentially foreign material, pAPC 
acquire the ability to migrate to lymphoid tissue. This tissue is structured for 
ensuring optimal interaction between pAPC and the rare lymphocytes that can 
recognise the presented peptides (Randolph et al., 2005). Activated pAPC also 
upregulate co-stimulatory molecules (such as CD80 and CD86) and produce 
polarising cytokines (such as interleukin-12 (IL-12)) (Greenwald et al., 2005). All 
of these factors are necessary to ensure productive interaction with T 
lymphocytes and therefore generation of an adaptive response. 
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1.1.2.2 T Lymphocytes 
T lymphocytes are central to adaptive immunity: they act directly as immune 
effectors, for example by mediating cytolytic activity; they also coordinate the 
activity of other immune cells (such as macrophages and B lymphocytes). T 
lymphocytes originate from common lymphoid precursors. Their precursors 
seed the thymus and then undergo several stages of differentiation there 
(Miosge and Zamoyska, 2007). It is during this process that the unique T cell 
receptors (TCRs) that are characteristic of the mature cell population are 
generated. These TCR sequences are not encoded in the germline but are 
produced by a random process of gene recombination and nucleotide addition 
that operates on TCR variable region genes and occurs in each cell during 
development. A highly diverse pool of TCR in the mature T lymphocyte 
population is generated (an estimated 1018 unique receptors are possible (Blom 
et al., 1999; Medzhitov and Janeway, 2000). The TCR is the antigen-specific 
receptor that binds particular peptide - MHC complexes and controls 
proliferation of naïve cells and effector function of differentiated ones.  
Resting T lymphocytes are often described according to their expression of 
particular molecules, which generally indicate the types of activity they can 
perform. For example, some T lymphocytes express CD4 and others CD8. The 
former interacts with MHC class II molecules (Konig et al., 1996) and as a 
consequence CD4 T lymphocytes are largely restricted to antigen-specific 
interaction with professional antigen-presenting cells. CD4 T lymphocytes can 
be triggered by pAPC to produce cytokines such as interferon-gamma (IFN-
!), which promotes early innate activity (Kasten et al., 2010) (such macrophage 
anti-microbial activity); they also interact with MHC class II-bearing B 
lymphocytes and provide essential signals for the generation of certain antibody 
responses (Nutt and Tarlinton, 2011). CD8 interacts with MHC class I, so CD8 T 
lymphocytes can engage with the much larger pool of MHC class I-expressing 
cells (Jones et al., 1998). CD8 cytotoxic T lymphocytes (CTLs) contain perforin 
and can mediate direct cytotoxicity. They recognise virally-infected cells through 
TCR engagement of viral peptide-MHC class I complexes on the cell surface, 
which triggers the release of cytotoxic granules (Berke, 1994). 
It has already been stated that as part of their maturation process pAPC migrate 
into lymphoid tissue, where they present pathogen-derived peptides on their 
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surface. Naïve T cells continuously recirculate in the body through the blood 
and lymphoid tissue, and it is within the T cell area of lymph nodes that pAPC 
and T lymphocytes interact (Sallusto and Lanzavecchia, 2000). If a naive T cell 
engages, through its TCR, a mature pAPC bearing a complementary peptide-
MHC complex, the T cell stops migrating (Dustin et al., 1997). A stable immune 
synapse develops between the T cell and APC. This comprises a varied cluster 
of molecules (such as adhesion proteins) in addition to the TCR / peptide-MHC 
complex, which likely play an important role in control of synapse stability 
(Huppa and Davis, 2003). An array of signalling events, centred around the 
CD3 complex of proteins that are associated with the TCR, trigger T cell 
proliferation and subsequent differentiation of daughter cells into particular 
subtypes. The activation of naïve T cells is absolutely dependent upon the 
provision of co-stimulation by pAPC: CD80 and 86 engage CD28 expressed on 
the T cell. This requirement for CD28 co-stimulation is due to negative 
regulation of TCR signalling by phosphatase and tensin homolog (PTEN) in 
naïve T cells; this is often not the case for memory T cells (Buckler et al., 2006). 
Effector cells leave the lymph node and move to the site of inflammation where 
they mediate their function including direct cytotoxicity. Central memory cells 
recirculate in the organism and their role is to facilitate rapid secondary 
responses to that antigen (Sallusto et al., 1999). 
There are a number of lineages of CD4 effector T cells: the classical ones being 
the Th1 and Th2 subsets, although the Th3, Treg and Th17 (amongst others) 
are now broadly accepted. The Th1 subset of CD4 T cells is characterised by 
high production of the cytokine IFN-! and cell-mediated immunity. The Th2 
subset is characterised by high production of the cytokines IL-4, -5 and -13, and 
is associated with antibody-mediated responses, including immunoglobulin E 
(IgE)-associated allergy and anti-helminth immunity (Dong and Flavell, 2001).  
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1.1.2.3 B Lymphocytes 
Like T cells, B lymphocytes originate from common lymphoid precursors; they 
complete their development however in the bone marrow (Hardy and 
Hayakawa, 2001). Also akin to T lymphocytes, all mature B cells possess an 
antigen-specific receptor: the B cell receptor (BCR). The precise sequence is 
generated in a process of gene rearrangement, recombination and mutation 
similar, but not identical, to that which occurs in the case of the TCR (Borghesi 
and Milcarek, 2006). The mature B cell population thus contains cells bearing 
BCRs with a very large range of specificities (up to 1014 unique immunoglobulin 
sequences) (Medzhitov and Janeway, 2000). Importantly, the BCR is not 
restricted to binding structures in the context of MHC proteins. The BCR can be 
secreted (without the membrane-spanning domain) by a type of differentiated B 
cell, the plasma cell, and is known in that form as antibody (Oracki et al., 2010). 
Antibodies mediate protection through three main mechanisms: they bind and 
neutralise particles (such as viruses, preventing their binding to entry receptors 
(Corti et al., 2011)), they bind structures on the surface of pathogens and 
thereby target them for removal by FcR-bearing (Nimmerjahn and Ravetch, 
2007) immune cells (such as macrophages), and they can trigger complement 
activation on pathogen surfaces (Ricklin et al., 2010). 
The B1 subset of B cells produces natural antibody that binds carbohydrates 
not present in mammals, providing constitutive protection against certain 
classes of bacteria. B2 B cells function as antigen-presenting cells and can 
differentiate into antibody-producing or memory cells (Hardy, 2006; Montecino-
Rodriguez and Dorshkind, 2006). Binding of the BCR to antigen triggers its 
efficient internalisation, processing and presentation of linked peptides (in an 
MHC class II-restricted fashion) to T cells. CD4 T cells recognising these 
peptides provide essential co-stimulatory signals (such as CD40L) for the 
proliferation and differentiation of these B cells. This occurs within specialised 
regions of lymphoid tissue known as germinal centres. Further gene 
rearrangement can occur resulting in production of antibody of different 
isotypes, a process known as class switching. Gene point mutation also occurs 
within the expressed immunoglobulin locus of germinal centre B cells, and 
through a T cell-driven selection mechanism (affinity maturation), high affinity 
BCR (and thus antibody) against antigen can be generated (McHeyzer-Williams 
et al., 2001). 
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1.2 Lymphocyte Migration 
1.2.1 Cell Biology 
The movement of cells, guided by chemical gradients, evolved early in the 
evolution of life. The type of movement, and the mechanism by which it is 
achieved, is different between prokaryotic and eukaryotic cells. Within 
eukaryota, from amoebae to human leukocytes, the general mechanisms are 
remarkably conserved (Swanson and Taylor, 1982). 
Leukocytes move following what is termed a common amoeboid program; there 
are small differences in behaviour and underlying mechanism between cell 
subsets. For example, three sections of a migrating lymphocyte can be easily 
discerned: a leading edge, mid-region and uropod. Migrating monocytes are 
exceptional in that they have no noticeable uropod (Friedl and Weigelin, 2008). 
Lymphocytes are highly dynamic; they can change rapidly from moving quickly 
(characterised by a few, weak adhesive interactions and high actin turnover) to 
absolute arrest (tight integrin-mediated adhesion and low actin turnover). They 
can also adopt a state of limited movement that may, for instance, be used 
during scanning of antigen-presenting cells (Friedl et al., 1998; Wolf et al., 2003; 
Lammermann et al., 2008). 
The front portion of a migrating leukocyte is termed the leading edge. Rapidly 
forming and degrading filamentous actin networks occurring in this region 
underlie the cell extensions (pseudopods and lamellipods) into the environment 
(Pollard and Borisy, 2003). Membrane is continuously endocytosed and then 
preferentially exocytosed at the leading edge to facilitate this process (Traynor 
and Kay, 2007). Dendritic actin polymerisation is associated spatially and 
temporally with extension of the cell at the leading edge, but is not the only 
mechanism driving it. Detachment of cytoskeletal support from the membrane at 
the leading edge would lead to membrane blebbing under hydrostatic pressure 
of the cytosol (Cunningham, 1995; Charras et al., 2005). It has been postulated 
that actin polymerisation in the bleb follows its formation, perhaps stabilising it 
(Charras et al., 2006).  
Integration of signals received from the environment at the leading edge guide 
directional migratory behaviour (Negulescu et al., 1996; Wei et al., 1999; 
Stanley et al., 2008). In steep gradients of chemoattractant (substances to 
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which cells are attracted), pseudopodia are projected directly up the gradient of 
attractant (Gerisch and Keller, 1981). Evidence suggests that 
Phosphatidylinositol 3-kinase (PI3K) is a central controller of signalling activity 
at the leading edge (Franca-Koh et al., 2007; Marone et al., 2008). G protein-
coupled receptor (GPCR) signalling causes recruitment of the PI3K! subunit to 
the membrane, and local generation of phosphatidylinositol (3,4,5) triphosphate 
(PIP3) (Parent et al., 1998; Janetopoulos and Devreotes, 2001). Other types of 
receptor, for example the TCR, also couple to PI3K and thereby induce cell 
migration (in the case of $ chain receptors via the PI3K% subunit (Rommel et al., 
2007)). An array of docking proteins couple PIP3 (in the plasma membrane) to 
actin-binding effectors. For example, Rac, via Wiskott-Aldrich syndrome protein 
(WASP)- family proteins, couples to the Arp2/3 complex that causes branching 
of actin filaments. Rac activity is central to cell migration; Rac-negative cells are 
largely unable to migrate (Nombela-Arrieta et al., 2004; Goley et al., 2006; 
Stambolic and Woodgett, 2006). Cofilin also seems to play an important role 
regarding actin polymerisation at the leading edge (Svitkina and Borisy, 1999; 
DesMarais et al., 2004).  
Spontaneous formation of pseudopods may be more important in weaker 
gradients of chemoattractant (Bosgraaf and Van Haastert, 2009). PIP3 and Rac 
are constitutively active at a low level in migrating cells, and this probably drives 
the process. There is a very high rate of actin turnover and random pseudopod 
formation in PTEN-negative cells (Iijima and Devreotes, 2002). Differences in 
signal strength transduced by receptors in each pseudopod could underlie 
differential rates and positions of pseudopod growth and retraction, thereby 
biasing the rate and direction of movement (Andrew and Insall, 2007).  
Cell migration can be triggered through pathways other than PI3K signalling. 
p38 mitogen-activated protein kinase (MAPK) and dedicator of cytokinesis 2 
(DOCK2) seem to have important roles (Hoeller and Kay, 2007), as they also 
link to Rac and can therefore influence actin filament dynamics. End-stage 
chemoattractants (which guide cells towards a particular source and migration 
end-point) activate p38 MAPK and inhibit PI3K. PI3K activity is not required for 
chemotaxis of neutrophils to N-formylmethionyl-leucyl-phenylalanine (fMLP) 
(Heit et al., 2008), whereas it is necessary for migration to CXCL8 (Knall et al., 
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1997). This seems to offer an explanation for how prioritisation of end-stage 
over intermediate chemoattractants is achieved. 
The mid-region of a migrating leukocyte contains the nucleus. It is held 
immobile by crosslinked actin filaments around the nucleus, and is carried 
forward with the cell (Laevsky and Knecht, 2003; Friedl and Weigelin, 2008). 
The cell is anchored to the matrix at the rear, the uropod, with intercellular 
adhesion molecule-1 (ICAM-1) and -3, and #1 integrin having important roles. 
The uropod is relatively richer in mitochondria, which likely power the 
contraction of this part of the cell as it moves forward. The enzyme PTEN, 
excluded from the leading edge, dephosphorylates various effectors of actin 
polymerisation in the mid-region and uropod (Funamoto et al., 2002; Heit et al., 
2008). 
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1.2.2 Chemokine Signalling 
1.2.2.1 Chemokines 
Chemokines are a family of endogeneous compounds in mammals that direct 
the migration of immune and other cell types. They are small proteins, mostly 
between 7 and 14 kDa in size, and they are related in sequence. CXCL8 was 
the first to be cloned and characterised (Baggiolini et al., 1994). The crystal 
structure of CXCL8 has been resolved and shows the presence of a Greek-key 
domain that is characteristic of the family. 
Chemokines have traditionally been classified with reference to the N terminal 
cysteine residues that are common to the family. C chemokines have one N-
terminal cysteine (there is another some distance away in the primary 
sequence), CC chemokines have two adjacent cysteines, CXC chemokines 
have one intervening non-cysteine amino acid, and the CX3C chemokines have 
three such separating residues. The CXC chemokines can themselves be 
further sorted into those that contain ELR in their primary sequence (including 
CXCLs 1, 2, 3, 5 and 6) and are mostly neutrophil chemoattractants, and those 
that do not (Van Coillie et al., 1999; Zlotnik and Yoshie, 2000). CX3CL1 and 
CXCL16 are exceptional chemokines, as they can exist in both a soluble form 
and as a tethered molecule on endothelial cells (functioning as an adhesion 
molecule) (Schwarz et al., 2010; van der Voort et al., 2010). 
In the context of the immune system, chemokines have two main functions: to 
direct the migration of immune cells (Stein and Nombela-Arrieta, 2005), and 
trigger the activation of adhesion molecules called integrins (Shamri et al., 
2005). Chemokines coordinate the movement of immune cells so that they are 
placed appropriately for their function at any particular time, a crucial function 
for effective immunity. They can be produced by a great number of different cell 
types, and may be either constitutively produced or induced by some stimulus. 
Macrophages and endothelial cells produce chemokines (for example, CXCL8) 
on receipt of danger signals (for example in response to ligation of TLRs) and 
this is associated with recruitment of innate effector cells. Lymphatic 
endothelium and lymph node stroma constitutively produce chemokines (CCL19 
and 21) that control the recirculation of naïve T cells and recruit mature DC to 
lymphoid tissue (Bromley et al., 2008).  
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Many chemokines bind with low affinity to glycosaminoglycans (GAGs) that are 
located in the extracellular matrix and on the surface of cells. This interaction is 
important for the establishment of solid-phase gradients for migrating cells to 
follow (Patel et al., 2001). Chemokines that are bound to a solid substrate 
strictly induce cell haptotaxis (or –kinesis, if non-directional); in soluble form, 
they induce chemotaxis (-kinesis) (Carter, 1967). The nature of the interaction 
with glycosaminoglycans has been examined in detail for CXCL12 (Amara et 
al., 1999; Lortat-Jacob et al., 2002). Changes in the structure of GAGs, for 
example during inflammation, are known to affect the presentation of 
chemokine ligands to their receptors (Proudfoot et al., 2001; Turnbull et al., 
2001; Proudfoot et al., 2003).  
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1.2.2.2 Chemokine Receptors 
Chemokine receptors belong to the G-protein-coupled receptor superfamily. 
Their nomenclature is derived from that of their ligands: CC chemokines (e.g. 
CCL5) bind receptors denoted CCR (CCL5 can bind CCRs 1, 2 and 5); CXC 
chemokines (e.g. CXCL12) bind CXCR (CXCR4). Many chemokine receptors 
couple to the G"i G protein, and effect cell migration in part due to G#! -driven 
activation of PI3K (Brock et al., 2003). There is evidence that certain receptors 
can co-opt the other signalling pathways. CXCR4 is able to utilise some of the 
TCR signalling domains within the CD3 complex (Rossi and Zlotnik, 2000; 
Kumar et al., 2006). 
Immune cell migration in mammals is mainly controlled by regulation of 
expression of chemokines and their receptors (Rabin et al., 1999). Some 
chemokines, such as CXCL12, are produced constitutively. Bone marrow 
stromal cells and lymphatic endothelial cells produce CXCL12, inducing homing 
of memory B cells to the bone marrow and contributing to the recirculation of 
resting T cells (which express the cognate receptor CXCR4) (Karin, 2010). 
Other chemokines, such as CCL5 and CXCL10, are produced during 
inflammation. The receptors for these ligands, CCR5 and CXCR3 respectively, 
are upregulated on the activation of T cells (Loetscher et al., 1998; Nakajima et 
al., 2002). Differentiated, effector T cells therefore have a chemokine receptor 
profile that facilitates their migration to inflamed sites in the periphery (Campbell 
et al., 2003). Effector T helper cell subsets have characteristic profiles of 
chemokine receptor expression (Siveke and Hamann, 1998). Th1 cells typically 
express CCR5 (Loetscher et al., 1998) and CXCR3, whereas Th2 cells express 
CCRs 3, 4 and 8 (Sallusto et al., 1997; D’Ambrosio et al., 1998; Sallusto et al., 
1998). 
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1.2.3 Regulation of Lymphocyte Migration by Chemokines 
1.2.3.1 In Homeostasis 
Resting naive T cells express high levels of CCR7. CCL19 and 21, the ligands 
for CCR7, are produced by lymphatic tissues (Forster et al., 2008): high 
endothelial cells (HEC) produce CCL21 (and can present CCL19 that has been 
transcytosed from inside the lymph node), and fibroblastic reticular cells CCL19 
and 21. Professional antigen-presenting cells do not constitutively express 
CCR7, but it is upregulated on maturation (Randolph et al., 2005). The 
consequence is that large numbers of naïve T cells traffic through individual 
lymph nodes, where they can scan the surface of resident mature pAPC for 
foreign antigen. A T cell will typically spend between 6 and 24 hours within a 
node under non-inflammatory conditions before egress. The majority of resting 
T cells egress by squeezing into the cortical sinusoids and are then carried 
under flow into the efferent lymphatics (Beauchemin et al., 2007; Grigorova et 
al., 2010). 
T cells enter lymph nodes via high endothelial venules (HEVs). L-selectin, 
expressed at high levels on the surface of T cells, interacts with surface 
carbohydrate (e.g. PNAd and GlyCAM-1) on HEC (Galkina et al., 2007) and 
causes the T cells to roll along the endothelium. Interactions between ICAM-1 
on the endothelium and lymphocyte function-associated antigen -1 (LFA-1) (an 
integrin) on the T cell cause cell arrest (Warnock et al., 1998). CCR7 signalling 
is necessary for cell entry into the node: monocytes express L-selectin and 
ICAM-1, but not CCR7, and cannot enter via HEV. Chemokine receptor 
signalling triggers changes in integrin conformation, enhancing adhesion and 
promoting endothelial diapedesis of the cell into the node parenchyma 
(Miyasaka and Tanaka, 2004). 
The microstructure of the lymph node is highly specialised to promote effective 
immunosurveillance. Movement of cells within lymph nodes, from their entry till 
exit, occurs along stromal cell networks (Bajenoff et al., 2006). Fibroblastic 
reticular cells (FRCs) form a scaffold along which lymphocytes can migrate. 
CCL19 and CCL21 are bound to the reticular network and appear to induce 
haptokinetic migratory behaviour. DC associate with the reticular network (Gretz 
et al., 1997; Link et al., 2007), promoting the interaction of lymphocytes and 
APC.  
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1.2.3.2 In Inflammation 
1.2.3.2.1 Within Secondary Lymphoid Tissue 
In the early stages of an immune response, innate immune cells (activated by 
danger signals) secrete pro-inflammatory cytokines such as Tumour necrosis 
factor-alpha (TNF-") and IL-6. These diffuse from their site of production and 
influence the behaviour of multiple cell types in a paracrine fashion. They also 
enter the tissue lymphatics, which drain the cytokines into local lymph nodes. 
There they induce lymph node shutdown, a non-specific block in lymphocyte 
egress. Interferon-! within the node causes downregulation of CCL21 and 
CXCL13, and the relocalisation of resident DC and T cells. This might promote 
development of an adaptive response (Mueller et al., 2007).  
Lymph node activation is marked by upregulation of ICAM-1 and increased 
presentation of CCR7 ligands by HEV (Forster et al., 1999). CXCL9 and 
CXCL10 are newly presented and cause recruitment of NK cells and activated T 
cells into the node. Chemokines such as CCL21, produced by stromal cells and 
mature DC, increase the general motility of resting T cells within the node 
(Stachowiak et al., 2006; Woolf et al., 2007; Worbs et al., 2007). Prolonged 
signalling through the TCR results in cell activation, a complete loss in 
responsiveness to chemotactic factors, and cessation of migration (Dustin et al., 
1997). The TCR-driven accumulation of PIP3 in the cell membrane results in 
activation of the mammalian target of rapamycin (mTOR) pathway and 
ultimately a loss in expression of kruppel-like factor 2 (KLF2). This transcription 
factor is a master regulator of multiple adhesion molecules, chemokine 
receptors and others, including CD62L, CCR7 and Sphingosine 1-phosphate 
receptor 1 (S1PR1) (Finlay and Cantrell, 2010).  
Chemokine signalling plays additional roles in promoting interactions between 
other cell types in inflamed lymph nodes. CD8 T cell activation requires help 
from both professional antigen presenting cells and CD4 T cells. DC – CD4 T 
cell conjugates can produce ligands for CCR5, and attract CD8 T cells that 
express the receptor. The germinal centre reaction and development of high 
affinity antibody is similarly CD4 T cell-dependent. A subset of CD4 T cells 
differentiates after activation to become follicular helper cells. These cells 
downregulate CCR7 and upregulate the receptor CXCR5 - which binds the 
follicular chemokine CXCL13 (von Andrian and Mempel, 2003; Cyster, 2005). 
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1.2.3.2.2 Homing to the Periphery 
As T cells differentiate following activation, they upregulate inflammatory 
chemokine receptors, lipid receptors and various types of adhesion molecule. 
Some of these are common to all differentiated T cells, whereas other 
molecules are specific to certain subsets, and confer destination specificity to 
the cell migration program. The precise chemokine receptor profile of effector T 
cells is imprinted during the priming interaction with dendritic cells. Cells 
activated within gut-associated lymphoid tissue upregulate the chemokine 
receptor CCR9 (which guides migration to the small intestine), whereas skin-
homing T cells express CCRs 4 and 10. The ligands for these receptors are 
produced at particular sites: CCL25, the ligand for CCR9, is expressed by 
endothelial cells in the small intestine (Kunkel and Butcher, 2002); CCL17, the 
ligand for CCR4, by endothelial cells of skin but not intestinal venules (Reiss et 
al., 2001).  
Adhesion molecules act in concert with chemokines to control effector cell 
migration to specific sites in the periphery. Mucosal vascular addressin cell 
adhesion molecule-1 (MAdCAM-1) is expressed by vascular endothelial cells 
within the gut, and binds the "4#7 integrin expressed on a particular subset of T 
lymphocytes (Berlin et al., 1993). T cells activated within skin-draining lymph 
nodes upregulate cutaneous lymphocyte antigen (CLA), a carbohydrate-
modified form of PSGL-1 that interacts with E-selectin (Fuhlbrigge et al., 1997). 
Ingress of effector T cells into peripheral tissue proceeds in a broadly similar 
way to lymph node entry via HEV. A carbohydrate - selectin tethering interaction 
induces cell rolling along the endothelium. The lymphocyte can then sample for 
chemokines and complementary adhesion molecules on the endothelium. 
ICAM-1 and (in inflamed tissue) Vascular cell adhesion molecule -1 (VCAM-1) 
on endothelial cells interact with LFA-1 and Very late antigen -4 (VLA-4) on 
lymphocytes (Ley et al., 2007). Inflammatory chemokines bound to surface 
GAGs engage their cognate receptors on the migrating cells, driving changes in 
integrin affinity and avidity. This causes cell arrest and induces endothelial 
diapedesis. Adhesion to laminin in the basement membrane is mediated by the 
"6#1 integrin (Dangerfield et al., 2002). Early in the inflammatory process 
neutrophils move through areas of reduced laminin and collagen density 
(Steadman et al., 1997). Matrix metalloproteinases and serine proteases 
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produced by leukocytes and activated in their immediate surroundings break 
down the laminin and collagen mesh (El-Shabrawi et al., 2004; Young et al., 
2007). The cumulative effect of matrix degradation by different immigrating cell 
types over time creates paths of least resistance and therefore preferred tissue 
entry points. Inside the tissue, the bulk of cell migration occurs along tracks 
close to the vasculature. The "6#1 and "4#1 integrins play important roles in 
anchoring the cell uropod, while chemokine gradients provide appropriate 
directional cues (Friedl and Weigelin, 2008). 
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1.3 The Sphingosine 1-phosphate Signalling Axis 
1.3.1 S1P 
Sphingosine 1-phosphate (S1P) is a 379 Da bioactive lipid. It is amphipathic: 
consisting of a polar headgroup and a long saturated aliphatic tail (Figure 1). It 
has a wide range of effects on different cell types in multiple organ systems, 
mediated via both cell surface and intracellular receptors. Cellular responses 
are modulated through changes in the subcellular localisation of S1P, its import 
and export from the cell, protein carrier binding and changes in receptor 
expression by target cells (Rosen et al., 2009).  
 
1.3.1.1 Generation 
Sphingosine 1-phosphate is formed on phosphorylation of the primary hydroxyl 
group of its immediate precursor sphingosine, an 18 carbon aliphatic amino 
alcohol. The phosphorylation reaction is catalysed by one of the isoenzymes 
sphingosine kinases 1 and 2 (SK1 & 2). Most sphingosine is derived from the 
breakdown of the membrane component sphingomyelin, which is enriched in 
the lipid rafts of eukaryotic cell membranes (Rivera et al., 2008). Degradation of 
sphingomyelin yields ceramide, which can be interconverted with sphingosine. 
De novo synthesis of S1P begins with the condensation of serine and palmitoyl 
CoA. This is catalysed by serine palmitoyltransferase in the endoplasmic 
reticulum. A series of further enzyme-catalysed steps result in the generation of 
ceramides of various lengths (Kihara et al., 2007; Tani et al., 2007; Lynch and 
Macdonald, 2008; Takabe et al., 2008). 
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!"#$%&'($%)*+,"#'("#-.)*Figure 1. Sphingosine 1-phosphate. 
The chemical structure of sphingosine 1-phosphate. 
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Sphingosine kinases 1 and 2 are homologous and consist of five conserved 
domains (Pyne et al., 2009). They do however display different catalytic 
properties, subcellular locations, tissue distribution and temporal expression 
patterns. SK1 prefers D-erythro sphingosine as a substrate, whereas SK2 
phosphorylates a wider range of substrates (including the sphingosine analogue 
FTY720 (Kharel et al., 2005)). Single sphingosine kinase knockout (KO) mice 
appear largely normal and their blood S1P concentrations are near normal, 
indicating functional redundancy. Double KO mice do not survive beyond 
embryonic stage because of multiple developmental defects, notably in the 
vasculature (Maceyka et al., 2005; Mizugishi et al., 2005; Takabe et al., 2008).  
Numerous growth factors, cytokines, hormones, various GPCR ligands and 
lysophospholipids can induce SK1 activity (Hait et al., 2006; Taha et al., 2006; 
Takabe et al., 2008). The pro-inflammatory effect of TNF-" on endothelium is 
absolutely dependent on SK1 activity (Xia et al., 2002; Limaye, 2008). SK1 is 
phosphorylated (seemingly by extracellular signal-related kinase (ERK) 1/2 
(Pitson et al., 2003)) and moves to the plasma membrane on activation (Young 
et al., 2003; Stahelin et al., 2005). The relative activity of the sphingosine 
kinases and S1P degrading enzymes is an important determinant of cell fate. 
Ceramide and sphingosine promote apoptosis, whereas S1P suppresses 
apoptosis and causes cell proliferation (Olivera et al., 1999; Goetzl et al., 2000; 
Chalfant and Spiegel, 2005). 
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1.3.1.2 Degradation 
In vivo, the half-life of S1P is short, estimated in mice to be around 15 minutes 
(Venkataraman et al., 2008). S1P can be cleared either by dephosphorylation, a 
reversible process, or irreversible splitting of the molecule. Enzymes of the lipid 
phosphate phosphatase (LPP) family (three isoforms have been described: 
LPP1-3) dephosphorylate S1P to sphingosine. They have relatively broad 
specificity, acting on other lysophospholipids including ceramide 1-phosphate. 
LPP activity can be detected on the cell surface, and it is known that ecto-LPP 
can regulate signalling of S1P through its surface receptors (Brindley et al., 
2002). Sphingosine 1-phosphate phosphatases 1 and 2 (SPPs 1 and 2) perform 
the same function, but are specific to sphingoid bases. These enzymes are 
located intracellularly; extracellular substrate accesses the enzyme via 
adenosine triphosphate-binding cassette (ABC) transporters. Sphingosine is 
very hydrophobic and can cross the membrane much more easily than S1P; 
dephosphorylation is an efficient mechanism of clearance of S1P from the 
extracellular space (Peest et al., 2008; Pyne et al., 2009). 
S1P lyase (SPL) degrades its substrate irreversibly to phosphoethanolamine 
and hexadecanal (Bandhuvula and Saba, 2007). The enzyme is very widely 
expressed in mice and humans, and is upregulated on inflammation. It functions 
intracellularly and is resident on the ER membrane with the active site facing 
the cytosol (Ikeda et al., 2004; Bandhuvula and Saba, 2007). Knockout mice do 
not survive beyond weaning, with multiple problems observable in the heart, 
lungs and bone. Disturbances of lipid metabolism and accumulation of very high 
levels of S1P likely underlie the observed pathology (Bandhuvula and Saba, 
2007). S1P lyase expression is absent in platelets (Yatomi et al., 1997) and 
erythrocytes (Hanel et al., 2007), the latter being the major site of synthesis in 
the body (Ito et al., 2007). Expression is higher in the thymus and secondary 
lymphoid tissue. The maintenance of low levels of S1P in those compartments 
is required for normal lymphocyte recirculation, as demonstrated by inhibition of 
S1P lyase using 2-acetyl-4 tetrahydroxybutylimidazole (THI) (Schwab et al., 
2005).  
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1.3.1.3 Transport 
Most of the S1P in blood is associated with erythrocytes, which act as a 
reservoir for the compound (Hanel et al., 2007; Bode et al., 2010). In serum, the 
majority of S1P is associated with lipoproteins (particularly HDL) and albumin. 
The interaction with such carriers has been shown to influence the action of the 
ligand (Murata et al., 2000). Binding to serum proteins means that S1P can be 
carried far from its site of synthesis in blood. 
S1P cannot cross lipid bilayers unassisted, due to its amphipathic character. 
ABC transporters drive active transport. In platelets and astrocytes ABCA7 and 
1 (respectively) have a major role (Sato et al., 2007), and in mast cells ABCC1 
(Mitra et al., 2006). An ATP-dependent transporter for S1P has been identified 
in rat erythrocytes (Kobayashi et al., 2009). Erythrocytes isolated from plasma 
do not release S1P: HDL and serum albumin trigger its export (Bode et al., 
2010).  
Transmembrane transport of S1P is necessary for binding to cell surface 
receptors, on the same, neighbouring or distant cells. Chemotaxis to platelet-
derived growth factor (PDGF) is dependent on cellular expression of both SK 
and S1PR1 (Rosenfeldt et al., 2001). PDGF signalling causes a membrane-
proximal local increase in S1P production. The S1P is then exported and binds 
S1PR1 on the extracellular surface to induce migration (Hobson et al., 2001).  
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1.3.2 S1P Receptors 
The receptors for S1P, denoted S1PR1 - 5, are heterotrimeric G protein coupled 
receptors, with seven transmembrane domains (Rosen and Goetzl, 2005). 
Sequences within the endothelial differentiation gene (EDG) gene family (that 
code for the S1PR) have amino acid identities in the range 25-52%. The affinity 
of S1P for these receptors (dissociation constant (Kd)) is mostly in the single-
digit nanomolar range (Rosen et al., 2008). Several S1PR types are expressed 
on immune cells. S1PR1 is expressed widely, whereas the others are more 
limited in their distribution. S1PR4 is expressed by T lymphocytes (Wang et al., 
2005), S1PR5 by NK cells (Jenne et al., 2009) and S1PR3 by DC (Czeloth et 
al., 2005) (the latter two receptors play important roles in control of cell 
migration). Binding of agonist to the receptor can trigger a multitude of signalling 
pathways, some common to several of these receptors and others unique (Pyne 
and Pyne, 2000; Speigel and Milstein, 2000; Sanchez and Hla, 2004). The 
signaling biology of the receptors is complicated by the fact that multiple 
receptor subtypes are often expressed on the same cell and certain individual 
receptor subtypes can be split into subpopulations based upon the coupled 
heterotrimeric G proteins: "i, "q or "12/13 (Ishii et al., 2004; Rosen et al., 2008). 
Additionally, S1PR and Lysophosphatidic acid receptors can form homo- and 
heterodimers (Van Brocklyn et al., 2002; Zaslavsky et al., 2006). 
S1PR1-5 are responsible for mediating many of the effects of S1P on cell 
biology including proliferation, cell migration, invasion, angiogenesis, and 
vascular maturation, actin cytoskeleton rearrangement and adherens junction 
assembly (Pyne and Pyne, 2000; Spiegel and Milstein, 2000). S1P can also act 
intracellularly and independently of S1PR1-5 to enhance cell proliferation and 
suppress apoptosis (Van Brocklyn et al., 1998; Maceyka et al., 2002). SK2 can 
physically associate with, and S1P can suppress the activity of, histone 
deacetylases 1 and 2 (HDACs 1 & 2) in the nucleus (Hait et al., 2009). 
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1.3.2.1 S1PR1 
S1PR1 is expressed by a wide variety of tissues in mice and humans. S1PR1-
KO mice die between E12.5 – E14.5 due to severe haemorrhage resulting from 
a defect in vascular stabilisation (Liu et al., 2000). Conditional gene deletion and 
experiments using selective receptor agonists show that the receptor has 
additional roles in angiogenesis, immune cell trafficking, regulation of vascular 
tone and endothelial barrier function (Garcia et al., 2001; Matloubian et al., 
2004; Singleton et al., 2005). It is the most highly expressed S1P receptor on 
lymphocytes. It seems to be exclusively responsible for mediating the effects of 
S1P on T cell trafficking, as shown in multiple experiments using S1PR KO 
mice and selective receptor agonists (Sanna et al., 2004). Natural and 
functionally similar S1PR1 agonists are also sufficient for the maintenance and 
enhancement of endothelial integrity (Rosen et al., 2007; Limaye, 2008). S1PR1 
signalling can influence activity of members of the Rho GTPase family and 
therefore cytoskeletal organisation, adherens and tight junction assembly, and 
focal adhesion (McVerry and Garcia, 2005).  
Human S1PR1 is 382 amino acids long and has a molecular weight of 42 kDa. 
Mutagenesis studies indicate that S1P binds the receptor with the phosphate 
group on the outer surface (a relatively hydrophilic environment) and the 
hydrophobic fatty acid chain located between the transmembrane helices 
(Fujiwara et al., 2007). S1P may need to dissociate entirely from its carrier in 
order to dock onto the receptor. It might even insert in the outer leaflet of the 
plasma membrane first, and then bind the receptor in cis. Ligand-bound S1PR1 
couples to the G protein G"i alone, with complete inhibition of S1PR1-mediated 
responses by pertussis toxin (Lee et al., 1996). Agonism of this receptor has 
been shown, in many different cell types, to cause an increase in MAPK activity, 
decrease in adenylate cyclase activity (Lee et al., 1998; Okamoto et al., 1998; 
Zondag et al., 1998), increase in phospholipase C (PLC) activity, increase in 
Rac activation and increase in PI3K activity (Okamoto et al., 1998; Pyne and 
Pyne, 2000).  
Surface expression of S1PR1 is modulated at the transcriptional and post-
transcriptional levels. The most important regulator of gene transcription in T 
cells is the protein KLF2 (Bai et al., 2007). KLF2 expression is potently 
downregulated on T cell activation. Plasma-membrane S1PR1 is internalised 
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into endosomal compartments on receptor activation (Liu et al., 1999). The G 
protein receptor kinase GRK2, activated by receptor signalling, phosphorylates 
the C-terminal tail of S1PR1. #-arrestin binds to the phosphorylated motif and 
facilitates assembly of clathrin-coated pits (Kihara et al., 2007). S1P and 
phorbol 12-myristate 13-acetate (PMA; which activates protein kinase C) 
stimulate the phosphorylation of residues on the tail of S1PR1 via distinct 
mechanisms and are associated with different pathways leading to loss of the 
receptor from the cell surface (Watterson et al., 2002). S1PR1 can also undergo 
polyubiquitinylation upon internalisation, the extent of which is dependent on the 
type and concentration of agonist (Oo et al., 2007). The poorly ubiquitinylated 
receptor recycles from the late endosomal compartment back to the plasma 
membrane whereas the highly ubiquitinylated receptor is degraded in 
lysosomes (Rosen et al., 2008). Lastly, activation of T cells via the TCR induces 
translocation of S1PR1 from the plasma membrane to the nuclear envelope; 
there the receptor can effect changes in gene transcription (Goetzl et al., 2007; 
Liao et al., 2007). 
 
 
 
 
 27!
1.3.3 The Vascular Gradient of S1P 
1.3.3.1 Compartmentalisation 
A vascular gradient of S1P contributes to control of T cell recirculation through 
the blood, secondary lymphoid tissue and lymphatic vasculature (Figure 2). The 
amount of S1P in these compartments is determined by the quantity and activity 
of S1P synthetic and degrading enzymes. Most measurements place the 
concentration of S1P in human serum in the single unit micromolar range, with 
some variation in reported values (Hanel et al., 2007; Hla et al., 2008). In 
serum, it is mostly bound to carriers such as high-density lipoprotein and 
albumin (Murata et al., 2000). Erythrocytes express sphingosine kinases, lack 
S1P lyase, and are the primary source of S1P in blood (Pappu et al., 2007). 
They can buffer its concentration there (Hanel et al., 2007), and also pass S1P 
to other cell types including endothelial cells (Bode et al., 2010). The vascular 
endothelium also contributes to S1P in blood. Shear flow stimulates increased 
synthesis and secretion of S1P by vascular endothelial cells (Pappu et al., 
2007; Venkataraman et al., 2008). 
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Figure 2. The compartmentalisation of S1P in the lymphatic and vascular systems. 
The concentration of S1P in blood is in the single unit micromolar range. Chronic stimulation 
with ligand results in internalisation of S1PR1 from the surface of T cells located in that 
compartment. High levels of S1P lyase activity underpin a very low concentration of S1P in 
lymphoid tissues under normal conditions. S1PR1 can recycle back to the surface of resting T 
cells that have recently ingressed. S1P, originating from lymph, is sampled by T cells located at 
exit structures in lymphatic tissue, and is required for their efficient egress. Under normal 
conditions the concentration of S1P in peripheral tissues is low, but it can increase due to 
upregulation of synthetic enzyme activity during inflammation. 
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Lymph contains approximately one quarter the level of S1P in blood (Schwab et 
al., 2005; Pappu et al., 2007). Lymphatic endothelial cells are the source of S1P 
in lymph; expression of the enzyme by lymphatic endothelium is required for 
normal lymphocyte egress from lymph nodes (LNs) and Peyer’s patches (Pham 
et al., 2010). Neural crest-derived perivascular cells provide the S1P required 
for egress of T cells from the thymus (Zachariah and Cyster, 2010).  
S1P is present at very low levels in primary and secondary lymphoid tissue, and 
indeed many peripheral tissues under normal conditions. The amounts of S1P 
in the thymus, lymph nodes and spleen of mice are approximately 20, 40 and 
150 ng per g of tissue respectively (Edsall and Spiegel, 1999). There is a high 
level of S1P lyase activity in non-inflamed lymphoid tissues, and this is required 
for normal lymphocyte recirculation (as shown by inhibition of the enzyme 
(Schwab et al., 2005)). 
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1.3.3.2 S1P Signalling in Homeostatic Lymphocyte Trafficking 
S1PR1 becomes expressed as thymocytes undergo their final stages of 
differentiation. This confers upon them a capacity to egress into the high S1P 
environment of the blood. The egress of resting naïve T cells from lymph nodes 
is similarly dependent upon signalling of S1PR1. However, in the case of 
recirculating T cells, surface expression of the receptor is cyclically modulated 
by homologous desensitisation, rather than by transcription.  
The high concentration of S1P in blood means that any S1PR1 present on the T 
cell surface is quickly internalised to endosomes, with a consequent loss in 
sensitivity to that ligand. On entering secondary lymphocyte tissue, where the 
concentration of S1P is kept low, S1PR1 that is currently sequestered recycles 
back onto the T cell surface (Lo et al., 2005). This allows lymph node -resident 
lymphocytes to sample S1P at exit structures (primarily the cortical sinuses). 
Intravital imaging of LN egress structures shows cortical sinus probing by T 
cells. Local S1PR1 signalling in the probing pseudopod probably stabilises it 
and repolarises the cell for egress (Grigorova et al., 2009). S1PR1 signalling 
antagonises that mediated by CCR7, which promotes retention of T cells within 
the node, thus allowing the cells to leave (Dustin and Chakraborty, 2008; Pham 
et al., 2008). The requirement for S1PR1 for T cell egress is supported by 
multiple experiments. For example, agonist–induced downmodulation of S1PR1 
on lymphocytes results in their retention in lymphoid tissue, presumably as it 
leaves them unable to transduce egress signals and conditional S1PR1 
knockout T cells cannot egress lymph nodes (Matloubian et al., 2004). 
Injection of labelled T cells into a mouse shows that they are capable of moving 
from HEV entry points into cortical sinuses in less than 30 minutes, indicating 
rapid re-acquisition of sensitivity to S1P. These cells (a fraction of all cells that 
enter the node) probably move directly between closely apposed entry and exit 
structures, rather than migrating through the parenchyma that would necessarily 
extend their lymph node residence time (Grigorova et al., 2010). Unactivated T 
cells typically transit a murine lymph node in 6-10 hours (Tomura et al., 2008).  
The lymphocyte-extrinsic model of T cell egress postulates an important role for 
S1PR1 on endothelial cells. Agonism of S1PR1 on endothelial cells enhances 
cell-cell contacts and thus potentially reduces the ability of lymphocytes to 
traverse the egress barrier (Wei et al., 2005). This seems to be mediated 
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through S1P enhancement of the interaction between focal adhesion and 
adherens junction proteins (Sun et al., 2009). S1PR1 antagonists promote, 
rather than block, T cell egress in vivo. This would be consistent with a 
predicted reduction in lymphatic endothelial barrier integrity at lymph node exit 
sites and a higher rate of T cell egress (Sanna et al., 2006).
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1.3.3.3 S1P Signalling in Inflammation 
1.3.3.3.1 Within Secondary Lymphoid Tissue 
Inflammation in peripheral tissues is associated with production of pro-
inflammatory cytokines such as TNF-" and IL-6, and the maturation of antigen-
presenting cells that have been activated through danger receptors (Janeway 
and Medzhitov, 2002). These components drain via the afferent lymphatics to 
the local lymphatic tissue and activate the node for the initiation of an adaptive 
response. There is often a transient block in lymphocyte egress from an 
activated node called lymph node shutdown. TNF-", IFN-!  and  interferon-
alpha (IFN-") have all been implicated as causal factors in this process (Young, 
1999; Seabrook et al., 2005), and it is probable that they act in concert. An 
important role for IFN-" is clearly demonstrated by the fact that IFNAR1-null 
lymphocytes are less efficiently sequestered in activated lymph nodes than wild-
type cells. It has now been shown that IFN-" signalling triggers a complex 
cascade of events that regulate egress signal transduction by S1PR1 (Shiow et 
al., 2006). 
CD69 is a type II transmembrane protein and C-type lectin of 23 kDa (Lopez-
Cabrera et al., 1993; Testi et al., 1994). It is an early activation marker of a 
number of immune cell types, notably T cells. Several stimuli cause the 
upregulation of CD69 on the surface of T cells; treatment of resting T cells with 
IFN-"/# will cause a significant amount of protein to appear on the cell surface 
within 1 hour (Shiow et al., 2006). CD69 protein is present in the cytoplasm of 
resting T cells (Risso et al., 1991), and this pool can be rapidly trafficked to the 
plasma membrane. Various stimuli, such as stimulation through the TCR, will 
also dramatically upregulate transcription and de novo protein synthesis (Ziegler 
et al., 1994).  
CD69 physically associates with S1PR1 on the cell surface. Domain-swapping 
experiments show that the intracellular membrane proximal domain and 
transmembrane domain of CD69 are necessary for this interaction. 
Mutagenesis studies show that S1PR1 membrane helix 4 is crucial (Bankovich 
et al., 2010). Importantly, the interaction of these two proteins is associated with 
a loss in the capacity for S1PR1 to signal (Shiow et al., 2006). The half-life of 
the ligand-bound CD69 - S1PR1 complex is significantly longer than that of 
ligand bound S1PR1 alone, and CD69 overexpression is associated with a 
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greater rate of degradation of S1PR1. So, protein-protein interaction might 
induce a conformational change in S1PR1 more akin to its ligand-bound state, 
thus enhancing desensitisation of the receptor (Bankovich et al., 2010). The net 
effect is that T cells expressing significant levels of CD69 cannot respond to 
S1P at lymph node exit structures and egress into the cortical sinuses. In 
animals stimulated with polyinosinic:polycytidylic acid (poly I:C), which 
stimulates IFN-" production and results in strong induction of CD69 on lymph 
node resident T cells, cortical sinusoids appear collapsed under intravital 
microscopy (Grigorova et al., 2010). This is consistent with a block in access of 
T cells to these structures. 
 
Innate cytokines therefore play a crucial role in the generation of a lymph node 
environment best suited for lymphocyte retention and antigen scanning. In the 
event of a rare productive interaction between a T cell and a professional 
antigen-presenting cell, S1PR1 transcription is reduced as KLF2 is ubiquitinated 
and degraded (Carlson et al., 2006). The specific lymphocyte clone thus 
remains in an environment optimised for proliferation and control of 
differentiation of daughter cells. With KLF2 expression restored in differentiated 
cells, S1PR1 re-appears on the cell surface. Both antigen-specific effector and 
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Figure 3. Regulation of T cell egress from the lymph node cortex. 
In homeostatic conditions, resting T cells that have recently entered a lymph node have low 
levels of S1PR1 on the cell surface. Internalised receptor moves back to the cell surface in the 
low S1P environment of an uninflamed lymph node (this can be blocked by administration of the 
S1PR1 superagonist FTY720-phosphate (FTY720-P), which downregulates the receptor). Re-
acquisition of S1PR1 surface expression allows T cells to receive exit signals by sampling S1P 
inside cortical sinusoids. In conditions of inflammation, innate immune cytokines (such as 
interferon-alpha/beta) trigger upregulation of CD69 on the surface of lymph node-resident T 
cells. CD69 interacts with S1PR1 protein, preventing transduction of signals required for cell 
egress. Loss of CD69 expression by T cells relieves this inhibition, allowing the cells to leave. 
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memory T cells therefore acquire the ability to leave the lymph node 
(Matloubian et al., 2004).  
In addition to its role in regulation of T lymphocyte trafficking, S1P can also act 
alongside other mediators to influence T cell differentiation and B cell responses 
within lymphoid tissue. In particular, there is some evidence for a role for S1P in 
the generation of regulatory T cells. In an in vitro model, S1P acted similarly to 
IL-23 in its ability to promote CD3/CD28-stimulated CD4+ T cells incubated with 
Transforming growth factor–beta (TGF-#), IL-1 and IL-6 to differentiate into 
Th17 cells (Liao et al., 2007). Constitutive S1PR1 signaling in B cells seems to 
promote B cell localisation in the marginal zone of spleen, in opposition to the 
effect of the follicular-homing chemokine CXCL13 (Cinamon et al., 2004; 
Cinamon et al., 2008). The effect is continual B cell shuttling of antigen from the 
marginal zone to follicles, perhaps a mechanism to transport antigen from the 
blood to follicular dendritic cells. This is an essential requirement for the 
generation of T-dependent B cell responses. The essential role for S1P in high 
affinity B cell mediated immunity is further demonstrated by the fact that S1PR1 
on immunoglobulin G (IgG)-secreting plasma cells is required for their egress 
from the spleen into the blood, and ultimately residence in the bone marrow 
(Kabashima et al., 2006). 
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1.3.3.3.2 In Peripheral Tissues 
The amount of S1P is low in uninflamed peripheral tissues, but increases during 
acute inflammation (Graler et al., 2005). TNF-", VEGF and histamine open 
paracellular gaps between vascular endothelial cells, disrupting junctions and 
focal adhesion complexes (Wang and Dudek, 2009). S1P, bound primarily to 
high-density lipoproteins and albumin in blood, can enter the tissue and bind 
S1P receptors on tissue-infiltrating leukocytes and other cells. Inflammatory 
cytokines such as TNF-" upregulate sphingosine kinase 1 in multiple cell types 
(Taha et al., 2006) and therefore raise the intra- and extracellular levels of S1P 
at the inflamed site. Furthermore, platelets release S1P when activated by 
thrombin, and mast cells when triggered by Fc&R cross-linking (Jolly et al., 
2002; Jolly et al., 2004).  
The increased level of S1P in inflamed tissue effects both innate and adaptive 
cells. For example, stimulation of S1PR1 and 2 on mast cells induce cell 
chemotaxis and degranulation respectively (Olivera et al., 2007). S1P 
significantly enhances the endocytic capacity of mature DC (Maeda et al., 
2007), and can promote their chemotaxis (Czeloth et al., 2005). Tissue S1P 
might also act later in the immune response, when antigen-specific T cells have 
trafficked to the inflamed site. Agonism of S1PR1 inhibits movement of T cells 
across lymphatic endothelium. This is dependent on the interaction of LFA-1 
and VLA-4 on T cells with their ligands ICAM-1 and VCAM-1 on the basal 
surface of the endothelium (Ledgerwood et al., 2008). In this way, S1P would 
act to restrain exit of effector T cells from the inflamed site and thereby enhance 
protective immunity. 
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1.4 Signalling Cross-talk 
1.4.1 Between S1P and Chemokine Receptors 
Both S1P receptors and chemokine receptors belong to the G protein-coupled 
receptor superfamily. In many cases they utilise shared G protein-coupled 
signalling pathways, for example both S1PR1 and many chemokine receptors 
(such as CXCR4) couple to the G"i G protein and activate PI3K through the 
G#! subunit (Cyster, 2005). If the receptors are activated either simultaneously, 
or sufficiently close in time, crosstalk between the two signalling axes might be 
expected. 
It has already been explained that crosstalk between the CCR7 and S1PR1 
signalling pathways determines T cell egress decision-making at lymph node 
exit structures. Resting naïve and differentiated effector T cells express both 
S1PR1 and CCR7. S1PR1 (which promotes cell egress) is ligated by S1P 
accessed by pseudopodia that probe the inside of cortical sinusoids. CCL19 
and CCL21, the ligands of CCR7, are produced by stromal cells within the node 
and promote cell retention. CCR7 and S1PR1 provide opposing chemotactic 
cues and the signals are integrated to determine cell behaviour. Consistent with 
this model, downmodulation of surface S1PR1 allowed CCR7-deficient T cells 
to egress more efficiently than wild-type T cells, and treatment with pertussin 
toxin to inactivate G"i-dependent signalling of CCR7 restored egress of S1PR1-
deficient T cells (Pham et al., 2008). 
S1P can modulate T cell chemotaxis to other chemokines. The in vitro 
transendothelial migration of splenic T cells towards CXCL12 was enhanced by 
S1P, and peripheral lymph node -derived cells required S1PR signalling to 
migrate in response to the chemokine (Yopp et al., 2005). Others have 
demonstrated a dose-dependent effect of S1P on responses to chemokines. 
Pre-treatment of CD4+ T cells with 10-100 nM S1P resulted in increased 
chemotaxis towards CCL5 and CCL21, whereas pre-treatment with 300 nM to 3 
µM S1P strongly suppressed migration (Graeler et al., 2002).  
Cross-talk between S1PR and chemokine receptors has also been observed in 
non-lymphocyte immune cell subsets. S1PR1 overexpression in haematopoietic 
stem cells caused a reduction in surface CXCR4 and potent inhibition of ligand- 
induced chemotaxis and signalling responses (Ryser et al., 2008). Others have 
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shown that S1P receptor signalling can support CXCR4-dependent migration of 
endothelial progenitor cells (Walter et al., 2007) and haematopoietic stem cells 
(Whetton et al., 2003). S1P reduced neutrophil chemotaxis in response to 
CXCL8 or fMLP (Kawa et al., 1997). Interestingly, S1PR3 was found to 
heterodimerise with CXCR1, the receptor for CXCL8 (Rahaman et al., 2006). 
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1.4.2 Involving Non- G protein-coupled Receptors 
Crosstalk can occur between pathways of completely different types, for 
example between GPCR and receptor tyrosine kinases. In lymphocytes, 
interaction between chemokine or S1P signalling and that of the TCR, 
inflammatory cytokines, and growth factors has been described.  
The chemokine receptor CXCR4 shows cooperative interaction with the T cell 
receptor. Chemokine binding to CXCR4 resulted in physical association with the 
TCR, in a PI3K -dependent manner. This allows CXCR4 to utilise the ITAM 
chains of the CD3 complex to signal, in addition to the coupled G proteins. 
Simultaneous triggering of the TCR and chemokine receptor resulted in 
synergistic enhancement of activator protein-1 (AP-1) transcriptional activity, 
CD69 expression, and IL-10 and IL-12 secretion (Nanki and Lipsky, 2000; 
Kumar et al., 2006). 
TNF-", an important inflammatory cytokine, mediates many of its effects in an 
S1P-dependent manner. S1P is a co-factor for TRAF2 and is crucial for Tumour 
necrosis factor receptor (TNFR) coupling to NF-'B activation (Alvarez et al., 
2010). TNF-" -mediated activation of sphingosine kinase is also important for 
protection of endothelial cells from apoptosis (Xia et al., 1999). S1PR signalling 
is absolutely required for PDGF-induced chemotaxis. PDGF (and similarly 
VEGF) trigger the activation and translocation of SK1 to the plasma membrane, 
and inside out signalling of S1P through S1PR1 (Hobson et al., 2001; 
Rosenfeldt et al., 2001). TGF-# and S1PR signalling are co-dependent in some 
cell types, where both are expressed (Xin et al., 2004). In human keratinocytes, 
Smads 2 and 3 are phosphorylated in response to S1P or TGF-# stimulation, 
and this response is absolutely dependent on the presence of receptors for both 
compounds (Sauer et al., 2004). Similarly, the presence of TGF#RII and S1PR3 
is necessary for FTY720-induced Smad phosphorylation in renal mesangial 
cells (Xin et al., 2006). It has been speculated that a S1PR3 - TGF#RII complex 
might form on the cell surface. 
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1.5 Aims of this Study 
The overall aim of this investigation was to further our knowledge of the ways in 
which S1P regulates T cell migration. Existing work points to two main areas of 
interest. First, there is some evidence to indicate that S1P can modulate T cell 
responses to chemokines. This is however limited and mechanistic data is 
lacking. The second aspect concerns the regulation of T cell egress from lymph 
nodes. While it is known that S1P provides a necessary signal for cell exit under 
non-inflamed conditions, the situation after T cell activation is less well 
understood. In particular, there are outstanding questions over the dynamics of 
S1P signalling after cell activation, and the extent to which activated T cells 
show the same dependence as resting cells on S1P for exit from lymph nodes. 
 
The objectives of this study were: 
 
• To see whether S1P can affect the migration of T cells towards a 
prototypical homeostatic chemokine 
• To investigate the mechanism behind the regulation of this chemokine 
response by S1P 
• To describe the changes in S1PR1 signalling that occur after stimulation 
of T cells through their antigen-specific receptor 
• To identify the way in which S1PR1 signalling is controlled during T cell 
activation 
• To assess in vivo the relevance of modulation of S1P signalling in 
activated T cells 
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Chapter 2. General Materials and 
Methods 
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2.1 General Laboratory Procedure 
All work was carried out with Good Laboratory Practice and in a manner 
compliant with the Newcastle University Safety policy. Prior to use of laboratory 
reagents, appropriate COSHH and BIOCOSHH forms were read, understood 
and signed. 
Qualified staff provided training for the purpose of ensuring safe and efficient 
use of equipment and reagents. In particular, work with the Gamma Cell 
Irradiator was undertaken in compliance with the University Local Rules 
regarding radiation protection; these included and expanded upon relevant legal 
requirements. 
2.2 Tissue Culture 
2.2.1 Cells 
2.2.1.1 Cell Lines 
All of the cell lines used in this study were grown from stocks that had been 
stored in liquid nitrogen. They had been previously screened for the presence of 
mycoplasma (MycoAlert Mycoplasma Detection Kit, Lonza, Switzerland), and 
shown to be negative.  
Cells were recovered from cryostocks as follows. Cryovials were removed from 
the liquid nitrogen store and their contents thawed rapidly in a 37 °C waterbath. 
The cells were washed in an excess of phosphate-buffered saline (PBS; Sigma-
Aldrich, USA) then resuspended at an appropriate density in relevant medium. 
They were cultured for at least one week before use in experiments. 
2.2.1.1.1 Jurkat T Cells  
The Jurkat T cell line (ATCC TIB-152) was established from peripheral blood T 
cells taken from a 14 year-old human male suffering from acute T cell 
leukaemia. The cells have a lymphoblast morphology and grow in suspension, 
with a doubling time of approximately 48 hours. They are pseudodiploid, with a 
modal chromosome number of 46. 
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2.2.1.1.2 Molt 4 T Cells 
The Molt 4 T cell line (ATCC CRL-1582) was derived from cells taken from a 19 
year-old human male suffering a relapse of acute lymphoblastic leukaemia. The 
cells have a lymphoblast morphology and grow in suspension, with a doubling 
time of approximately 24 hours. They are hypertetraploid, with a modal 
chromosome number of 95. 
2.2.1.2 Primary T Cells 
Human peripheral blood and its derivatives were used in this study. Trained 
persons performed phlebotomy, and informed consent was gained in each 
instance of donation by healthy volunteers. Peripheral blood samples (volumes 
up to 20 ml) were dispensed into plastic tubes and immediately mixed with 100 
U/ml heparin (Sigma-Aldrich, USA) to inhibit coagulation. 
Leukocyte apheresis cones were procured from the Newcastle-upon-Tyne 
Donor Centre of the NHS Blood and Transplant Service. Briefly, these were 
prepared by the NHSBT as follows. Peripheral blood was separated into 
fractions of plasma, platelets, leukocytes and erythrocytes by centrifugation. 
Most of the platelets were retained for clinical use, and many of the red cells 
and leukocytes returned to the donor. The leukocytes that remained in the 
centrifugation cone were made available for research. Only cones prepared on 
the same day were used. 
T cells were isolated from either fresh peripheral blood samples or leukocyte 
apheresis cones. RosetteSep human T cell negative selection cocktail 
(StemCell Technologies, France) was mixed with peripheral blood (50 µl per ml 
respectively) or apheresis product (75 µl per ml) and left for 20 minutes at room 
temperature. Blood or apheresis product (now diluted one part to three parts 
PBS + 2 % foetal bovine serum (FBS; Lonza, Switzerland)) was layered at room 
temperature over Lympholyte-H (Cedarlane Laboratories Ltd, Canada), and 
then centrifuged at 800 g for 20 minutes. The T cells at the density-medium – 
plasma interface were transferred to a separate tube and washed twice with 
PBS + 2 % FBS before use. 
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2.2.2 Culture Method 
Cell culture was performed with sterile technique inside Class II Microbiological 
Safety cabinets. 
2.2.2.1 Cell Counting 
The density of cells in suspension was determined using a phase 
haemocytometer (Fisher Scientific, UK). 20 µl of cell suspension was applied to 
the slide underneath a coverslip. The number of cells within the 5 x 5 grid was 
counted using an inverted microscope at 200x magnification. This was 
multiplied by 1x104 to give an estimate of the number of cells per ml of 
suspension. 
Viable cell counts were determined using the Trypan Blue-exclusion method. 
Equal volumes of cell suspension and 0.4 % Trypan Blue solution (Sigma-
Aldrich, USA) were mixed thoroughly, and the non-blue cells enumerated using 
the haemocytometer. The cell density was calculated as before, accounting for 
the additional 2x dilution step. 
2.2.2.2 Cell Maintenance 
Cells were cultured at 37 °C in a humidified atmosphere adjusted to contain 5 % 
CO2. They were grown in plastic tissue culture plates of 6, 24 or 96 well format, 
or cultured in vented 25 cm2 or 75 cm2 flasks (Greiner Bio-one, Germany). 
Both the Jurkat T cell and Molt 4 T cell lines were grown in complete RPMI 
1640 medium. This comprised RPMI 1640 medium (Sigma-Aldrich, USA) 
supplemented with 2 mM L-Glutamine, 100 U/ml penicillin, 0.1 mg/ml 
streptomycin (all Sigma-Aldrich) and 10 % FBS (Lonza, Switzerland). Serum-
free RPMI 1640 medium was comprised as complete medium with the 
exception that the FBS was replaced with 0.5 % fatty acid-free bovine serum 
albumin (BSA; Sigma-Aldrich). Cells that had been previously cultured in 
serum-containing medium were washed once in PBS before resuspension in 
serum-free conditions. Primary human T cells were cultured in X-VIVO 15 
medium (Lonza, Switzerland). This was a chemically-defined serum-free 
medium that can support the survival of resting T cells and the proliferation of 
activated cells. The manufacturer confirmed that the medium did not contain 
sphingosine 1-phosphate, sphingosine or lysophosphatidic acid. 
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Jurkat T cells and Molt 4 T cells were maintained during routine culture at 
between 1x105 and 1x106 cells per ml. The cells were placed into fresh medium 
at least every 3 days. Resting human T cells were kept at a density of between 
1x106 and 1x107 per ml in X-VIVO 15 medium. They were adjusted to a density 
of 1x106 cells per ml before activation. 
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2.3 Reconstitution of S1P Receptor Ligands 
2.3.1 S1P 
D-erythro-sphingosine 1-phosphate (Sigma-Aldrich) was dissolved in methanol 
at 1 mg/ml by heating to 65 ºC until the solution was clear and colourless. The 
S1P was divided into 0.1 mg aliquots in glass vials then dried with a stream of 
nitrogen gas for long-term storage at -80 ºC.  
Before in vitro use the dried S1P was dissolved in 0.01 M NaOH at 1 mg/ml by 
heating to 80 ºC until the solution was clear and colourless. The S1P was then 
diluted into PBS + 0.5 % fatty acid-free BSA (Sigma-Aldrich) to a concentration 
of 125 $M S1P then aliquotted and used immediately or stored at -20 ºC for up 
to one month. 
2.3.2 SEW2871 
SEW2871 (Sigma-Aldrich) was dissolved in dimethyl sulphoxide (DMSO; 
Sigma-Aldrich) at a concentration of 2 mg/ml (% 4.54 mM). DMSO was added to 
the solid compound, and the product vial sealed. It was heated to 37 ºC in a 
waterbath and repeatedly vortexed until the solution was clear and colourless. 
The solution was then aliquotted into glass vials and stored at -20 ºC in the dark 
(for up to three months).  
Before use, the solution was brought to 37 ºC in a waterbath and vortexed to 
ensure that the SEW2871 was completely dissolved. The ligand was further 
diluted in RPMI + 0.5 % fatty acid-free BSA, unless otherwise specified. 
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2.4 Migration Assays 
2.4.1 General Principle 
Cell migration can be measured using a two-chamber assay, similar to that 
developed by Boyden (Boyden, 1962). Bare transwell permeable supports 
(Corning Life Sciences, polycarbonate-type; Sigma-Aldrich, USA) are placed 
into tissue culture plates, splitting each well into two compartments separated 
by a permeable membrane. The insert membrane is about 10 µm thick and 
covered densely with pores. Whereas chemoattractants and similar factors can 
easily diffuse across the membrane, cells may or may not be able to cross, 
depending upon the pore size selected.  
Cells suspended in medium are placed into the upper compartment, and 
medium with or without added factors into the lower compartment. The plate is 
left at 37 °C in an atmosphere of 5 % CO2 for a specified length of time 
(typically two to three hours). The number of cells that have entered the lower 
compartment after that time is determined, providing a measure of their 
migratory response. By placement of chemoattractant in the lower compartment 
alone, directional chemotactic responses up a gradient of chemokine can be 
studied. Alternatively, by placement of a specific stimulus in both compartments, 
the chemokinetic, non-directional effect on cell motility can be examined. 
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2.4.2 Specific Experimental Parameters 
Before each experiment the bottom and sides of each lower compartment were 
blocked for 1 hour with PBS + 1 % BSA.  
Lymphocyte and lymphocyte cell lines migrated across bare membranes. 
Resting primary human T cells migrated through membranes with 3 µm 
diameter pores, while the Jurkat and Molt 4 T cell lines, and primary 
lymphoblasts, migrated through 5 µm pores. All migration assays were 
performed in a base medium of RPMI 1640 + L-Glutamine + Penicillin + 
Streptomycin + 0.5 % fatty acid-free bovine serum albumin. Both 24 well format 
and 96 well format transwell systems were used. The total volumes of medium 
added to the upper and lower compartments, for the 24 and 96 well format 
inserts, were: 100 and 600 $l, and 75 and 235 $l respectively. 
Migration was measured after 2 hours incubation at 37 °C, 5 % CO2, unless 
otherwise stated. The inserts were removed and cells extracted from the lower 
compartments by pipetting of 500 µl or 200 µl (24 well format or 96 well format 
chambers respectively) of cell suspension from each compartment into separate 
tubes. A defined number of CountBright Absolute Counting Beads (Invitrogen, 
UK) was added to each tube, and absolute cell numbers determined using a 
flow cytometer. 
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2.5 Immunofluorescent Techniques 
Fluorescence is the phenomenon in which a substance absorbs light at a 
particular wavelength and then rapidly emits light at a slightly longer 
wavelength. Fluorochromes are functional groups that are fluorescent; they can 
be linked to molecules and larger structures in order to make them detectable 
with instruments configured to detect fluorescence. 
The immunofluorescent technique involves labelling a cell sample with 
fluorochrome-conjugated antibodies so that the quantity of fluorescence 
associated with a particular cell can be correlated to the abundance of a specific 
antigen. Intact cells can simply be incubated with antibodies to label surface 
antigens, or they can be permeabilised to allow access of antibodies to 
intracellular targets. 
2.5.1 Flow Cytometry 
The flow cytometer measures the optical properties of single cells as they pass 
through the functional core of the instrument. Allied with immunofluorescent 
staining, it can be used to measure the expression level of multiple surface and 
intracellular proteins by individual cells in a population. Proliferation of cells can 
be measured over time by labelling the starting population with a fluorescent 
dye (such as carboxyfluorescein succinimidyl ester (CFSE)).  
The input to the instrument is a single-cell suspension placed under pressure 
and focussed into a stream inside the flow cell. Laser light, focussed on each 
cell as it passes through the compartment, is scattered or absorbed by the 
sample. This light is detected by very sensitive components called 
photomultiplier tubes (PMT). One PMT lies in line with the laser light, and its 
output yields a forward-scatter (FSC) value; another is located perpendicular to 
the light source and yields a value for side-scatter (SSC). These measurements 
give some indication of the gross properties of individual cells; FSC and SSC 
values are loosely positively correlated with size and granularity respectively. 
The flow cytometer usually contains additional lasers that excite fluorochromes 
or fluorescent molecules inside or tagged onto the surface of cells in the 
sample. Photomultiplier tubes, situated perpendicular to the excitation lasers, 
detect the fluorescently-emitted light. These detectors are shielded with optical 
band-pass filters that permit the transmission of light of only a narrow range of 
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wavelengths. Each PMT is therefore capable of detecting light emitted from one 
or a few different fluorescent molecules. Table 1 details the fluorochromes used 
in this study and the corresponding flow cytometer settings. 
 
Wavelength of 
excitation laser light 
(nm) 
Fluorescent 
species 
Band-pass filter 
characteristics – mid-
point and width of 
transmission interval 
(nm) 
488 FITC 
CFSE 
RPE 
530 / 30 
530 / 30 
585 / 40 
633 APC 660 / 20 
 
Table 1. Fluorochromes and associated flow cytometer settings used in this 
investigation. Antibodies tagged with three different fluorochromes were used in this study. In 
some experiments, cells were labelled with the dye CFSE so that their division could be 
followed. This table shows the wavelengths of the excitation lasers, and the characteristics of 
the band-pass filters, that were used with respect to each fluorescent species. 
 
2.5.1.1 Compensation 
After excitation, fluorochromes and fluorescent dyes emit light over a range of 
wavelengths. The exact profile of the relative quantity of light emitted at different 
wavelengths by a particular fluorescent molecule is known as its emission 
spectrum.  
Multiple dyes and fluorochromes have overlapping emission spectra, and can 
be picked up by a single detector. In situations where multicolour labelling is 
used, it is necessary to subtract the contribution of emission of one fluorescent 
species to the signal in detectors other than the primary detector. This ensures 
that the size of the signal from any one detector corresponds only to the 
quantity of light emitted from one particular fluorochrome or dye. Compensation 
beads, labelled with each of the fluorochromes used in any individual 
experiment, are now typically used to facilitate this compensation process. 
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The problem described can be avoided entirely by using fluorochromes and 
dyes with emission spectra that do not overlap. In this study, for example, cells 
dyed with CFSE were also labelled with a CD69-specific antibody conjugated to 
APC. These fluorescent molecules have emission maxima of approximately 515 
nm and 660 nm respectively, and there is negligible spectral overlap. 
2.5.1.2 Instrument and Software 
A FACSCanto II flow cytometer (BD Biosciences) was used for data acquisition. 
The output data was analysed with either FlowJo 7.6 (Treestar, USA) or 
FACSDiva 6.1.3 software (BD Biosciences, USA). 
2.5.1.3 Method of Labelling Surface Proteins 
Typically, between 100 000 and 500 000 cells were stained in individual 12 x 75 
mm plastic test tubes. All steps were performed with ice-cold buffers and cells 
were kept on ice during the staining process and before data acquisition. Unless 
otherwise specified, the dot plots and histograms in this thesis represent at least 
10 000 events. 
After treatment or culture, cells were washed twice with PBS + 1 % BSA by 
sequential resuspension in 2 ml buffer and centrifugation at 500 g for 5 minutes. 
Cells were stained with primary antibody for between 20 minutes and 1 hour on 
ice. In some cases, cells were then stained with a secondary antibody (for 
coupling to a fluorochrome) for 1 hour on ice. Cells were washed three times 
with PBS + 1 % BSA then resuspended usually in the same buffer, in a volume 
of between 200 µl and 400 µl. Unless otherwise stated, samples were stained 
with an antigen-specific antibody and separately with a species and isotype-
matched antibody, coupled to the same fluorochrome, as a control. 
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2.5.2 Confocal Microscopy 
The confocal microscope can be used to generate detailed three-dimensional 
images of microscopic structures. Used in conjunction with immunofluorescent 
labelling, it is a powerful tool for measuring the expression level and 
determining the localisation of specific proteins within or on the surface of 
individual cells. 
The microscope functions as follows. Laser light is focussed onto a small region 
(the focal volume) within the sample. Light reflected from, or emitted by (in the 
case of fluorescence), that precise region is allowed to reach the detector 
(usually a photomultiplier tube). Light originating from outside that particular 
volume is blocked. In the case of fluorescence microscopy, band-pass filters are 
placed in front of detectors so that only fluorescently-emitted light is received. 
The signal from a detector is used to generate a single image unit – a pixel – 
corresponding to the original focal volume. So, with multicolour labelling and 
appropriate detectors, many units of information can be gathered from an 
individual focal volume. By scanning across (x and y axes) and through (z axis) 
a specimen, and acquiring each pixel of information, an image can be 
assembled. 
2.5.2.1 Instrument and Software 
Data was captured with a TCS SP II AOBS UV confocal microscope (Leica 
Microsystems, Germany). Samples were illuminated with a 488 nm argon laser 
for excitation of the FITC fluorochrome, and with a 405 nm diode laser for the 
DNA stain 4,6-diamidino-2-phenylindole dihydrochloride (DAPI). Analysis was 
performed with LCS software (also Leica Microsystems). 
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2.5.2.2 Method of Immunolabelling 
Cytospins were prepared for staining as follows. Suspension cells were washed 
with cold PBS + 1 % BSA. 50 – 100 000 cells were cytospun at 1000 rpm for 3 
minutes (Shandon Cytospin 3, Thermo Scientific, USA) onto charged glass 
slides (Superfrost Plus, VWR) and left to air-dry. The cells were fixed in 
methanol at -20 ºC for 10 minutes and air-dried. The section was circumscribed 
with a hydrophobic barrier pen (Delimiting Pen, Dako, Denmark). 
The cells were blocked for 1 hour with PBS + 1 % BSA. They were stained 
overnight, in a humidified box at 4 ºC, with primary antibody diluted into PBS + 1 
% BSA. The cells were washed twice for 5 minutes with PBS then stained with 
a fluorescently-conjugated secondary antibody (diluted into PBS + 1 % BSA) for 
three hours. The cells were washed three times for 5 minutes with PBS. The 
sections were counterstained with 1 µM DAPI for 2 minutes and washed once 
more with PBS. They were then mounted with fluorescent mounting medium 
(Dako) and coverslip. Slides were stored in the dark at 4 °C and examined 
within two weeks with the confocal microscope.  
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2.6 Western Blotting 
2.6.1 Preparation of Whole Cell Lysates 
Cells were treated as described then washed in cold PBS and lysed with a 
buffer containing protease and phosphatase inhibitors (CelLytic M (Sigma 
Aldrich, USA)), Complete Protease Inhibitor Cocktail (Roche), Halt Phosphatase 
Inhibitor Cocktail (Pierce, Thermo Scientific, USA). As a guide, approximately 
30 µl buffer was used per million cells to be lysed. 
2.6.2 Protein Quantification 
Protein concentrations were determined using a bicinchoninic Acid (BCA) assay 
kit (Pierce, Thermo Scientific, USA). This is based upon the Biuret test, in which 
peptide bonds reduce Cu2+ ions to Cu1+ ions in an alkaline solution. Two 
molecules of BCA then chelate each Cu1+ ion, forming a purple reaction 
product. A spectrophotometer can therefore be used to correlate the intensity of 
absorbance of light at a specific wavelength (562 nm) and the abundance of 
peptide bonds in a sample of defined volume.  
Equal volumes of unknown samples were assayed in duplicate along with the 
standards (typically 0, 125, 250, 500, 1000, 2000 and 4000 µg/ml BSA) for each 
experiment. 10 µl of samples and standards were mixed with BCA working 
reagent in a 96 well plate. After 20 minutes incubation at room temperature 
absorbances were measured using a spectrophotometer. A linear regression 
was performed with the standard data, and sample concentrations estimated by 
interpolation. A representative standard curve is shown in Figure 4.
 53!
Figure 4. BCA standard curve. 
Bovine serum albumin was dissolved in PBS at 125, 250, 500, 1000, 2000 and 4000 
µg/ml. 10 µl of each standard and PBS alone were assayed in duplicate. The 
absorbances at each concentration have been plotted and a best-fit line (least-
squares algorithm) is shown. Points are means ± s.e.m. 
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2.6.3 SDS-PAGE 
Sodium dodecyl sulphate - polyacrylamide gel electrophoresis (SDS-PAGE) is a 
process in which proteins contained within a sample are separated according to 
their size as they move through a small pore matrix of polyacrylamide. This 
concept is based on the technique described by Laemmli (Laemmli, 1970). The 
sample is first denatured with a reducing agent in the presence of the anionic 
detergent SDS. The reducing agent breaks disulphide bonds holding together 
the higher-order structure of the proteins, and the polypeptide chain becomes 
associated with SDS molecules. The number of bound SDS molecules is 
proportional to the length of the polypeptide chain, therefore the magnitude of 
the electrical charge is approximately proportional to protein mass. By applying 
an electric field across the polyacrylamide gel, proteins are induced to migrate 
from the sample well through the gel towards the anode. Smaller proteins move 
relatively faster than larger proteins, leading to separation of the individual 
protein components. 
2.6.3.1 Specific Experimental Parameters 
Generally, between 10 and 40 µg protein were loaded per lane of a 0.75 mm 
thick 12 % resolving polyacrylamide gel. Samples were mixed with 5 parts 
lysate to one part 6x SDS sample loading buffer (300 mM 
Tris(hydroxymethyl)aminoethane (Tris).Cl (pH 6.8), 600 mM diothiothreitol, 12 
% (w/v) SDS, 0.6 % bromophenol blue, 60 % glycerol (all Sigma-Aldrich)), 
heated to 99 °C for 10 min, then loaded onto the gel. 
10 µl Prestained Protein Marker, Broad Range (New England Biolabs) was 
loaded into one well of each gel prior to electrophoresis. The proteins contained 
in the mixture were covalently-conjugated to a blue dye. The apparent 
molecular weight of the proteins in the ladder were 175, 80, 58, 46, 30, 25, 17 
and 7 kDa. 
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Composition of Polyacrylamide Gels 
4 % stacking gel 12 % resolving gel 
1.8 ml 30 % (w/v) acrylamide / bis-
acrylamide solution 
5.0 ml stacking gel buffer (0.25 M 
Tris.HCl, 0.2 % (w/v) SDS, pH 6.8) 
4.0 ml water 
50 µl 10 % (w/v) ammonium 
persulphate solution 
10 µl N,N,N,N – 
tetramethylethylenediamine 
7.5 ml 30 % (w/v) acrylamide / bis-
acrylamide solution 
9.0 ml resolving gel buffer (0.75 M 
Tris.HCl, 0.2 % (w/v) SDS, pH 8.8) 
2.0 ml water 
180 µl 10 % (w/v) ammonium 
persulphate solution 
18 µl N,N,N,N - 
tetramethylethylenediamine 
 
Proteins were separated using a mini vertical electrophoresis unit (SE260, GE 
Life Sciences). The proteins were separated in a discontinuous buffer system, 
with a Tris-Glycine electrophoresis buffer (0.025 M Tris.Cl, 0.192 M Glycine, 0.1 
% (w/v) SDS, pH 8.3). Running conditions were: constant current of 20 mA per 
gel, for between one and two hours at room temperature. 
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2.6.4 Wet Electroblotting 
Proteins were transferred from the polyacrylamide gel to polyvinylidene fluoride 
(PVDF) membrane by wet electroblotting in a tank transfer unit (TE22, GE Life 
Sciences). The transfer buffer was comprised 0.025 M Tris, 0.192 M Glycine, 20 
% methanol. Running conditions were either 250 mA constant current for 90 
minutes, or 30 V constant voltage overnight, both with water cooling. 
2.6.5 Immunoblotting 
The PVDF membrane was typically blocked: for 1 hour in 5 % (w/v) milk powder 
(Marvel, Premier Foods) in Tris-buffered saline solution + 1% Tween 20 (TBST) 
for non-phospho-protein targets; for 1 hour in 5 % (w/v) essentially 
immunoglobulin-free bovine serum albumin (Sigma-Aldrich) in TBST for 
phospho-protein targets. TBST was Tris-buffered saline solution (20 mM 
Tris.HCl, 137 mM NaCl, pH 7.6) supplemented with 0.1 % v/v Tween-20 
(Sigma-Aldrich).  
The membrane was rinsed in TBST then incubated with primary antibody, 
diluted into blocking buffer, for 3 hours at room temperature or overnight at 4 
°C. The membrane was washed three times for 10 minutes with TBST.  
The membrane was incubated for 1 hour with secondary antibody (specific for 
the species of the primary antibody, and coupled to horseradish peroxidase) 
diluted into blocking buffer. After four washes of 10 minutes with TBST, the 
bound secondary antibody was detected by enhanced chemiluminescence 
(Pierce SuperSignal West Pico Substrate and Kodak film). 
2.6.5.1 Reprobing Western Blots 
Stripping is the process in which primary and secondary antibodies are 
detached from the PVDF membrane. The PVDF membrane may be re-probed 
for a second target without interference from antibodies bound in the first round 
of blotting. Here, the membrane was stripped by incubation of the membrane 
with a low pH buffer (0.2 M Glycine, 0.1 % (w/v) SDS, 1 % Tween-20, pH 2.2; 
all Sigma-Aldrich).  
After the first chemiluminescent reaction, the membrane was washed three 
times with TBST for 10 minutes then placed into an excess of stripping buffer. 
The membrane was incubated with this buffer for a total of 1 hour, replacing 
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with fresh buffer every 15 minutes. The membrane was then washed three 
times 10 minutes with TBST before re-probing. 
2.7 Measurement of Gene Expression 
Gene expression involves first transcription of genomic DNA to messenger 
ribonucleic acid (mRNA), then translation of mRNA into protein. Some 
expressed genes are not translated; RNA is the functional product. This 
includes certain ribosomal RNA (rRNA) such as 18S. The abundance of a 
specific mRNA species in a cell usually, but not always, gives a good indication 
of the amount of corresponding protein. It is important to note that other 
regulatory mechanisms, such as those controlling protein turnover, can result in 
a significant disparity between the quantity of observed protein and abundance 
of its coding mRNA. Nevertheless, measurement of the abundance of specific 
mRNAs is used to compare gene expression between different types of cells 
and before and after application of various stimuli to them. 
2.7.1 RNA Isolation 
In this study, total RNA was extracted from cells using TRI Reagent (Sigma-
Aldrich). The sample (tissue or cell pellet) is first homogenised in a mixture of 
phenol and guanidine thiocyanate. The latter compound helps to completely 
denature the released proteins. These include, importantly, nucleases that 
might otherwise degrade the exposed nucleic acids. The RNA, DNA and protein 
components are then separated from each other by addition of chloroform. The 
RNA can be extracted, washed and then resuspended for use in various 
reactions. 
In detail, the preparation of RNA proceeded as follows. Typically, 2 - 5x106 cells 
per prep. were washed with cold PBS then pelleted. Each sample was 
homogenised in 1 ml TRI Reagent. The homogenate was then incubated at 
room temperature for 5 minutes to ensure complete dissociation of 
nucleoprotein complexes. 0.2 ml of chloroform was added and the components 
mixed. After 2 to 3 minutes incubation at room temperature the sample was 
centrifuged at 12 000 g for 15 minutes at 4 °C. The aqueous phase containing 
the RNA was extracted to a separate tube and the remainder discarded. The 
RNA was then precipitated with 0.5 ml of isopropanol, incubating the mixture for 
10 minutes at room temperature. The RNA was pelleted by centrifugation at 12 
 58!
000 g for 10 minutes at 4 °C, then washed with 75 % ethanol (7500 g for 5 
minutes at 4 °C). Finally, the RNA was resuspended in water (typically 50 µl per 
sample). RNA samples were aliquotted and stored at -80 °C. 
The water used to resuspend the RNA was previously treated with 
diethylpyrocarbonate (DEPC). Briefly, DEPC was added to deionised (>18 M&) 
distilled water to a final concentration of 0.1 %, and the mixture incubated at 
room temperature for 1 hour. The DEPC was then removed by autoclaving, 
yielding a supply of water free of RNase activity. 
Every RNA preparation was examined by spectrophotometry (Figure 5) using a 
Nanodrop instrument (Thermo Scientific). Only those with a ratio of 
absorbances at 260 nm and 280 nm close to 2, and a relatively low absorbance 
at 230 nm (indicative of a pure preparation) were used in further experiments. 
 
Figure 5. A typical absorbance spectrum of an RNA sample. 
5x106 Molt 4 T cells were washed in cold PBS then pelleted. Total RNA was prepared following 
the method previously described. 2 µl of the sample was taken and measured on the Nanodrop 
spectrophotometer. The absorbance spectrum is shown in the figure. The ratio of the 
absorbances at 260 nm and 280 nm, and at 260 nm and 230 nm, are 2.00 and 2.09 
respectively. 
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2.7.2 cDNA Synthesis 
In order for the relative quantities of specific RNA species to be measured, they 
must first be copied to form complementary DNA (cDNA). Reverse 
transcriptases can copy RNA to cDNA; these enzymes are present in a number 
of viruses that employ reverse transcription as part of their replication cycle in 
host cells. Reverse transcriptase (RT) is strictly an RNA-dependent DNA 
polymerase. It binds an RNA template and catalyses the formation of a 
complementary single-stranded DNA molecule. RT usually also have 
ribonuclease H (RNase H) activity and degrade the RNA template as the DNA 
strand in synthesised.   
Here, the enzyme SuperScript III (Invitrogen) was used. It is an engineered 
version of Moloney Murine Leukaemia Virus reverse transcriptase. The cDNA 
synthesis reactions were primed with random hexamers. This is a very non-
specific priming method, facilitating the copying of almost all RNA species 
present, including non-polyadenylated RNA. 
cDNA synthesis reactions were performed in thin-walled polymerase chain 
reaction (PCR) tubes (VWR) placed into a G-Storm GS482 Thermocycler 
(Labtech International, UK). A typical reaction proceeded as follows. 1 µg RNA 
was mixed with 500 ng random hexamers (Invitrogen, USA) and 10 mM 
deoxynucleotide triphosphates (dNTPs) (Rovalab, Germany) in a 13 µl reaction 
volume at 65 °C for 7 minutes. The following components were then added: 4 µl 
5x first strand buffer, 1 µl 0.1 M dithiothreitol, 1 µl (100 U) SuperScript III 
enzyme (all Invitrogen). The tube was incubated for 5 minutes at 25 °C, then the 
temperature raised to 50 °C for 1 hour. Finally, the enzyme was inactivated at 
70 °C for 15 minutes. The cDNA was aliquotted and stored at -80 °C before 
use. 
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2.7.3 Real-time PCR 
2.7.3.1 Principles of PCR 
Polymerase chain reaction is an enzyme-catalysed process in which sections of 
DNA are amplified geometrically to yield many copies of the original sequence. 
A heat-stable DNA-dependent DNA polymerase (such as Taq polymerase) 
elongates from oligonucleotide primers complementary to short sequences on 
the sense and anti-sense strands at either end of the target DNA sequence. 
The use of a heat-stable polymerase in a thermal cycling process is 
fundamental to the reaction. In the first step, complementary DNA strands in 
which the target sequence is located are separated at high temperature 
(generally around 95 °C for 15 seconds). The reaction mixture is then cooled (to 
a temperature dependent upon the primer sequences and composition of the 
reaction mixture, but typically in the range 40 - 60 °C) for 1 minute and the 
oligonucleotide primers anneal to their specific sequences at either end of the 
target. The temperature of the reaction mixture is then raised (usually to 
temperatures in the region of 72 °C, and for 1 – 2 minutes for amplicons up to 2 
kb) and the polymerase catalyses the addition of complementary dNTPs to the 
elongating strands in the 5’ to 3’ direction. The thermal cycling process is then 
repeated, usually for between 20 and 40 cycles. This results in geometric 
amplification of the sequence bounded by the forward and reverse primers, with 
the number of copies equal to 2n, where n is the number of cycles.  
Careful primer design is necessary to achieve an optimal PCR reaction. The 
length and specificity of the primers, their annealing temperature, and their 
affinity for each other must all be considered. There are software-based 
packages such as OligoPerfect (Invitrogen) that can assist with this. 
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2.7.3.2 Real-time PCR 
Real-time polymerase chain reaction (RT-PCR) is an adaptation of basic PCR. 
In RT-PCR the progress of the reaction is followed as it proceeds, allowing the 
(relative or absolute) quantity of copies of a particular target at the start of the 
reaction to be calculated. Slightly different reaction components and measuring 
equipment to those used in standard PCR are required. RT-PCR stands in 
contrast to end-point PCR; in the latter process a specific sequence is amplified 
for a set number of cycles and the quantity of copies determined at the end of 
the reaction. 
2.7.3.2.1 TaqMan Gene Expression Assays 
TaqMan Gene Expression Assays (Applied Biosystems, USA) were used in this 
investigation. TaqMan MGB fluorescent probes, specific for the target 
sequence, were added to each reaction mixture at the start. 
Briefly, the TaqMan technology functions as follows. The fluorescent probes 
have the reporter fluorescent dye 6-FAM at their 5’ end, and the quencher MGB 
at their 3’ end. An intact probe does not fluoresce due to the proximity of the 
reporter and quencher that are anchored to the sequence. During each cycle, 
when the reaction mixture cools after the denaturation step, the probe is able to 
hybridise with its target sequence. The number of probes that bind in any one 
reaction is proportional to the number of copies of target sequence. During the 
following elongation step, the polymerase encounters the bound probe and the 
5’ nuclease activity of the enzyme separates the reporter from the quencher. 
The reporter becomes fluorescent. The detection instrument excites the free 
reporter molecules and measures the fluorescently-emitted light. The amount of 
fluorescence is proportional to the number of copies of the target sequence, 
assuming the other components (such as the probes and enzyme) are not 
limiting.  
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A typical RT-PCR reaction was comprised: 1 µl TaqMan Gene Expression 
Assay (primer and probe mix; Applied Biosystems), 9 µl cDNA (50 ng equivalent 
of RNA), and 10 µl TaqMan Universal PCR Master Mix (including polymerase 
and dNTPs; Applied Biosystems). For the 18S control, 9 µl cDNA (diluted 5000x 
to 0.01 ng equivalent of RNA) was used. Control reactions without cDNA 
template were run for each assay, with no amplification observed. 
The reactions took place in 96 tube format PCR plates (VWR) placed into an 
ABI Prism 7000 Sequence Detection System (Applied Biosystems) instrument, 
which recorded the fluorescence of each reaction tube after each thermal cycle. 
The following program was used: one cycle; 2 minutes at 50 °C, then 10 
minutes at 95 °C; forty cycles, 15 seconds at 95 °C, then 1 minute at 60 °C. 
2.7.3.2.2 Relative Quantitation of Gene Expression 
Experiments to compare gene expression between samples were designed and 
analysed following the instructions set out in the Guide to Performing Relative 
Quantitation of Gene Expression Using Real-Time Quantitative PCR (Applied 
Biosystems). 
Inventoried TaqMan Gene Expression Assays (Applied Biosystems) were used 
for the quantitation of expression of S1PR1 (ID: Hs00173499_m1), S1PR3 
(Hs01019574_m1) and 18S (Hs99999901_s1). The primers and probes for 
S1PR1 and S1PR3 were exon-spanning, so as to avoid interference from any 
contaminating genomic DNA. 18S was used as the endogeneous control. 
Equal quantities of cDNA from the samples to be compared were run, in 
triplicate, using the same reaction conditions. The relative quantities of the 
target cDNA sequence in the samples were inferred from their corresponding 
amplification curves: specifically, the number of cycles taken for 'Rn to reach a 
common threshold. This was set where geometric amplification of the target 
sequence was seen to begin.  
Data was expressed in the 2-'Ct format, where 'Ct = Ct [target] – Ct [reference]. 
The Ct values used in this equation were the mean of the three corresponding 
raw output values.  
The uncertainty in the value of 'Ct was calculated as follows:  
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sdelta =  ((starget2 + sreference2); where sdelta is the standard deviation of the 'Ct 
value, starget is the standard deviation of the Ct [target] value and sreference is the 
standard deviation of the Ct [reference] value. 
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2.8 Statistics 
For the real-time PCR data, differences between groups were tested for 
significance using Rest 2008 software (Corbett Research, UK). Else, the 
Student’s two-tailed t test for unpaired data was used to compare groups.  
Statistical analysis and graphing of data was performed with Prism 4.0c 
software (GraphPad Software, USA).  
P values less than or equal to 0.05 were considered significant (*), P ) 0.01 
highly significant (**), and P ) 0.001 very highly significant (***). 
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Modulation by S1P of T cell Responses to CXCL12 
3.1 Introduction 
Chemokines are small proteins that control immune cell migration around the 
body. Some are produced constitutively and function in homeostatic processes, 
such as the regulation of lymphocyte recirculation. Others cause the migration 
of immune effectors to inflamed sites and are produced on inflammatory 
signalling in certain cell types (Rossi and Zlotnik, 2000). More recently, it has 
become clear that the endogeneous lysophospholipid sphingosine 1-phosphate 
is another important player in regulation of leukocyte migration in vivo (Spiegel 
and Milstien, 2011). G protein-coupled receptors for both chemokines and S1P 
are present on T cells, and T cells can be exposed to one or both substances 
simultaneously during their life cycle. Published work has lent support to the 
hypothesis that the chemokine and S1P signalling pathways may interact in 
determining the precise nature of leukocyte migration. For example, signalling 
of both the S1P receptor S1PR1 and the chemokine receptor CCR7 influence 
egress decision making of T cells at lymph node exit sites (Pham et al., 2008). 
The family of receptors for S1P are denoted S1PR1-5. Splenic T cells express 
predominantly S1PR1 and S1PR4, and much lower levels of S1PR3 and 
S1PR5 (Graeler and Goetzl, 2002). Although S1PR3 is expressed at a very low 
level by resting T cells, it is upregulated on activation of splenic T cells (Graeler 
and Goetzl, 2002), albeit still to a low level, and is expressed strongly by the 
Jurkat activated T cell line (Jin et al., 2003). S1PR4 does not appear to have 
any role in control of T cell migration, but can alter T cell proliferation and 
cytokine secretion (Wang et al., 2005). S1PR1 is more highly expressed than 
S1PR4 and S1P has a greater affinity for the former (Kd = 8 nM and 63 nM 
respectively) (Lee et al., 1998; Van Brocklyn et al., 2000). S1PR1 is required for 
T cell egress from lymph nodes and agonism of the receptor can induce the 
chemotaxis of resting T cells (Matloubian et al., 2004). S1PR1, similarly to many 
other GPCR, is desensitised, by receptor internalisation, on chronic exposure to 
its ligand S1P (Oo et al., 2007). 
This property of the receptor is an important determinant of the in vivo effects of 
S1P. The effect of the vascular gradient of S1P is to induce cyclical modulation 
of surface S1PR1 on T cells as they transit through the various lymphoid 
compartments, and thereby changes in the responsiveness of T cells to 
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signalling through the receptor (Lo et al., 2005). The re-acquisition of surface 
S1PR1 on T cells in the S1P low environment of lymphatic tissue is essential for 
their capacity to egress. Abrogation of surface S1PR1 expression using 
FTY720, a super-agonist of the receptor, blocks T cell egress (Matloubian et al., 
2004). Inside resting lymph nodes, T cells located close to cortical sinuses 
probe the insides of the structures and sample S1P there (Grigorova et al., 
2009). Ligands for the entry receptor CCR7, CCL19 and 21, are expressed 
abundantly by antigen-presenting and stromal cells in the lymph node cortex 
(Luther et al., 2000; Vissers et al., 2001). These act to retain lymphocytes within 
the node. Signalling of S1PR1 seems to antagonise such retention signals 
thereby promoting egress (Pham et al., 2008). 
Recent evidence has shown that S1P can modulate chemotaxis of T cells and 
other leukocyte subsets to many other chemokines. S1P has been shown to 
reduce chemotaxis of neutrophils towards the end-stage chemoattractants 
CXCL8 and fMLP (Kawa et al., 1997). S1P enhanced the migration of splenic T 
cells towards CXCL12 and was required for the movement of peripheral lymph 
node derived cells towards the same chemokine (Yopp et al., 2005). Dose-
dependent effects of S1P have also been reported. Whereas pre-treatment of 
CD4+ T cells with 10-100 nM S1P resulted in increased chemotaxis of CD4+ T 
cells towards CCL5 and CCL21, 300 nM to 3 µM S1P strongly suppressed 
migration towards them (Graeler et al., 2002). Although such studies clearly 
indicate an effect of S1P on migration towards certain chemokines, they have 
not examined in detail the effect of S1P on responses of T cells to a particular 
chemokine. 
CXCL12 is a prototypical homeostatic chemokine. It is pleiotropic with very well 
established roles in immune homeostasis, inflammation and cancer (Karin, 
2010). It is constitutively expressed and found in a number of compartments 
alongside S1P. CXCL12 along with CCL19 and CCL21 is present on the luminal 
surface of high endothelial venules under basal conditions and they act in 
concert to direct movement of resting T cells into secondary lymphoid tissue. 
CXCL12 seems to sensitise T cells to CCR7 signalling, augmenting CCR7 
responses including ERK phosphorylation and actin polymerisation (Bai et al., 
2009). CXCL12 appears to play a role in the homing of T cells to multiple 
tissues under basal and inflamed conditions. CXCL12 promotes LFA-1 
 68!
interaction with ICAM-1 (Campbell et al., 1998), and "4#7 interaction with 
MAdCAM-1 and fibronectin (Wright et al., 2002). In addition to these effects on 
migration, there is also abundant evidence for CXCR4 -mediated effects on T 
cell activation (Molon et al., 2005). CXCR4 utilises the TCR ITAM domains for 
signal transduction. It can also act synergistically with T cell activation to 
enhance cytokine secretion (Kumar et al., 2006). 
In this study, bare transwell assays were used to investigate the effect of S1P 
on T cell chemotaxis. This meant that the effect of S1P on endothelial barrier 
permeability did not need to be considered. Signalling assays were also used to 
probe the effect of S1P treatment on multiple pathways downstream of CXCR4 
ligation. Pre-treatment with a high concentration of S1P (and the S1PR1 
selective agonist SEW2871) enhanced the migration of Jurkat T cells towards 
the homeostatic chemokine CXCL12. This appeared to be a highly selective 
effect. It was not due to an S1P-mediated effect on surface abundance of a 
receptor for this chemokine, CXCR4. Nor did it correlate with other ligand-
induced responses to CXCL12 including the magnitude of ERK 1/2 
phosphorylation and inhibition of adenylate cyclase activity. Interestingly, S1P 
pre-treatment did not affect migration of Molt 4 T cells (which have a different 
S1P receptor profile) towards the same chemokine. 
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The aims of this chapter were as follows: 
• To examine the responses of Jurkat T cells to S1P 
• To determine whether or not the migration of Jurkat T cells towards 
CXCL12 was affected by S1P pre-treatment 
• To investigate how signalling downstream of CXCR4 was modified by 
S1P 
• To compare the effects of S1P on Jurkat T cell and Molt 4 T cell 
responses to CXCL12 
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3.2 Materials and Methods 
Agarose gel electrophoresis 
For analysis of RNA quality, the RNA was first heated to 65 ºC for 5 minutes. 1 
µg total RNA per lane was then separated by electrophoresis in a 1 % agarose 
gel in Tris – boric acid – EDTA buffer (pH 8.3). 
For analysis of PCR products, half of a 25 µl reaction (starting with a quantity of 
cDNA equivalent to 100 ng RNA input into the RT reaction) was run per lane. 
DNA was separated in a 1 % agarose gel in Tris - boric acid – EDTA buffer. 
All gels were pre-stained with ethidium bromide (0.5 µg/ml). They were 
visualised under UV illumination after electrophoresis. Images were captured 
using an AlphaImager system (Alpha Innotech, USA). 
cAMP assays 
In each experiment, cells were stimulated with the specified concentration of 
forskolin (Sigma Aldrich) with or without the specified receptor ligand for 30 
minutes at 37 ºC in 5 % CO2. Cyclic adenosine monophosphate (cAMP) was 
detected using a colorimetric competitive-binding assay kit (R&D Systems). 
Briefly, the procedure was as follows. After stimulation, the cells were washed in 
cold PBS then pelleted. cAMP was released by lysis in the supplied acidic 
buffer then three freeze-thaw cycles in liquid nitrogen and a 37 ºC waterbath. 
Samples were mixed with known quantities of horseradish peroxidase-
conjugated cAMP, and the non-conjugated cAMP originating from the sample 
left to compete for binding to a capture antibody. After washing, enzyme activity 
was measured using the catalysed conversion of a specific substrate to a 
product absorbing light at 450 nm (measured on a Dynex MFX instrument). A 
standard curve was run for each assay using known concentrations of 
unconjugated cAMP as the competitor. The concentration of cAMP in each 
experimental sample was inferred from the curve by interpolation, using the 
corresponding absorbance values. 
PCR and Real time PCR 
RNA was prepared from cell pellets using TRI reagent (Sigma Aldrich). cDNA 
was synthesised using SuperScript III Reverse Transcriptase and random 
hexamers as primers (Invitrogen). 
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Standard end-point PCR. A 570 bp sequence within the human GAPDH gene 
was amplified from cDNA (a volume equivalent to 100 ng RNA input into the 
prior RT reaction) using TaqMan Universal PCR mastermix (Applied 
Biosystems). The thermocycling parameters were: 10 minutes at 95 ºC (1 
cycle); 30 seconds at 95 ºC, 1 minute at 65 ºC, 30 seconds at 72 ºC (35 cycles). 
The primer sequences were: 
GAPDH forward: 5’ ACCCAGAAGACTGTGGATGG 3’ 
GAPDH reverse: 5’ AGGGGTCTACATGGCAACTG 3’. 
Real-time PCR. Expression of S1PR1 and S1PR3 were determined semi-
quantitatively using specific TaqMan Gene Expression assays 
(Hs00173499_m1 and Hs01019574_m1 respectively), with 18S as the 
reference (Hs99999901_s1; all Applied Biosystems). The amplifications were 
run on an ABI Prism 7000 instrument (Applied Biosystems). 
Phospho-kinase array 
Cells were treated as described, washed in cold PBS then lysed. The protein 
content of lysates was measured by BCA assay. Equal quantities of total protein 
were assayed in parallel using a Proteome Profiler Phospho-kinase Array kit 
(R&D Systems). This used nitrocellulose membranes covered with an array of 
capture antibodies against various protein targets. Lysates were washed over 
the membranes and proteins left to bind overnight. Proteins bound to the array 
membrane were then detected by immunoenzymatic labelling and enhanced 
chemiluminescence (recorded onto X-ray film). The film was scanned and the 
intensities of the dots on the array (mean gray value in a region of constant 
area) measured using Photoshop CS3 v10 software (Adobe Systems). The 
signal corresponding to each protein was normalised to the intensity of the 
appropriate positive control spot on each membrane section. 
Flow cytometry 
For flow cytometry, Jurkat and Molt 4 T cells were stained with various 
fluorochrome-conjugated monoclonal antibodies or appropriate isotype-matched 
control antibodies. The specific antibodies used were: S1PR1 (218713; R&D 
Systems), CXCR4 (12G5; R&D Systems). Data was acquired on a FACSCanto 
II instrument (BD) and analysis performed using FACSDiva (BD) and FlowJo 
(Treestar) software. 
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For immunofluorescence confocal microscopy, Jurkat T cells were blocked for 1 
hour with PBS + 1% BSA, before sequential staining with anti-human S1PR3 
antibody (SC22210; Santa Cruz Biotechnology), fluorescein-conjugated anti-
goat IgG (F2016, Sigma Aldrich), and DAPI (Sigma Aldrich). Images were 
captured with a Leica TCS SP2UV confocal microscope and analysed with 
Leica LCS Lite software. 
Western blotting and ELISA 
Proteins were separated by SDS-PAGE and transferred to PVDF membrane as 
previously described. The primary antibodies used for immunoblotting were: 
pERK 1/2 [T202/Y204] (SC16982; Santa Cruz Biotechnology), ERK 1 [pan] 
(MK12; BD Biosciences), phospho-Akt [Ser473] (D9E; Cell Signaling 
Technology), Akt [pan] (C68E7; Cell Signaling Technology), "-tubulin (B-5-1-2; 
Sigma Aldrich), S1PR1 (H-60; Santa Cruz Biotechnology), phosphorylated 
lymphocyte-specific protein tyrosine kinase (pLck) [Y394] (SC101728; Santa 
Cruz Biotechnology), Lck [pan] (SC28882; Santa Cruz Biotechnology). The 
secondary antibodies were: horseradish peroxidase-conjugated anti-rabbit IgG 
(A6154; Sigma Aldrich), anti-mouse IgG (A9044; Sigma Aldrich) and anti-goat 
IgG (A5420; Sigma Aldrich). 
Phospho-ERK 1 [T202/Y204] / 2 [T185/Y187] and ERK 1/2 [pan] were also 
detected using a cell-based enzyme-linked immunosorbent assay (ELISA) 
(R&D Systems). 100 000 Jurkat T cells were added to each well of a 96 well-
format plate (coated beforehand with 10 µg/ml poly-lysine in PBS (Poly-L-Lysine 
hydrobromide; Sigma Aldrich) for 30 minutes) and left to attach for 1 hour. The 
cells were then treated as desired before fixation with 8 % formaldehyde. 
Phospho-ERK 1 / 2 and ERK 1 / 2 were detected by double immunoenzymatic 
labelling. The relative quantities of these proteins were deduced from the 
spectrally distinct fluorescence of substrates associated with each target. Data 
was acquired on a Dynex MFX instrument operating with excitation and 
emission wavelengths of 540 nm and 600 nm (phospho-ERK 1 / 2) and 360 nm 
and 450 nm (ERK 1 / 2). 
Chemotaxis assays 
Migration of Jurkat and Molt 4 T cells was measured using transwell chambers 
(polycarbonate, 5 µm pore size; Corning Costar, Sigma Aldrich). Assays were 
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over 2 hours (unless otherwise stated), after which cells were extracted from the 
lower chamber and enumerated by flow cytometry. 
Statistics 
Prism 4.0 (GraphPad Software, USA) was used to analyse data. Statistical 
comparisons between groups were made using the Student’s two-tailed T test 
for unpaired data. P values > 0.05 were considered not significant (n.s.), ) 0.05 
significant (*), ) 0.01 highly significant (**), ) 0.001 very highly significant (***). 
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3.3 Results 
Primary resting T cells express S1PR1 and respond to S1P in chemotaxis 
assays (Graeler and Goetzl, 2002). To see whether Jurkat T cells had a similar 
phenotype, they were analysed for expression of S1PR1 and S1PR3 proteins 
by immunofluorescence. A monoclonal antibody against S1PR1 stained serum-
starved Jurkat T cells only slightly (Figure 6). Using confocal microscopy, they 
were shown to express significant levels of S1PR3, with staining predominantly 
on the perimeter of cells and outside the nuclear compartment (indicated by 
DAPI staining) (Figure 7). Treatment of cells with 1 µM S1P resulted in an 
increase in the amount of S1PR3 staining in the nucleus with time (Figure 8). 
This is consistent with ligand-induced internalisation of the receptor into that 
compartment.
Figure 6. Jurkat T cells stained poorly for surface S1PR1. 
Jurkat T cells were serum-starved overnight then stained with an S1PR1-specific monoclonal 
antibody (blue) or a fluorescently-labelled isotype-matched control monoclonal antibody (red). 
Analysis was by flow cytometry. Data are representative of three independent experiments. 
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Figure 7. Jurkat T cells expressed S1PR3 on their surface.  
Jurkat T cells were serum-starved overnight, then cytospins prepared. They were stained 
with a polyclonal antibody against S1PR3 and fluorescent secondary antibody (green). Cells 
were further stained with DAPI (blue) then visualised by confocal laser-scanning microscopy 
(CLSM). First panel, no primary antibody; second panel, S1PR3 polyclonal antibody; third 
and fourth panels, representative images (mid-point of cell on z-axis) of a single cell – upper 
image DAPI alone, lower image S1PR3 alone. Data are representative of three independent 
experiments. 
Figure 8. Ligand-induced internalisation of S1PR3.  
Jurkat T cells were serum-starved overnight then incubated for various times with 1 µM S1P. 
They were rapidly cooled, cytospins prepared, and these stained for S1PR3, and with DAPI, 
as before. Imaging was by CLSM. Images shown were taken at the mid-point on the z-axis, 
as determined by DAPI staining. Data are representative of two independent experiments. 
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The response of Jurkat T cells to S1P was investigated further. Cells were 
stimulated for various times with 1 µM S1P and the extent of phosphorylation of 
ERK 1 / 2 determined, either by cell-based ELISA or western blotting. As 
expected, an early spike in the quantity of phospho-ERK 1 / 2 was followed by a 
gradual reduction over time (to within 25 % of background 30 minutes after 
ligand addition) (Figure 9). Jurkat T cells also migrated towards S1P in bare 
transwell assays, most efficiently at a ligand concentration of 10 nM (Figure 10). 
This is close to the Kd of S1P for S1PR1 of 8 nM (Lee et al., 1998). 
Chequerboard analysis indicated that the migration was chemokinetic rather 
than chemotactic in nature. Whereas the response to the known chemotactic 
stimulus CXCL12 was greatly reduced with the presence of the ligand in the 
upper as well as the lower compartment, this was not the case for S1P (Figure 
11). 
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Figure 9.  Phosphorylation of ERK 1 / 2 following stimulation of Jurkat T cells with 
S1P. 
Upper panel, Jurkat T cells were serum-starved overnight then stimulated for various times 
with 1 µM S1P. -, stimulation with vehicle for 5 minutes; +, stimulation with 100 nM CXCL12 
for 5 minutes. Phospho-ERK 1 (T202/Y204) / phospho-ERK 2 (T185/Y187) and ERK 1 / 2 
(pan) were detected by cell-based ELISA. The fluorescence signals corresponding to 
phospho-ERK 1 / 2 have been normalised to those of total ERK 1 / 2 at each time point. 
Graph shows means ± range of duplicate determinations. Data are from one experiment. 
Lower panel, Jurkat T cells were stimulated either with vehicle for 5 minutes (-) or 1 µM 
S1P for various times. Cells were lysed and phospho-ERK 1 (T202/Y204) / phospho-ERK2 
(T185/Y187) and ERK 1 detected by western blotting. Data are representative of two 
independent experiments. !
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Figure 10. The efficiency of Jurkat T cell migration towards S1P was concentration-
dependent.  
Jurkat T cells (500 000 per well) were placed into bare transwell migration assays and left to 
migrate for 3 hours towards various concentrations of S1P or vehicle (-). Cells in the lower 
compartment were enumerated by flow cytometry. Graph shows means ± range of duplicate 
determinations. Data are from a single experiment. 
Figure 11. Chequerboard analysis of S1P-induced Jurkat T cell migration.  
Jurkat T cells (500 000 per well) were left to migrate for 3 hours with 10 nM S1P (S) 
or 6.25 nM CXCL12 (C) either in the lower compartment alone, or both the upper and 
lower compartments. Cells in the lower compartment were enumerated by flow 
cytometry. Graph shows means ± s.e.m. Data are representative of two independent 
experiments. !
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The next step was to test whether treatment with S1P would affect cell 
migration towards a chemokine. Jurkat T cells were shown to express high 
levels of CXCR4 by immunofluorescence flow cytometry (Figure 12). Consistent 
with this, they migrated efficiently towards a ligand for the receptor, the 
homeostatic chemokine CXCL12. Pre-treatment of Jurkat T cells with 1 µM S1P 
for 1 hour immediately before the assay significantly increased the efficiency of 
chemotaxis (Figure 13, upper panel). When S1P was substituted with the 
S1PR1-specific agonist SEW2871, a similar effect was observed (Figure 13, 
lower panel). So, although flow cytometric analysis indicated that there was a 
very low level of S1PR1 on the cell surface, it was clearly sufficiently abundant 
to exert a strong effect on this chemotactic response. 
 
 
 
Figure 12. Jurkat T cells expressed high levels of CXCR4 on their surface.  
Jurkat T cells were stained with a fluorescently-labelled monoclonal antibody against CXCR4 
(blue) or isotype-matched control antibody (red), then analysed by flow cytometry. Data are 
representative of three independent experiments. 
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Figure 13.  Pre-treatment of Jurkat T cells with either S1P or SEW2871 enhanced 
their migration towards CXCL12.  
Upper panel, Jurkat T cells (100 000 per well) pre-treated with vehicle (-) or 1 µM S1P (S) 
for 1 hour were left to migrate for 2 hours towards 6.25 nM CXCL12 (C) or vehicle (-) in 
the lower compartment. Graph shows means ± s.e.m. Lower panel, as before, except that 
S1P was substituted with 10 µM SEW2871 (W). Graph shows means ± s.e.m. Cells in the 
lower compartment were enumerated by flow cytometry. Upper panel representative of 
three independent experiments, the lower representative of two. 
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One obvious explanation for the increased migration associated with S1P 
treatment would be increase in the amount of CXCR4 on the cell surface. 
However, treatment of Jurkat T cells with S1P for one hour did not change the 
intensity of staining for that receptor (Figure 14) (nor did two or three hours 
incubation with S1P (data not shown)).  
 
Figure 14. Treatment of Jurkat T cells with S1P did not change the amount of CXCR4 
on the cell surface.  
Jurkat T cells were treated for 1 hour with vehicle or 1 µM S1P then stained with a 
fluorescently-labelled monoclonal antibody against CXCR4. Analysis was by flow cytometry. 
Data are representative of three independent experiments. 
1 h treatment with 1 !M S1P 1 h treatment with vehicle 
CXCR4 - FITC 
%
 o
f m
ax
 
10
0
10
1
10
2
10
3
10
4
FL2-H
0
20
40
60
80
100
%
 o
f 
M
a
x
102 103 104 105 102 103 104 105 100 101 102 103 104
FL2-H
0
20
40
60
80
100
%
 o
f 
M
a
x
 82!
Ligand-bound CXCR4 couples to the heterotrimeric G protein G"i and inhibits 
the activity of membrane-resident adenylate cyclase (Busillo and Benovic, 
2007). Forskolin is commonly used to activate adenylate cyclase in assays 
designed to measure G"i coupling to that enzyme. To test whether S1P 
affected signal transduction downstream of CXCR4, Jurkat T cells were treated 
for 1 hour with S1P or vehicle, then stimulated with CXCL12 and forskolin. S1P 
did not affect the magnitude of reduction of cAMP levels caused by stimulation 
with CXCL12 (Figure 15). Similarly, ERK 1 / 2 phosphorylation following 
stimulation of cells with CXCL12 was unaffected by S1P (Figure 17).  
These data suggested that the effect of S1P pre-treatment on CXCR4 signalling 
was highly selective. PI3K signalling and the enrichment of PIP3 at the leading 
edge of a migrating cell is usually required for chemotaxis. The kinase Akt is 
phosphorylated and activated on binding PIP3 at the plasma membrane. To 
further elucidate the mechanism of the S1P-induced effect on Jurkat T cell 
migration, its ability to modulate phosphorylation of Akt was tested. Jurkat T 
cells were incubated with S1P or vehicle for 1 hour, then stimulated with 
CXCL12 for 10 minutes. Phosphorylated Akt and total Akt were subsequently 
detected in whole cell lysates by western blotting. Similar levels of phospho-Akt 
were observed whether or not the cells were pre-treated with S1P (Figure 16). 
Unusually, stimulation of untreated cells with CXCL12 did not result in any 
noticeable increase in phosphorylated protein. This is probably related to the 
reported deficiency in PTEN activity in Jurkat T cells (Shan et al., 2000). !!!!!!!!!!
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Figure 15. Pre-treatment of Jurkat T cells with S1P did not affect the magnitude of  
the CXCL12-stimulated inhibition of adenylate cyclase activity.  
Upper panel, cAMP in solution at 240 pmol/ml was serially diluted and the set assayed 
using a competitive ELISA. A four-parameter logistic curve has been fitted to the data. 
Graph shows means ± s.e.m. of duplicate determinations. A standard curve was prepared 
for each experiment. Lower panel, equal numbers of Jurkat T cells were pre-treated with 1 
µM S1P or vehicle for 1 hour, then stimulated with either 50 µM forskolin and vehicle or 50 
µM forskolin and 6.25 nM CXCL12. Graph shows means ± s.e.m. Data are representative 
of two independent experiments. 
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Figure 17. Phosphorylation of ERK 1 / 2 following stimulation of Jurkat T cells with 
CXCL12 was not affected by S1P.  
Jurkat T cells were incubated with vehicle or 1 µM S1P for 1 hour, then stimulated with vehicle 
or 6.25 nM CXCL12 for 5 minutes. Phospho-ERK 1 (T202/Y204) / phospho-ERK2 (T185/Y187) 
and ERK 1 were detected in whole cell lysates by western blotting. Data are representative of 
three independent experiments. 
Figure 16. Pre-incubation of Jurkat T cells with S1P did not affect intracellular levels of 
phospho-Akt.  
Jurkat T cells were treated with 1 µM S1P or vehicle for 1 hour, then stimulated with 6.25 nM 
CXCL12 or vehicle for 10 minutes. The cells were lysed and phospho-Akt (Ser473) and Akt 
(pan) detected by western blotting. Representative of two independent experiments. 
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Because none of the signalling pathways assayed so far appeared to be 
affected by S1P, a phospho-kinase array was used to screen a large number of 
potential targets. Jurkat T cells were incubated for 1 hour with S1P or vehicle 
then stimulated with CXCL12 or vehicle for 5 minutes. Whole cell lysates were 
prepared and probed using a sandwich-type immunoarray. The results of one 
experiment are shown. The graph shows that several proteins were most highly 
phosphorylated in the condition of S1P pre-treatment followed by CXCL12-
stimulation of Jurkat T cells (Figure 18).  
Phosphorylation of Lck was more than two-fold higher in cells that had been 
pre-treated with S1P then stimulated with CXCL12, compared with cells that 
were pre-treated with vehicle control but similarly stimulated with chemokine. 
Additionally, Lck activity is known to be required for chemotaxis towards 
CXCL12 (Inngjerdingen et al., 2002). This protein was therefore selected for 
further investigation. To better understand the dynamics of Lck phosphorylation 
after receptor ligation, Jurkat T cells were first stimulated with CXCL12 for 
various times and cell lysates prepared. Western blotting for phospho-Lck 
(Y394) and total Lck showed that the phosphorylation response was biphasic, 
with most phospho-protein one minute after addition of chemokine, and another 
peak apparent at 10 minutes. The one-minute time-point was chosen to test the 
effect of pre-incubation of Jurkat T cells with S1P. In two of three independent 
experiments treatment with S1P was associated with a small increase in 
phosphorylation of Lck after CXCL12 stimulation (Figure 19). This was not 
however consistent or statistically significant when analysed by densitometry. 
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Figure 18. A phospho-kinase array was used to screen for an effect of S1P on CXCL12 
signalling.  
Jurkat T cells were pre-treated with either 1 µM S1P or vehicle for 1 hour, then stimulated with 
6.25 nM CXCL12 or vehicle for 5 minutes. Cell lysates were prepared and samples containing 
equal masses of protein assayed using a sandwich immunoarray.  ECL signals were recorded 
onto light-sensitive film, which was then scanned into a computer. Protein target signal 
intensities were normalised to that of the positive control on each array part. Graph shows 
means of duplicate determinations in one experiment. Experiment was performed twice with 
similar results. 
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Figure 19. The effect of pre-treatment of Jurkat T cells with S1P on CXCL12-stimulated 
phosphorylation of Lck.  
Upper panel, Jurkat T cells were stimulated for various times with 6.25 nM CXCL12, or for 10 
minutes with pervanadate (+) or vehicle (-). The cells were lysed and phospho-Lck (Y394) and Lck 
detected by western blotting. Data is from one experiment. Lower panel, Jurkat T cells were 
incubated for 1 hour with 1 µM S1P or vehicle then stimulated for 1 minute with 6.25 nM CXCL12. 
The cells were rapidly lysed and phospho-Lck (Y394) and Lck detected by western blotting as 
before. Three independent experiments were performed. 
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These data showed that S1P, acting through S1PR1, significantly enhanced the 
migration of Jurkat T cells towards CXCL12. The other CXCL12 signalling 
responses examined here were not affected by S1P pre-treatment. To develop 
the study further, it was extended to include the Molt 4 T cell line. As earlier 
experiments had shown poor staining of S1PR1 protein on the surface of Jurkat 
T cells, the expression of S1PR1 (and S1PR3) was subsequently measured by 
semi-quantitative real-time PCR.  
First however, the method of RNA preparation and real-time PCR assays were 
validated. Total RNA was isolated from cell pellets as detailed in the Methods. A 
sample of RNA was heated to disrupt secondary structure and separated by 
electrophoresis. Sharp bands corresponding to the small (18S) and large (28S) 
ribosomal RNAs can be seen in (Figure 20, upper panel), indicating little 
degradation. Another sample of RNA was reverse transcribed to cDNA, and the 
latter used in a test amplification of a portion of the GAPDH coding sequence 
(Figure 20, lower panel). The efficiency of amplification of S1PR1, S1PR3, and 
the reference gene 18S, using TaqMan Gene Expression Assays were 
individually tested across a 103 – fold range of cDNA quantities. Efficiencies 
were within 10 % of maximum for all genes: Figure 21 is an example efficiency 
curve, generated using a TaqMan Gene Expression Assay for S1PR1.
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Figure 20. Quality assessment of isolated RNA and synthesised cDNA pool.  
RNA was isolated from Jurkat and Molt 4 T cells. Upper panel, 1 µg samples of RNA were 
heated to 65 °C for 5 minutes then separated by agarose gel electrophoresis. The gel was 
pre-stained with ethidium bromide so that the nucleic acid could be visualised under UV 
illumination. Lower panel, RNA samples were reverse transcribed to generate a pool of 
cDNA. A 570 bp sequence within the GAPDH gene was amplified by PCR using specific 
primers. The PCR products were separated by agarose gel electrophoresis and the gel 
imaged under UV illumination. Data are from a single experiment. 
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Figure 21. The S1PR1 target was amplified efficiently by real-time PCR over a range of 
different starting quantities of cDNA.  
RNA isolated from Molt 4 T cells was reverse transcribed to cDNA. The preparation was 
serially diluted and those samples amplified by semi-quantitative real-time PCR using an 
exon-spanning S1PR1-specific TaqMan Gene Expression Assay. Graph shows means ± s.d. 
Data are from a single experiment. 
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The expression of S1PR1 and S1PR3 in the Jurkat and Molt 4 T cell lines were 
compared. S1PR1 expression was more than three times higher in Molt 4 than 
Jurkat T cells. Levels of S1PR3 were similar. Using a polyclonal antibody 
against S1PR1 (different to that used earlier to stain for surface receptor), Molt 
4 T cells were shown to express more protein in whole cell lysates than Jurkat T 
cells (Figure 22). 
 
 Figure 22. Molt 4 T cells expressed more S1PR1 than Jurkat T cells.  
Upper panel, cDNA was prepared from Jurkat and Molt 4 T cells. Expression of S1PR1 and 
S1PR3 were determined by semi-quantitative real-time PCR. 18S was the reference gene. 
Graph shows means ± s.d. Lower panel, S1PR1 protein was detected in Jurkat and Molt 4 T 
cell lysates by western blotting. The PVDF membrane was stripped and probed for "-tubulin 
to show equal protein-loading. Data are representative of two independent experiments. 
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Similar to Jurkat T cells, Molt 4 T cells expressed surface CXCR4 (Figure 24). 
Pre-treatment with S1P did not, however, affect their migration towards CXCL12 
(Figure 23). This might point to an important role for the quantity of S1PR1 in 
determining the ability of S1P to modulate cellular responses to chemokines. 
Figure 24. Molt 4 T cells expressed CXCR4.  
Molt 4 T cells were stained with a fluorescently-labelled monoclonal antibody against CXCR4 
(blue) or an isotype-matched control (red), then analysed by flow cytometry. Data are 
representative of three independent experiments. 
Figure 23. The efficiency of chemotaxis of Molt 4 T cells towards CXCL12 was 
unaffected by S1P.  
Molt 4 T cells were incubated for 1 hour with 1 µM S1P (S) or vehicle (-), then left to migrate 
for 2 hours towards either 6.25 nM CXCL12 (C) or vehicle (-). Migrated cells in the lower 
compartment were enumerated by flow cytometry. Data are representative of two independent 
experiments. 
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3.4 Discussion 
The role of chemokines in directing T cell migration in basal conditions, and in 
inflammation, is well established. CXCL12 for example is produced 
constitutively and contributes to homeostatic functions such as the entry of T 
cells into lymph nodes (Bai et al., 2009). More recently it has been shown that 
S1P signalling is required for T cell egress from lymphatic tissue (Matloubian et 
al., 2004). Here, using functional assays of cell migration and receptor 
signalling, the effect of the endogeneous lysophospholipid S1P on T cell 
responses to the chemokine CXCL12 were studied. These findings support a 
model in which S1P and chemokines do not solely have separate functions, but 
one where there is crosstalk between their signalling pathways. The increased 
complexity of regulation might allow for finer control of T cell migration in 
different immune compartments and immune states. 
For the experiment represented in Figure 8, Jurkat T cells were treated with 1 
µM S1P for various times and then cytospins prepared and stained for S1PR3. 
The preparations were examined using confocal laser-scanning microscopy. 
The data suggest that S1PR3 was internalised after treatment of serum-starved 
cells with S1P. However, an accompanying time-course of treatment of cells 
with vehicle was not included, and therefore spontaneous recycling of the 
receptor with time cannot be ruled out. Also, distortions of the cell membrane 
caused by cytospinning render this method of analysis of receptor recycling 
unreliable. Others have shown internalisation of S1PR3 from the surface of 
receptor-transfectants following treatment of cells with S1P. In their experiment 
they treated the cells with 1 µM S1P for 30 minutes, and showed using surface 
receptor staining and flow cytometry that about 60 % of the receptor was lost 
from the cell surface (Jongsma et al. 2009). 
Jurkat T cells expressed S1PR1 and S1PR3 at a similar level, measured by 
real-time PCR. However, while S1PR3 protein was easily labelled, the 
monoclonal antibody against S1PR1 used here stained the surface of Jurkat T 
cells poorly. The internalisation of this receptor on application of ligand to intact 
cells could therefore not be studied directly. Others have reported similarly poor 
staining of S1PR1 (M. Graeler and E. Goetzl, personal communication). Most of 
the published work on the quantitative aspects of S1PR1 expression has either 
involved use of real-time PCR or the protein has been examined in situ by using 
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epitope-tagged receptor constructs (FLAG; Matloubian et al., 2004) or 
polyclonal antibodies (Lo et al., 2005). The weak staining of S1PR1 on Jurkat T 
cells probably implies a low amount of receptor on the cell surface. 
Nevertheless, the S1PR1-specific agonist SEW2871 strongly enhanced cell 
migration towards CXCL12, indicating that the receptor was at a functionally 
significant level. Used at a concentration of 10 µM, SEW2871 is highly selective 
for S1PR1 (Gonzalez-Cabrera et al., 2007). These results support a model in 
which S1PR1 signalling is important in the modulation of lymphocyte migration. 
S1PR1, like S1PR3 and many other GPCR, undergoes homologous 
desensitisation on ligand binding, by internalisation of the receptor from the cell 
surface and protein degradation (Liu et al., 1999; Oo et al., 2007). S1PR1 is 
unusual in its sensitivity to, and speed of internalisation (Schwab et al., 2005; 
Grigorova et al., 2009). After 1 hour of stimulation with 1 µM S1P, little S1PR1 
probably remains on the surface of Jurkat T cells. A reciprocal relationship in 
surface expression of S1PR1 and CXCR4 would provide a simple explanation 
for the observed enhancement in migration towards CXCL12 after S1P 
treatment. It has been reported that overexpression of S1PR1 in haematopoietic 
progenitor cells resulted in suppression of their migration towards CXCL12, and 
that this was associated with a 1.8 fold decrease in CXCR4 expression (Ryser 
et al., 2008). CXCR4 can be held in intracellular stores, and moved rapidly to 
the surface of lymphocytes on PMA stimulation (Forster et al., 1998). 
Conceivably, CXCR4 could be translocated quickly from intracellular stores to 
the plasma membrane following downregulation of S1PR1. In these 
experiments, however, S1P treatment did not affect the intensity of staining of 
surface CXCR4, suggesting that an upregulation of the receptor does not occur. 
Heterodimerisation of chemokine receptors can subtly alter their signalling 
responses. CCR5/CCR2 dimers associate with G"11 rather than G"i, and this 
biases towards signal-induced changes in cell adhesion rather than chemotaxis 
(Mellado et al., 2001). In neutrophils, S1PR3 heterodimerises with the 
chemokine receptor CXCR1 (Rahaman et al., 2006). As there is a high degree 
of homology between the S1P receptors, it is possible that CXCR4 and S1PR1 
could complex on the surface of Jurkat T cells. The observation that S1P 
treatment did not affect CXCL12-mediated inhibition of adenylate cyclase 
suggests that G protein coupling to CXCR4 was not significantly altered. 
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Nevertheless, it remains a possibility that heterodimerisation of S1PR1 and 
CXCR4 may have a significant role in the effect of S1P on migration. Analysis of 
protein-protein interaction on the cell surface, using flow cytometry (and 
fluorescence resonance energy transfer between immunolabelled receptors) 
and co-immunoprecipitation, is needed to answer this question. 
Jurkat T cells are deficient in expression of the enzyme PTEN, which 
dephosphorylates PIP3 in the plasma membrane (Shan et al., 2000). High basal 
levels of PIP3 probably explain the constitutive phosphorylation of Akt at S473 
seen here. The observation that phosphorylation was not further increased on 
stimulation with CXCL12 was however unexpected. Jurkat T cells migrate 
efficiently towards CXCL12, and this presumably involves enrichment of PIP3 at 
the leading edge of cells. The formation of ‘signalling patches’ in the plasma 
membrane, to which pleckstrin homology domain-containing proteins are 
bound, has been reported as a mechanism for the sensitisation of chemotactic 
responses (Postma et al., 2004). Although S1P treatment did not cause any 
detectable change in the amount of phospho-Akt, modulation of signalling 
downstream of PIP3 cannot be ruled out. 
Lck was flagged as a protein of interest following the phospho-kinase array 
screen. The kinase is known to be phosphorylated and activated on stimulation 
of Jurkat T cells with CXCL12, and is necessary for chemotaxis towards that 
ligand (Inngjerdingen et al., 2002). Lck has also been implicated as having a 
significant role in the cooperative action of the TCR and CXCR4 (Kumar et al., 
2006). Phosphorylation of Lck at the activatory residue Y394 following 
chemokine stimulation was very variable, and no consistent effect of S1P 
treatment on this response was observed. A similar lack of reproducibility in 
assays to probe for phospho-Lck has been reported by others (Oreste Acuto, 
personal communication). Recent work has cast doubt on whether 
phosphorylation at Y394 is even a good marker of active kinase. Activated Lck 
is normally present in resting T cells, and TCR signalling does not increase the 
amount of it. Receptor signalling may licence existing pre-activated Lck to 
phosphorylate its substrates – perhaps through changes in conformation or 
localisation of the latter (Nika et al., 2010). 
Pre-treatment of Molt 4 T cells with S1P did not increase their migration towards 
CXCL12. The fact that their expression of S1PR1 was more than three times 
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higher than that of Jurkat T cells is probably significant. As previously stated, 
overexpression of S1PR1 has been associated with suppression, not 
enhancement, of migration towards CXCL12 (Ryser et al., 2008). Analysis of 
the dynamics of S1PR1 and CXCR4 expression on the cell surface after S1P 
treatment will help resolve this question. 
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Regulation of S1PR1 Signalling in Primary T cells and S1P- 
mediated Effects on Cell Chemotaxis 
4.1 Introduction 
In the course of its lifetime, a T cell may adopt one of a number of different 
migration programmes. They are initiated on receipt of signals from the 
environment and ensure appropriate cell movement for implementation of 
function at a particular stage. Altered migratory behaviour is associated with 
changes in the complement of cell surface and intracellular molecules, including 
chemokine receptors and S1PR1. Resting T cells express chemokine receptors 
such as CCR7 and CXCR4 whose ligands are expressed constitutively by 
lymphatic tissues, and which direct cell recirculation (Bai et al., 2009). 
Receptors such as CXCR3 and CCR5 bind ligands that are expressed at 
inflamed sites in the periphery and direct the trafficking of effector T cells to 
those locations. 
During immunosurveillance, under normal conditions, T cells continuously 
recirculate through lymphoid organs. Entry to lymph nodes is driven primarily by 
CCR7, and exit by antagonistic S1PR1 signalling at egress structures (Pham et 
al., 2008). The mean residence time of T cells in a particular lymphoid 
compartment is usually between 6 and 12 h (von Andrian and Mempel, 2003). 
Recycling of S1PR1 to the cell surface is quite rapid after T cell entry, causing a 
return of sensitivity to egress signals within 20 minutes (Grigorova et al., 2010). 
The time it takes for randomly moving T cells to encounter egress structures, 
and the relative strengths of CCR7 and S1PR1 -mediated signals transduced 
there, are probably the primary determinants of cell residence time. 
In a primary adaptive immune response, naïve T cells are activated within 
lymphoid tissue by interaction with antigen presenting cells. We know that the 
naïve T cells are arrested by interaction with the pAPC, and this presumably 
prevents them from accessing egress structures. Naïve T cells can form stable 
conjugates with DC bearing cognate peptide-MHC for up to 12 hours (Mempel 
et al., 2004). TCR triggering of T cells also causes a complete loss in sensitivity 
to S1P, and therefore susceptibility to lymph node egress signals. 24 hours after 
activation with CD3/CD28 antibodies, mouse splenic T cells responded 
negligibly to S1P in chemotaxis assays. This was associated with a complete 
loss of S1PR1 protein expression (Graeler and Goetzl, 2002). A similar loss in 
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S1PR1 gene expression and S1P-mediated chemotaxis one day after activation 
has been observed in vivo, in the context of antigen-specific activation 
(Matloubian et al., 2004). The differentiated daughter cells of the original 
activated parent leave typically between 3 and 5 days after activation (Reinhardt 
et al., 2001). 
Lymph node shutdown is a phenomenon triggered during certain immune 
responses and is characterised by a transient and profound reduction in T cell 
egress from lymphatic tissue (Korngold et al., 1983; Shiow et al., 2006). T cells 
are retained regardless of their specificity. It is speculated that this is a 
mechanism for increasing the probability of a productive adaptive immune 
response. An increase in the number of T cells scanning mature pAPC within 
the node clearly increases the chance of a rare specific T cell being activated. 
Previous in vivo work has implicated interferon "/# signalling, acting via 
upregulation of CD69 on T cells, as critical for egress blockade (Shiow et al., 
2006).  
CD69 interacts directly with S1PR1, inactivating signalling of the receptor and 
promoting its internalisation and degradation (Bankovich et al., 2010). T cells 
that enter an inflamed lymph node go from showing no or negligible surface 
expression of CD69 to clearly detectable levels within an hour of entry (Shiow et 
al., 2006; Grigorova et al., 2010). This is important, as modelling implies that 
half of the T cells entering a typical lymph node will contact cortical sinuses 
within 2 hours of entry (Grigorova et al., 2010). Rapid upregulation of CD69 is 
therefore required in order to block S1PR1-mediated egress of a large 
proportion of recently ingressed cells.  
Although published work shows a role for CD69 in regulation of T cell egress 
from inflamed lymph nodes, it has remained unclear whether CD69 plays an 
important role in the context of cell activation through the antigen-specific 
receptor. T cell activation by antigens or mitogens has been known for some 
time to cause rapid and potent upregulation of CD69 on the cell surface, usually 
peaking at 24 – 48 h, and that it can persist at detectable levels for six days 
(Hara et al., 1986). Stimulation of peripheral blood T cells with anti-CD3 mAb 
resulted in expression of CD69 within 2 hours (Testi et al., 1989), with the 
antigen detectable two days later. PMA stimulation induced detectable levels of 
CD69 at 3 hours, with maximum surface protein 12 hours after activation 
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(Lopez-Cabrera et al., 1993). These studies indicate that CD69 is present soon 
after cell activation and could potentially have a role in regulation of S1PR1 
signalling in this context. 
Here, anti-CD3/28 beads have been used to activate human peripheral blood T 
cells. CD69 was rapidly upregulated to very high levels and then diluted on cell 
division. CD69hi T cells, 24 hours after activation, did not respond to stimulation 
with the S1PR1-specific agonist SEW2871 by phosphorylation of Akt. Three 
days after activation, when the majority of cells were CD69lo, a signalling 
response was observed. In addition, S1P significantly enhanced the migration 
of these T cells towards a prototypical inflammatory chemokine. Attenuation of 
CD69 expression on 24 hour -activated T cells using specific small interfering 
ribonucleic acid (siRNA) increased their response to S1PR1 stimulation. These 
observations support a model in which CD69 plays an important role in control 
of S1PR1 signalling in T cells activated through CD3 and CD28. 
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The aims of this chapter were as follows: 
To study the dynamics of CD69 and S1PR1 expression following activation of T 
cells through CD3 and CD28 
To probe for simultaneous changes in the ability of S1PR1 to signal 
To identify whether there was a quantitative relationship between the surface 
expression of CD69 and the signalling capacity of S1PR1 
To study the effect of S1P receptor stimulation on the migration of resting and 
activated primary T cells 
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4.2 Materials and Methods 
Receptor ligands 
D-erythro sphingosine 1-phosphate (S1P) and SEW2871 were purchased from 
Enzo Life Sciences; CXCL10 and CXCL12 from R&D Systems.  
Cell isolation, culture and activation 
Total CD3+ T cells were derived from human peripheral blood or platelet-
depleted leukocyte cones. They were isolated using an erythrocyte-rosetting 
negative-selection kit (Stem Cell Technologies) and density-gradient 
centrifugation (Lympholyte H, Cedarlane Laboratories). T cells were cultured in 
X-VIVO 15 medium (Lonza) and activated with Dynabeads Human T Activator 
CD3/CD28 (Invitrogen), at a ratio of one bead per cell and a starting culture 
density of 1 x 106 cells per ml. 
Antibodies, cell labelling and flow cytometry 
T cells were labelled for 5 minutes at 37 °C with 1 µM CFSE (Sigma Aldrich) in 
PBS containing 0.1 % (v/v) FBS. They were chilled rapidly on ice then washed 
with cold RF10 before use. 
T cells were stained with various fluorochrome-conjugated monoclonal 
antibodies or appropriate isotype-matched control antibodies. The specific 
antibodies used were: S1PR1 (218713; R&D Systems), CXCR4 (12G5; R&D 
Systems), CD3 (CD3-12; AbD Serotec), CD69 (FN50; BD Pharmingen), CXCR3 
(49801; R&D Systems). Data was acquired on a FACSCanto II instrument (BD) 
and analysis performed using FACSDiva (BD) and FlowJo (Treestar) software.  
Real time PCR 
RNA was prepared from cell pellets using TRI Reagent (Sigma). cDNA was 
synthesised using SuperScript III Reverse Transcriptase and random hexamers 
as primers (Invitrogen). Expression of S1PR1 was measured semi-quantitatively 
using specific TaqMan Gene Expression assays (Hs00173499_m1), with 18S 
as the reference (Hs99999901_s1; both Applied Biosystems). The 
amplifications were run on an ABI Prism 7000 instrument (Applied Biosystems).  
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Protein assays 
Proteins were subject to SDS-PAGE and transferred to PVDF membrane as 
previously described. The primary antibodies used for immunoblotting were: 
phospho-Akt [Ser473] (D9E; Cell Signaling Technology) and Akt [pan] (C68E7; 
Cell Signaling Technology). The secondary antibody was horseradish 
peroxidase-conjugated anti-rabbit IgG (A6154; Sigma Aldrich). 
Phospho-Akt [Ser473] and Akt [pan] were also quantified using a cell-based 
ELISA (R&D Systems). Approximately 10 000 T cells were added to each well 
of a 96 well-format plate (coated with 10 µg/ml poly-lysine (Sigma Aldrich) for 30 
minutes) and left to attach for 1 hour. The cells were then treated as desired 
before fixation with 8 % formaldehyde. Phospho-Akt and total Akt were detected 
by double immunoenzymatic labelling. The relative quantities of these proteins 
were deduced from the spectrally distinct fluorescence of substrates associated 
with each target. The detector was a Dynex MFX instrument operating with 
excitation and emission wavelengths of 540 nm and 600 nm (phospho-Akt) and 
360 nm and 450 nm (Akt) respectively. 
Gene knockdown 
Resting T cells were transfected with 100 pmol siRNA per million cells by 
electroporation (Nucleofector I instrument; Amaxa, Lonza). For CD69 
knockdown, an equimolar mixture of three 21 nucleotide duplexes (MISSION 
siRNA; Sigma Aldrich) were used. The single strand sequences were: 
5’ GAGUUAGAUGUUGGUACUA 3’ 
5’ CUACUCUUGCUGUCAUUGA 3’ 
5’ CUCUCAUUGCCUUAUCAGU 3’ 
Separately, as a control, cells were transfected with an equal mass of MISSION 
siRNA Universal Negative Control 1 (Sigma Aldrich). 
The cells were rested for 5 hours after transfection then activated with 
Dynabeads Human T Activator CD3/CD28 at a ratio of 1 bead per T cell. 
In some cases, siRNA transfected cells were sorted 24 h after activation. This 
was done using a FACSAria II (BD) instrument, using the forward and side 
scatter characteristics of the input cells. 
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Chemotaxis assays 
Resting or three day-activated T cells migrated across 96 well-format 3 or 5 µm 
polycarbonate filters (Corning Costar) respectively for 2 h at 37 °C in 5 % CO2. 
The total volumes added to the upper and lower compartments were 75 and 
235 µl respectively. The base medium for the assays was FBS-free RPMI 1640 
with 0.5 % fatty acid-free BSA (Sigma Aldrich). On completion of the assay, 
migrated cells were mixed with a known number of Countbright beads 
(Invitrogen) and enumerated by flow cytometry. 
Statistics 
Prism 4.0c (GraphPad Software) was used for all statistical analyses. 
Comparisons between groups were made using the two-tailed Student’s t test 
for unpaired data. P values less than or equal to 0.05 were considered 
significant (*), P ) 0.01 highly significant (**), and P ) 0.001 very highly 
significant (***). 
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4.3 Results 
For these experiments, T cells were isolated either from fresh peripheral blood 
or leukocyte-enriched cones. The T cells were negatively selected using an 
erythrocyte-rosetting antibody cocktail and density gradient centrifugation. 
Purity was checked by staining a sample of the isolated cells with a 
fluorescently-conjugated monoclonal antibody against CD3. Figure 25 shows a 
typical scatter plot and fluorescence histogram: here, 98 % of the cells in the 
marked FSC / SSC gate expressed CD3. Purity was consistently above 95 % 
over several experiments. 
 
 
 
 
 
Figure 25. Negative selection was used to isolate highly pure populations of human 
resting T cells.  
Peripheral blood or leukocyte-enriched cones were mixed with an erythrocyte-rosetting 
negative selection cocktail of antibodies against antigens present on non-CD3+ T lymphocyte 
blood cell subsets. T cells were separated from rosetted cells and other components of blood 
in a density gradient centrifugation process. Purified cells were stained with an anti-CD3 
monoclonal antibody and analysed by flow cytometry. Left panel: representative FSC/SSC dot 
plot. Right panel: cells in gate shown in left panel represented. Isotype control stained cells 
red, CD3 monoclonal antibody stained cells blue (represents approx. 9500 events). Routine 
control experiment. !
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Peripheral blood T cells were rested overnight in serum-free conditions and 
then tested for expression of S1PR1. There was no excess staining with a 
monoclonal antibody against S1PR1 over that of the isotype-matched control 
antibody (Figure 26). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. Resting T cells showed no surface staining with a monoclonal antibody 
against S1PR1.  
Resting T cells were stained with a fluorescent monoclonal antibody against S1PR1 
(blue) or isotype-matched control antibody (red), then analysed by flow cytometry. Data 
are representative of three independent experiments. 
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As Jurkat T cells did also not stain to any significant extent with the same 
antibody (Chapter 3), but did respond to selective agonism of S1PR1 in various 
signalling assays, protein expression was not discounted. Indeed, RT-PCR 
showed expression of S1PR1 in resting T cells. Gene expression was 
significantly lower in T cells that had been activated with CD3/28 beads, at both 
one day and three days after their addition to culture (Figure 27). 
 
 
 
 
 
 
 
 
Figure 27. S1PR1 was expressed by resting T cells and downregulated on activation of 
them with CD3/28 beads.  
T cells were left at rest or activated for one or three days with beads coated with agonist 
antibodies specific for CD3 and CD28. Total RNA was isolated from the cell populations, 
which was then reverse transcribed to generate cDNA. The relative expression of S1PR1 
was determined by semi-quantitative RT-PCR; 18S was the reference gene. Data are 
representative of two independent experiments. !
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CD69, induced on the cell surface by type I interferons, is known to be an 
important regulator of S1PR1 (Shiow et al., 2006). Before investigation of the 
dynamics of CD69 expression after T cell activation by CD3/28 beads, it was 
first established whether or not freshly isolated peripheral blood T cells showed 
any surface expression of that protein. Immunofluorescence flow cytometry was 
used to show that only a small proportion of such T cells showed expression of 
CD69 on the cell surface (here, just over 1 % stained positive for CD69 (Figure 
28)). 
 
 
Figure 28. A low proportion of T cells isolated from peripheral blood stained positively 
for CD69.  
T cells isolated from peripheral blood were stained immediately with a fluorescently-
conjugated monoclonal antibody against CD69 (blue) or isotype-matched control antibody 
(red), and analysed by flow cytometry. Data are representative of three independent 
experiments. 
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Next, samples of resting T cells were activated with CD3/28 beads for various 
times, and the kinetics of upregulation of CD69 on the cell surface studied by 
immunofluorescence flow cytometry (Figure 29). After 4 hours a significant 
proportion of cells were CD69+, and by 24 hours almost all cells expressed the 
protein, and at a high level. The median fluorescence intensity values for the 
experiment shown were:  resting, 93; 1 h, 100; 2 h, 140; 4 h, 1039; 8 h, 1886; 
16 h, 4475; 24 h, 21 839. 
 
 
 
 
Figure 29. T cells activated with CD3 / 28 beads progressively upregulated CD69 over the 
course of 24 hours.  
T cells were left unactivated or stimulated for various times with CD3/28 beads then stained with 
a fluorescent monoclonal against CD69 and analysed by flow cytometry. 
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CD69 does probably not play an important role in regulation of cell motility in the 
few hours immediately after activation. In vivo, adhesive interactions between T 
cells and professional antigen presenting cells centred on the immune synapse 
are most important in mediating lymphocyte arrest in this time window. Our 
primary goal in this study was to understand in greater detail the dynamics of 
CD69 expression in the days following activation, when it may be more 
important. To do this, T cells were labelled with CFSE, activated with CD3/28 
beads, and then stained at various times for CD69. Dye labelling was used so 
that in addition to following CD69 expression with time, any correlation with cell 
division could be noted.  
T cells are known to respond to a number of stimuli, including various types of 
cell stress, by upregulating CD69. It was therefore necessary to test whether 
loading the cells with CFSE had any effect on CD69 expression. In the cases of 
resting, one day –activated and six day-activated T cells, CFSE loading had no 
significant effect on measured protein expression (Figure 30). 
 
Figure 30. Loading with CFSE did not cause CD69 to be expressed by resting T cells or 
affect the upregulation of CD69 following cell activation.  
T cells were loaded with carboxyfluorescein succinimidyl ester (CFSE) or not then left 
overnight. They were then either left unactivated or stimulated with CD3/28 beads for one or 
six days. The cells were stained with a fluorescently-conjugated monoclonal antibody against 
CD69 and analysed by flow cytometry. 
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T cells were loaded with CFSE and then either left to rest or activated with 
CD3/28 beads. Samples of resting T cells and 1 day, 3 day and 6 day -activated 
T cells were analysed for expression of CD69 by flow cytometry (Figure 31). 
Very few T cells in the resting population expressed CD69, whereas more than 
95 % of the cells stained strongly for CD69 24 hours after activation. The 
amount of CD69 on the cell surface decreased with time. The majority of T cells 
at day 3 still expressed CD69 (86.2%), whereas by day 6 CD69+ cells were in 
the minority (33.8%).
 113!
 
Figure 31. CD69 was rapidly and strongly upregulated on T cell activation and 
decreased with cell division.  
Resting T lymphocytes were loaded with CFSE and either left unactivated or activated with 
CD3/28 beads for one, three, or six days. The cells were then stained with a fluorescent 
monoclonal antibody against surface CD69 and analysed by flow cytometry. Data are 
representative of two independent experiments. 
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Using the CFSE fluorescence data, a quantitative analysis was performed to 
compare the mean fluorescence intensity of CD69 staining between the 
generations of three day -activated T cells (Figure 32). The mean fluorescence 
intensity of CD69 staining decreased by approximately one half with each 
successive generation. 
Figure 32. The decrease in surface CD69 protein was closely associated with cell division.  
T cells were loaded with CFSE and activated with CD3/28 beads for three days. They were 
stained with a monoclonal antibody against CD69, or isotype-matched control, and analysed by 
flow cytometry. Upper panel: distinct generations of T cells were identified by their CFSE-
mediated fluorescence, and gates established using this fluorescent parameter. Lower panel: the 
mean fluorescence intensity of specific CD69 staining of each generation was calculated by 
subtracting the mean fluorescence intensity associated with the isotype-matched control antibody 
from that with the CD69-specific monoclonal antibody. Graph shows means ± s.e.m. Data are 
representative of two independent experiments. 
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Previous studies have implicated CD69 as a negative regulator of both S1PR1 
expression and signalling capacity (Shiow et al., 2006; Bankovich et al., 2010). 
Although surface S1PR1 expression could not be detected by 
immunofluorescence staining, it was possible to test the ability of S1PR1 to 
signal. This was done by stimulating T cells with the S1PR1-specific agonist 
SEW2871 and then subsequently measuring the extent of Akt phosphorylation, 
a downstream consequence of receptor signalling. 
T cells were first left at rest or activated for one, three or six days with CD3/28 
beads. They were then stimulated with SEW2871 for 10 minutes and lysed. 
Phosphorylated (at serine 473) Akt and total Akt were detected in the cell 
lysates by western blotting (Figure 33, upper panel). Data from three 
independent experiments were analysed by densitometry, and expressed in the 
form of a stimulation index. The stimulation index refers to the proportional 
increase in amount of phospho-Akt caused by ligand stimulation, normalised to 
the quantity of total Akt. Resting T cells responded strongly to addition of the 
S1PR1 agonist, whereas no such response by one day-activated cells could be 
detected. Stimulation with SEW2871 caused significant Akt phosphorylation in 
day 3 and day 6 -activated cells, and to a similar extent of that in resting cells 
(Figure 33, lower panel). 
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Figure 33. The response of T cells to stimulation with an S1PR1 agonist was lost 24 hours 
after activation but returned by day 3.  
T cells were either left unactivated or stimulated for 1, 3 or 6 days with CD3/28 beads. The beads 
were removed from cell cultures and the cells rested for 3 hours. The cells were then stimulated 
for 10 minutes with 10 µM SEW2871, or vehicle, then lysed. Upper panel: pAkt (Ser473) and Akt 
were detected in total cell lysates by western blotting. Lower panel:  graphical representation of 
densitometry performed on immunoblots. The stimulation index represents the proportional 
increase in pAkt on stimulation with SEW2871, normalised to the total quantity of Akt. Graph 
shows means ± s.e.m.; n = 3. Data are representative of three independent experiments. 
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The observation that three-day activated cells responded strongly to stimulation 
with SEW2871 suggested that S1PR1 signalling could occur in cells expressing 
low levels of CD69.  
To explore this further, siRNA was used to attenuate the upregulation of CD69 
that follows T cell activation. T cells were transfected with negative control 
siRNA, with CD69-specific siRNA, or subjected to the transfection procedure 
without any siRNA, and left for six hours. The siRNA-transfected cells were then 
activated with CD3/28 beads for 24 hours. T cells transfected with CD69-
specific siRNA stained 56 % less intensely for CD69 than control- transfected 
cells (Figure 34). 
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Activated T cells; control siRNA 
 
 
 
Activated T cells; CD69 siRNA  
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The responses of the control siRNA -loaded and CD69 siRNA -loaded activated 
T cells to stimulation with an S1PR1-specific agonist were tested as previously 
described. Similar levels of phospho-Akt were detected in lysates of control and 
CD69 siRNA -transfected cells, whether ligand stimulated or not (Figure 35).  
 
 
 
 
 
 
 
Figure 34. Pre-loading T cells with CD69-specific siRNA reduced, but did not 
abolish, upregulation of CD69 following cell activation.  
T cells were isolated then rested overnight. They were split into three groups: one was not 
transfected with siRNA and left unactivated (first panel); the second was transfected with 
negative control siRNA (second panel) and then the cells activated with CD3/28 beads; 
the third group was transfected with CD69 siRNA (third panel) and the cells activated with 
CD3/28 beads. 24 hours after activation the beads were removed and samples of the 
cells stained with a monoclonal antibody against CD69. The cells were analysed by flow 
cytometry. The frequency of CD69-positive cells in each population and the mean 
fluorescence intensity of CD69 staining is shown in the table (fourth panel). Data are from 
a single experiment. Histograms relating to all cells represent approx. 10 000 events, 
those relating to gated cells approximately 9500, 1500 and 1000 events in the first, 
second and third parts respectively. 
Population 
Frequency of 
CD69+ cells (%) 
Mean fluorescence intensity 
(CD69) 
All 
cells 
Gated 
cells Gated cells 
Gated CD69+ 
cells 
Resting; no siRNA 0.8 0.2 - - 
Activated; control siRNA 24.8 37.0 1575 3770 
Activated; CD69 siRNA 17.9 17.7 684 2787 
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The high level of phosphorylated Akt detected in the unstimulated cell lysates 
was probably a consequence of the stress induced in those cells by 
electroporation. To reduce the amount of phosphorylated Akt in the 
unstimulated lysates, a strategy was developed to remove the highly stressed 
(probably pre-apoptotic) cells.  
T cells were transfected with siRNA then activated, as before. 24 hours after 
activation a subset of the cells were sorted out of the population according to 
their forward and side scatter characteristics (marked gate, Figure 36).  The 
activated T cells loaded with CD69 -specific siRNA stained 34 % less intensely 
for CD69 than the control cells (table, Figure 36). 
Figure 35. High levels of phospho-Akt were present in both unstimulated and 
SEW2871-stimulated siRNA-transfected cells.  
Samples of the siRNA-transfected cell populations were washed and rested for 3 hours 
with the CD3/28 beads removed. The cells were stimulated for 10 minutes with 10 µM 
SEW2871 or vehicle, then lysed. Equal quantities of protein were separated by SDS-
PAGE and pAkt detected by western blotting. Data are from a single experiment. !
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Figure 36. CD69 and control siRNA -loaded activated T cells were sorted based on their 
FSC / SSC characteristics and analysed for CD69 expression.  
T cells were either left unactivated or transfected with siRNA as before then activated with 
CD3/28 beads for approximately 24 hours. Samples of the cells were taken and sorted based 
on their FSC and SSC characteristics. They were also stained with a monoclonal antibody 
against CD69, and analysed by flow cytometry. Data are representative of three independent 
experiments. Histograms relating to all cells represent approx. 30 000 events; those relating to 
gated cells 26 000, 608 and 931 events in first, second and third parts respectively. 
Population Percentage of  CD69+ cells 
Mean fluorescence intensity 
(CD69) 
Whole cell 
population CD69
+ cells 
Resting T cells 0.2 101 - 
Activated T cells, control siRNA 67.4 5480 7971 
Activated T cells, CD69 siRNA 74.6 3622 4726 
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The ability of the sorted cells to respond to stimulation with SEW2871 was then 
tested. A more sensitive assay for phospho-Akt, a cell-based ELISA, was used. 
The cells were seeded into a 96 -well plate coated with poly-lysine and rested 
for 3 hours. They were then stimulated as before, for 10 minutes with either 10 
µM SEW2871 or vehicle. The cells were fixed with formaldehyde and the 
relative amounts of pAkt and Akt in the samples determined. Treatment with 
SEW2871 resulted in significantly greater phosphorylation of Akt in CD69 
siRNA-transfected cells than control cells. The basal level of phosphorylation of 
Akt in both cell populations was very similar (Figure 37). 
Figure 37. A comparison of the responses of CD69 siRNA-transfected and control 
siRNA-transfected activated T cells to stimulation with an S1PR1 -specific agonist.  
A flow cytometer / cell sorter was used to isolate the desired subsets of T cells based on their 
FSC and SSC characteristics (detailed in Figure 36). The sorted cells were washed and 
placed into serum-free medium. They were left to adhere to the bottom of poly-lysine coated 
plastic wells and rested for 3 hours. They were stimulated with either 10 µM SEW2871 (+W) 
or vehicle (-W) for 10 minutes then fixed with formaldehyde. pAkt (S473) and total Akt were 
detected using a cell-based ELISA. The relative amounts of pAkt in the samples were 
calculated by normalising the fluorescent signal value corresponding to pAkt to that of total 
Akt in each experimental well. Graph shows means ± s.e.m., n = 3. Data are representative 
of three independent experiments. 
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These data showed that the capacity for S1PR1 signalling to occur in T cells 
was transiently lost during cell activation through CD3 and CD28, and that this 
was in part due to the upregulation of CD69. Three days after activation T cells 
became again responsive to stimulation of S1PR1. 
As resting and activated T cells express different sets of chemokine receptors, 
the next step was to compare modulation of their chemotactic responses by 
S1P. Resting T cells were shown to express CXCR4 by flow cytometry (Figure 
38). Pre-treatment of the cells with either S1P or the S1PR1-specific agonist 
SEW2871 for one hour potently suppressed their subsequent migration towards 
CXCL12. In both cases this was highly significant (Figure 39). 
 
Figure 38. Resting T cells expressed CXCR4.  
Resting T cells were isolated and stained either with a fluorescently-conjugated monoclonal 
antibody against CXCR4 (blue) or the appropriate isotype-matched control (red). Cells were 
analysed by flow cytometry. Data are representative of three independent experiments. 
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Figure 39. Pre-treatment with S1P or SEW2871 potently inhibited the migration of 
resting T cells towards CXCL12.  
Upper panel; Resting T cells were isolated and either treated for 1 hour with 1 µM S1P (S) or 
vehicle (-), then left to migrate for 2 hours towards either 6.25 nM CXCL12 (C) or vehicle (-). 
Cells were enumerated by flow cytometry. Lower panel, same as upper panel except 
SEW2871 (W) was substituted for S1P. Graph shows means ± s.e.m. Data are 
representative of three independent experiments. 
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The migration of T cells towards many chemokines, including CXCL12, is 
dependent upon PI3K -catalysed formation of PIP3 at the leading edge of 
migrating cells (Curnock et al., 2002). As Akt contains a pleckstrin homology 
domain and binds to PIP3, phosphorylation of this kinase was used in a test for 
any effect of S1P on this signalling pathway. T cells were pre-treated for 1 hour 
with either 1 µM S1P or vehicle then stimulated with CXCL12 for 5 minutes and 
lysed. Similar amounts of phosphorylated Akt (S473) were observed in the 
lysates of CXCL12 -stimulated cells, whether or not the cells were pre-treated 
with S1P (Figure 40). 
 
 
 
 
Figure 40. S1P pre-treatment did not affect the extent of Akt phosphorylation caused by 
stimulation with CXCL12.  
Resting T cells were incubated for 1 hour with either 1 µM S1P or vehicle, and then stimulated 
either with 6.25 nM CXCL12 or vehicle for 5 minutes. Whole cell lysates were prepared and 
phospho-Akt (Ser473) and total Akt detected in them by western blotting. Data are representative 
of two independent experiments. 
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As previously stated, activated T cells express a different profile of chemokine 
receptors to resting cells, and consequently have different homing preferences. 
CXCL10 is a prototypical inflammatory chemokine expressed early at inflamed 
sites in the periphery, and binds the chemokine receptor CXCR3. Three days 
after activation with CD3/28 beads, T cells expressed high levels of this 
receptor (Figure 41). 
!
 
Interestingly, S1P pre-treatment significantly enhanced the migration of three 
day-activated T cells towards CXCL10 (Figure 42). Thus, although S1P did 
effect the migration of both resting and activated T cells, it had opposing effects 
on them. 
Figure 41. Three day-activated T cells expressed high levels of the chemokine receptor 
CXCR3.  
T cells were activated with CD3/28 beads for three days and then the beads removed. The cells 
were stained either with a fluorescently-conjugated monoclonal antibody against CXCR3 (blue; 
representing approx. 5000 events) or an appropriately matched isotype-control antibody (red), 
and analysed by flow cytometry. Data are representative of two independent experiments. 
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Figure 42. Pre-treatment with S1P enhanced the migration of three day-activated T cells 
towards CXCL10.  
T cells were activated for three days with CD3/28 beads and the beads removed. The cells 
were rested for 3 hours, then treated for 1 hour either with 1 µM S1P (S) or vehicle (-). The 
cells were then left to migrate for 2 hours towards either 100 nM CXCL10 (C) or vehicle (-). 
Migrated cells were enumerated by flow cytometry. Graph shows means ± s.e.m. Data are 
representative of two experiments. 
- / - S / - - / C S / C
0
500
1000
1500
2000
2500
3000 *
Cell pre-treatment / chemoattractant
 N
um
be
r o
f m
ig
ra
te
d 
ce
lls
CX140510.pzf:Data 1 graph - Fri Aug 12 11:10:57 2011
 128!
4.4 Discussion 
The current model of regulation of egress of T cells from lymphoid tissue 
encompasses two aspects: the situation in homeostatic conditions and in non-
specific lymph node inflammation. The relationship between the dynamics of 
CD69 expression on activation of T cells through their antigen-specific receptor 
and changes in S1PR1 signalling have not previously been studied in detail. 
Here, various approaches including flow cytometry, RNA interference and 
phospho-protein assays have been used to address this question. These 
findings support a model of regulation of S1PR1 signalling in CD3/28 activated 
T cells in which CD69 has a major role. Rapid upregulation of CD69 is induced 
on cell activation, reaching very high levels by 24 hours. Cells do not respond 
through S1PR1 at this time. Surface CD69 is then diluted on cell division, and 
the ability of S1PR1 to signal returns after three days in daughter T cells. 
The strong upregulation of CD69 over the course of 24 hours after activation 
with CD3/28 beads was expected and is broadly consistent with that reported 
by others (Risso et al., 1991). Significant expression of CD69 was observed at 4 
hours. This is consistent with the idea that there is a pre-synthesised 
intracellular pool of CD69 that can be translocated from inside the cell to the cell 
surface on receipt of various stimuli (Risso et al., 1991). It is known that CD3/28 
stimulation is a potent inducer of CD69 transcription, with evidence of binding 
sites in the 5’ untranslated region (UTR) of CD69 for NFkB, Egr and AP-1 
transcription factors (Lopez-Cabrera et al., 1995). It has been previously 
reported that CD3 and CD28 can act synergistically to induce very high levels of 
CD69 (Secchierio et al., 2000). CD69 is known to interact directly with S1PR1 
on the cell surface (Shiow et al., 2006) and will trigger degradation of S1PR1 
when overexpressed (Bankovich et al., 2010). It is a possibility that the very 
high levels of CD69 induced by CD3/28 stimulation are at least in part 
responsible for the rapid degradation of S1PR1 protein that is seen in the first 
day after activation (Graeler and Goetzl, 2002). 
Published work has shown that CD69 can appear at a very low level on T cells 
just one hour after entry into inflamed lymph nodes, with progressive 
upregulation over three hours (Grigorova et al., 2010). The authors propose a 
model in which it is implied that the quantity of CD69 on the cell surface after 
two hours is sufficient to block T cell egress. The exact point at which CD3/28 
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activated T cells lost responsiveness to stimulation through S1PR1 was not 
addressed here. Intracellular levels of pAkt were significantly increased one 
hour after addition of activation beads (data not shown) and this masked any 
effect of stimulation with SEW2871. CD69-mediated regulation of S1PR1 
signalling immediately after activation through CD3/28 is probably not important. 
In this instance, CD3 signalling triggers complete cell arrest (Dustin et al., 1997) 
and the cells are probably prevented from reaching exit structures in the first 
place. 
CD69 expression on the cell surface is at its height around 24 hours after 
activation, and S1PR1 signalling is blocked at this time. CD69 expression then 
decreased as the cells divided. Although the vast majority of three-day activated 
T cells were CD69-positive, they nevertheless responded to stimulation with the 
S1PR1 –specific agonist. The strength of their response, measured as the 
amount of Akt phosphorylation, was unexpected. It is shown here that S1PR1 
gene expression is reduced significantly on cell activation, and remains low 
three days later. With evidence for complete loss of protein 24 hours after 
activation (Graeler and Goetzl, 2002), only low levels of S1PR1 could 
conceivably return to the cell surface by day three. The lack of a reliable 
monoclonal antibody against S1PR1 precludes the resolution of this matter. The 
data here are consistent with a report which showed that in vivo activated T 
cells re-acquire at least some responsiveness to S1P by day three, although not 
to the extent of resting cells (Matloubian et al., 2004). In this report, the 
magnitude of the response to stimulation with SEW2871 was similar six days 
after activation, by which time two-thirds of the cells were CD69-negative. 
Published work shows that effector and memory T cells begin to appear in the 
circulation three days after cell activation in a primary response, and are widely 
disseminated in the periphery, including in other lymphoid tissues by day five 
(Matloubian et al., 2004; Miller et al., 2004). 
Considered as a whole, there was a large degree of variation in CD69 
expression in three day -activated T cells. Part of this is attributable to the 
mixture of cells of different generations. The mean fluorescence intensity of 
CD69 staining decreased by approximately one half with each generation 
across four distinct generations. CD69 gene expression is only transiently 
enhanced by cell activation, with little mRNA detectable 24 hours after PMA 
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stimulation of peripheral blood lymphocytes (Lopez-Cabrera et al., 1993). It is 
probable that there is little neosynthesis of CD69 after 24 hours, and that 
existing protein simply splits equally between daughters on cell division.  
That there might be differential responsiveness to stimulation of S1PR1 of 
different generations of cells at a single time point was not investigated. The 
mean fluorescence intensity of CD69 staining of all cells at three days was 
approximately one-fifth of that at 24 hours. More than half of the cells at three 
days belonged to generations two and three, and their mean fluorescence 
intensity (MFI) (of CD69) was only one-tenth that at 24 hours. It seems probable 
that the later generations of cells were more responsive to stimulation of S1PR1 
than the earlier ones, simply by virtue of their lower mean expression of CD69. 
Cells that have not proliferated and differentiated would not possess the 
capacity to exert their appropriate functions once they had left the lymphoid 
compartment, and it would make sense for these to be retained inside the node. 
Effector and memory T cells observed outside the node have invariably 
undergone multiple rounds of cell division (Miller et al., 2004). 
siRNA was used to attenuate the extent of upregulation of CD69 after T cell 
activation through CD3 and CD28. While the percentage of CD69-positive cells 
was not altered greatly, the amount of CD69 protein on the cell surface was 
reduced – and this resulted in a measurable increase in the amount of Akt 
phosphorylation caused by stimulation with SEW2871. One interpretation of this 
data is that below a certain threshold of CD69 expression, all S1PR1 protein is 
not inactivated and receptor signalling can be triggered. Alternatively the 
attenuated upregulation of CD69 may interfere with the ability of that protein to 
trigger efficient degradation of S1PR1. Measurement of the amounts of S1PR1 
protein both on the cell surface and inside the cell is needed in this experiment 
to clarify this matter. 
The suppression of resting primary T cell migration towards CXCL12 by S1P 
was unexpected, as it had been previously observed that Jurkat T cell migration 
towards this chemokine was enhanced (Figure 13). The reason for this is not 
clear, although one report has shown cell-type and S1P concentration –
dependent differences in the ability of S1P to modulate migration of mouse T 
cells towards CXCL12. It was shown that for peripheral lymph node -derived T 
cells, lower concentrations of S1P, in the 10 – 100 nM range, enhanced 
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chemotaxis, whereas 1 µM S1P (the concentration used in this study) had a 
slightly inhibitory effect. The inhibitory effect was not seen with splenic T cells. 
FTY720 inhibited migration of mouse PLN T cells towards CXCL12 (Yopp et al., 
2005). Low concentrations of S1P probably induce persistent S1P receptor 
signalling, whereas high concentrations of S1P (or FTY720) would be expected 
to downregulate the receptor from the cell surface. Perhaps differences 
between Jurkat and primary T cells in surface expression, and/or the dynamics 
of recycling, of S1PR1 underlie the disparity observed.  
The opposing effects of S1P pre-treatment on T cell migration towards CXCL12 
and CXCL10 might be related to differences in types of G"i G proteins coupled 
to their cognate receptors – CXCR4 and CXCR3 respectively. Efficient 
migration towards CXCL12 is dependent on the presence of both the G"i2 and 
G"i3 proteins, whereas migration mediated through CXCR3 is enhanced by 
downregulation of G"i3. Additionally, G"i3-deficient T cells did not show S1P-
mediated inhibition of CXCL12, rather an enhancement (Jin et al., 2008). 
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S1P Receptor-dependent Regulation of Egress of Activated 
T Cells from Lymph Nodes 
5.1 Introduction 
The recirculation of resting T cells under normal conditions is controlled by 
homeostatic chemokines and S1P, broadly controlling lymph node entry and 
exit respectively. A vascular gradient of S1P (with high levels of S1P in blood, 
intermediate levels in lymph and very low levels in lymphoid tissue (Hla et al., 
2008)) induces a characteristic pattern of recycling of S1PR1 between the cell 
surface and endosomes as a T cell recirculates (Lo et al., 2005). Inside the low 
S1P environment of uninflamed lymph nodes, S1PR1 recycles quickly from 
endosomes back to the surface of T cells and they become competent to 
egress soon after entry (Matloubian et al., 2004; Grigorova et al., 2010).  
In inflamed lymph nodes, T cell exit is blocked for up to several days. Interferon-
"/# signalling causes upregulation of CD69, and this protein interacts with 
S1PR1 on the cell surface, causing the receptor to be internalised and 
degraded (Shiow et al., 2006; Bankovich et al., 2010; Grigorova et al., 2010). 
The block in egress contributes to a non-specific accumulation of T cells, 
increases the probability of productive interactions between mature antigen-
presenting cells and T cells expressing the appropriate antigen-specific 
receptor, and thereby promotes adaptive immunity.  
In contrast to the situation outlined above, a number of significant questions 
remain regarding the control of egress from lymph nodes of T cells activated 
through their antigen-specific receptor. T cells are known to arrest on 
stimulation through their antigen-specific receptor (Dustin et al., 1997). This 
occurs alongside an initial rapid upregulation of CD69 on the cell surface 
following T cell receptor stimulation, subsequently downregulated with cell 
division. Simultaneously, the capacity for S1PR1 to signal in T cells is first lost 
following activation, then re-acquired after about three days (Chapter Four). 
These changes correlate with the appearance of activated T cells in the 
circulation about three days after the initial priming event in lymphatic tissue 
(Matloubian et al., 2004). Nevertheless, it is still not entirely clear to what extent 
activated T cells require S1P signalling to egress lymph nodes. According to the 
existing model, S1P signalling through S1PR1 is required to antagonise CCR7-
mediated retention signals. But while resting naïve T cells are CCR7hi, cell 
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activation downregulates this receptor (although it becomes re-expressed on 
central memory T cells (Sallusto et al., 1999)). Published work has shown that T 
cells genetically deficient in CCR7 are poorly sequestered in lymph nodes by 
FTY720 treatment, suggesting a limited requirement for S1P signalling for them 
to leave (Pham et al., 2008). 
Much of our knowledge regarding the contribution of S1PR1 signalling to 
promoting egress of resting T cells from lymphatic tissue comes from studies 
utilising the compound FTY720. FTY720 is in fact a pro-drug, and is rapidly 
phosphorylated in vivo by sphingosine kinase 2 (Kihara and Igarashi, 2008) to 
form the biologically active compound. Structurally similar to S1P, FTY720-P 
binds all the S1P receptors except S1PR2 (Brinkmann et al., 2002). Most 
importantly, it is a ‘super-agonist’ of S1PR1. In a !(35S) guanosine triphosphate 
assay, the EC50 of FTY720-P for S1PR1 was 0.14 nM, compared with 0.9 nM 
for S1P (Hogenauer et al., 2008). In vitro, seconds of incubation with FTY720-P 
caused significant internalisation of S1PR1 over the course of several hours 
(Graler and Goetzl, 2004), and it is much more potent than S1P at causing 
ubiquitination and degradation of S1PR1 (Oo et al., 2007). FTY720-P therefore 
behaves as a functional antagonist of S1PR1 on lymphocytes in vivo, 
downregulating the receptor and completely desensitising the cells to S1P-
mediated egress signals in lymph nodes. Treatment of mice with FTY720 
caused lymphocytes to become sequestered in lymph nodes, packed next to 
sinus-lining endothelium and unable to exit. This preceded and caused a 
profound drop in blood lymphocyte numbers (Mandala et al., 2002). 
Daily treatment of mice, rats, dogs and monkeys with FTY720 significantly 
prolonged allograft survival (Brinkmann et al., 2001). FTY720 was even trialled 
as an anti-rejection therapy in humans, although significant side-effects 
(including bradycardia, hypertension and macula oedema) and comparable 
efficacy to existing therapies meant that its use did not proceed beyond the trial 
stage (Budde et al., 2002; Tedesco-Silva et al., 2005; Salvadori et al., 2006). 
Impressive results have been reported in a phase III trial for multiple sclerosis 
(Kappos et al., 2010). Because FTY720 treatment resulted in a dramatically 
reduced number of allograft-infiltrating T cells in animal models, and that this 
correlated with sequestration of T cells in lymphoid tissue, it was initially 
assumed that FTY720 could block egress of activated T cells from lymph nodes 
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(Chiba et al., 1998). Consistent with this, FTY720 appeared to work 
therapeutically, rather than just prophylactically, to block immune responses. 
For example, in rats, FTY720 administered 3 to 4 days after engraftment 
prolonged graft survival (Xu et al., 1998). Furthermore, Pinschewer et al. 
showed that FTY720 could block the homing of LCMV-specific TCR transgenic 
effector T cells out of lymph nodes into skin in a delayed-type hypersensitivity 
reaction model (Pinschewer et al., 2000). 
Recent data however has cast doubt on the existing explanation for these 
findings. These studies suggested that disruption of T cell recirculation by 
FTY720, with a consequent impairment of immune priming, might be the 
primary mechanism of its immunosuppressive effect (Xie et al., 2003; 
Nakashima et al., 2008). Here, a novel approach has been used to clarify 
whether or not the egress of newly formed activated T cells from lymph nodes is 
dependent on S1P signalling (and can therefore be blocked by FTY720 
treatment). By injecting fully MHC-mismatched cells into the mouse footpad, a 
specific alloimmune response was generated. Enzyme-linked immunosorbent 
spot (ELISPOT) was used to measure the frequency of alloreactive cells in 
various immune compartments after six days. The response was modulated 
with daily administration of FTY720-P, delayed for 48 hours after footpad 
injection to exclude any effect of the drug on movement of sensitising material 
to the draining popliteal node.  
Sensitisation with allogeneic cells injected into the footpad resulted in an 
increase, measured after six days, in the frequency of alloreactive cells in the 
draining popliteal lymph node and other lymphoid compartments. This 
confirmed the generation of a specific alloimmune response. Treatment of 
unimmunised mice with FTY720-P resulted in depletion of T cells from their 
peripheral blood, confirming biological activity of the drug. Importantly, FTY720-
P treatment of immunised animals resulted in an increase in the frequency of 
alloreactive cells within the popliteal node measured at the day six time point. 
This was correlated with a higher percentage of CXCR3-positive cells in the 
activated lymph nodes of drug-treated mice, consistent with a blockade in 
egress of activated T cells. These findings suggest that the egress of (at least a 
proportion of) activated T cells from lymph nodes is dependent on intrinsic S1P 
receptor signalling. 
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The aims of this chapter were as follows: 
• To design a suitable mouse model of alloimmunity 
• To optimise a method for measurement of the frequency of alloreactive 
cells in lymphoid tissue 
• To study the effect of treatment with FTY720-P on the egress of 
activated alloreactive cells from lymph nodes 
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5.2 Materials and Methods 
Reagents 
FTY720 (S) Phosphate (also referred to here as FTY720-P and FTY-P) was 
purchased from Cambridge Bioscience (Cambridge, UK). It was dissolved in 
ethanol at 1 mg/ml then aliquotted for storage at -20 °C. 1 mg/ml FTY720-P was 
diluted further in sterile water + 2 % #-cyclodextrin (Sigma-Aldrich) to 100 µg/ml, 
and then mixed thoroughly, on the day of use. 
Animals and procedures 
Female mice of the BALB/c and C57BL/6 strains were purchased from Charles 
River (Margate, UK). They were maintained under pathogen-free conditions and 
used at between six and eight weeks of age. All animal procedures were done 
in accordance with UK Home Office and EU Institutional Guidelines and within 
the parameters of current personal and project licences. 
Work with live mice was performed by trained staff at the Comparative Biology 
Centre (Medical School, Newcastle University, UK). Blood samples were taken 
either via the tail vein while alive, or by cardiac puncture during terminal 
anaesthesia. Lymph nodes and spleens were removed within 30 minutes of 
death. Unilateral mouse footpad injections (subcutaneous) were performed by 
Professor John Robinson (Institute of Cellular Medicine, Newcastle University, 
UK). Each injection comprised 5 million splenocytes suspended in 25 µl RPMI 
1640 medium.  
Mice were injected either intraperitoneally (i.p.) or intravenously (i.v.) with 100 µl 
100 µg/ml FTY720-P as required. 
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Isolation of cells from lymph nodes and peripheral blood 
Popliteal lymph nodes, mesenteric lymph nodes, spleens and blood samples 
were removed from dead mice six days after injection of their footpads with 
allogeneic splenocytes. Cell suspensions were prepared from lymph nodes and 
spleens by pressing them through 70 µm cell strainers into RPMI 1640 medium. 
In the case of splenocyte preparations, the cells were layered over Histopaque-
1083 (Sigma-Aldrich) and separated by density-gradient centrifugation. The 
leukocytes were isolated from the interface and the rest discarded. Splenocytes 
and lymph node-derived cells were washed twice with RPMI 1640 medium 
before use.  
Blood samples were taken either by cardiac puncture or dropwise from a 
puncture wound in the tail vein. Samples were immediately mixed ex vivo with 
100 U  / ml heparin to prevent coagulation. Erythrocytes were lysed by 
resuspension of cells in 1 ml of Red Blood Cell Lysing Buffer Hybri-Max (Sigma-
Aldrich) per sample, and incubation for 1 minute at room temperature. 
Remaining cells were washed twice with RPMI 1640 medium before use. 
Isolation of T cells from splenocytes 
Total CD3+ T cells were isolated from splenocyte preparations using a negative-
selection kit (EasySep Mouse T Cell Enrichment Kit; StemCell Technologies, 
Grenoble, France). The purity of the cells was verified by flow cytometry. 
Irradiation of cells 
In some experiments cells were exposed to 20 Gray (Gy) !-radiation before use. 
This was done using a high-activity sealed-source Gamma Cell Irradiator 
(Nordion, Ottowa, Canada), with an effective exposure of sample containers to 
the 60Co source of 3.02 Gy per minute. Samples were exposed for a total of 6 
minutes and 37 seconds in each instance. 
ELISPOT assay 
Cells were cultured in 96-well format Immobilon MultiScreen-P plates (Millipore, 
Watford, UK). The plates were first activated and coated with a capture rat anti-
mouse IFN-! antibody (AN18; Mabtech, SE-131 28 Nacka Strand, Sweden) 
diluted into carbonate-bicarbonate buffer (Sigma-Aldrich) overnight at 4 °C. The 
plates were then washed twice with PBS and blocked with RPMI 1640 + 10 % 
FBS + 2 mM L-Glutamine + 100 U/ml Penicillin + 0.1 mg/ml Streptomycin 
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(Sigma-Aldrich) for one hour at room temperature. Before use in cell culture, the 
plates were washed once further with PBS. 
Unless otherwise stated, the recall mixed leukocyte reaction assays were 
constituted as follows in each well of the 96-well format plate. 10 000 C57BL/6 – 
derived cells (from blood, lymph node or spleen) were mixed with 200 000 
BALB/c splenocytes in a total volume of 200 µl RPMI 1640 + 10 % FBS + 50 
µM #-mercaptoethanol + 2 mM L-Glutamine + 100 U/ml Penicillin + 0.1 mg/ml 
Streptomycin (Sigma-Aldrich). The cells were cultured for approximately 18 
hours before being discarded. In some cases cells were stimulated with 5 µg/ml 
concanavalin A (Sigma-Aldrich) as a positive control. 
ELISPOT assays were developed as follows. The cells were discarded and 
plates washed six times with PBS. The biotinylated IFN-! detection antibody 
(R4-6A2; Mabtech), diluted in PBS, was applied and the plates left overnight at 
4 °C. The detection antibody was discarded and the plates washed six times 
with PBS. The streptavidin-alkaline phosphatase conjugate (Mabtech) was 
diluted in PBS and applied for one hour to the plates at room temperature. They 
were washed another six times with PBS. 50 µl of BCIP/NBT liquid substrate 
system for membranes (Sigma-Aldrich) was added to each well. Development 
was for 5 – 10 minutes at room temperature, and the reaction was stopped by 
removal of substrate and thorough washing with tap water. 
Spots were enumerated using an ELISPOT reader (AiD, Strassberg, Germany). 
Flow cytometry 
Splenocytes and lymph node-derived cells were stained with fluorescently-
conjugated monoclonal antibodies or isotype-matched controls. The specific 
antibodies used were: CXCR3 (220803; R&D Systems) and CD3 (KT3; AbD 
Serotec). Data was acquired on a FACSCanto II instrument (BD Biosciences) 
and analysis performed using FACSDiva 6.1.3 (BD Biosciences) and FlowJo 
7.6 (Treestar) software.  
Statistics 
Prism 4.0c (GraphPad Software, USA) was used for all statistical analyses. 
Comparisons between groups were made using the Students’ t test for unpaired 
data. P values ( 0.05 were considered significant (*), ( 0.01 highly significant 
(**), and ( 0.001 very highly significant (***). 
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5.3 Results 
In this study, alloimmune responses were generated in vivo by subcutaneous 
injection of BALB/c splenocytes into the footpads of C57BL/6 mice. Prior to 
those experiments however, the mixed leukocyte reaction between C57BL/6 T 
cells and BALB/c splenocytes was studied ex vivo. T cells were isolated by 
negative selection from the splenocytes of C57BL/6 mice. Analysis of the cells 
after selection showed that the population of T cells was of very high purity 
(Figure 43). 
 
Using a constant number of BALB/c splenocytes as stimulators, a panel of 
mixed leukocyte reactions (MLRs) with different numbers of C57BL/6 T cell 
responders were set up. In this experiment, some of the stimulators were 
irradiated before the assay (to inhibit any cytokine production by them) and 
others not. The number of IFN-! spot- forming cells in each well after 18 hours 
of co-culture was determined by ELISPOT. Figure 44 shows the appearance of 
experiment wells at the end-point of a typical (unspecified) assay. Figure 45 
(upper panel) shows the results of the various MLRs. 
Figure 43. T cells were purified from whole splenocytes.  
Spleens were removed from C57BL/6 mice and disrupted to release splenocytes. The 
splenocytes were mixed with a cocktail of antibodies against non-T cell markers, which 
were then coupled to magnetic particles. T cells were separated from the population by 
negative selection using a magnet. Cell samples before and after selection were stained 
with a fluorescently-labelled monoclonal antibody against CD3 (blue) or appropriate 
isotype-matched control (red), and analysed by flow cytometry. 
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As expected, very few IFN-! spot-forming cells were found among stimulators 
(irradiated or not) or responders cultured alone. The T cell mitogen 
concanavalin A, added to stimulators or responders alone, or a mixture of the 
two, resulted in a very high number of IFN-! producing cells. With the number of 
BALB/c splenocytes kept constant in each reaction, the number of IFN-! spot-
forming cells detected was linearly correlated with variation in the number of 
C57BL/6 T cells (Figure 45 (lower panel)). With unirradiated stimulators and 10 
000 C57BL/6 T cells in the reaction, the mean number of spot-forming cells was 
7.67 (Standard error of the mean (SEM): 1.20). Alternatively expressed, 1 in 
1300 cells was stimulated to produce sufficient IFN-! to be detected in this 
assay. Irradiation of the stimulators reduced the number of IFN-! spot-forming 
cells detected by approximately one half, compared with the equivalent reaction 
with unirradiated cells. With 10 000 C57BL/6 T cells in the reaction, the mean 
number of spot-forming cells was 3.67 (SEM: 0.33), equivalent to 1 in 2730 
cells. 
Figure 44. The number of IFN- ! spot-forming cells in a cell sample was determined 
using the ELISPOT technique.  
Samples containing potentially IFN- ! producing and non-producing cells were placed into 
the wells of a 96-well plate, in which the bottom of each well was coated with IFN- ! capture 
antibody adsorbed to PVDF membrane. The cells were cultured for 18 hours then removed. 
An IFN- ! detection antibody coupled to enzyme-catalysed production of an insoluble 
precipitate was used to detect bound cytokine. The wells were imaged with a CCD-camera 
and individual spots counted by specialist software. 
51 28 15 
10 0 
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Figure 45. Measurements of the number of IFN- ! spot-forming cells resulting from 
various mixed leukocyte reactions.  
Upper panel, splenocytes were isolated from BALB/c mice and splenic T cells (purified by 
negative selection) from C57BL/6 mice. The BALB/c cells were used as stimulators (S) and 
the C57BL/6 T cells as responders (R) in mixed leukocyte reactions. The cells were 
(co)cultured for 18 hours before being removed and the number of IFN- ! spot-forming cells in 
each well determined by ELISPOT. Where present, 200 000 stimulators were used per well. 
Where present, the number of responders was varied from 100 000 (100k) to 1000 (1k) per 
well. The stimulators were either irradiated (i) or not (ni). In some cases cells were stimulated 
with 5 µg/ml concanavalin A (ConA). #, spots were too numerous to be counted reliably. Data 
shows means ± s.e.m. (triplicate determinations). Lower panel, separate linear regression 
analyses of data with unirradiated and irradiated stimulators. 
 143!
5x106 BALB/c splenocytes were injected subcutaneously into the left hind 
footpad of each of five C57BL/6 mice. Six days later, the mice were killed and 
the lateral and contralateral popliteal lymph nodes (PLN) removed (Figure 46). 
The number of cells derived from the draining (lateral) popliteal lymph nodes 
was approximately four times that from the contralateral nodes (mean cell 
counts: 2.01x106 and 0.49x106 respectively) (Figure 47). This was consistent 
with the generation of a localised immune response. !
!!
!!
Figure 46. Excision of a popliteal lymph node.  
A mouse was killed and an incision made in the skin of the hind limb, running from the foot to the 
abdomen. The skin was peeled back and secured with pins. The popliteal node, located behind 
the knee, was separated from the body using forceps placed behind the node and scissors to cut 
any restraining tissue. This was done aseptically in a category II laminar flow cabinet with an 
ethanol-rinsed mouse dissection kit. 
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Next, three mice were sensitised as before and the draining popliteal nodes 
removed after six days. The lymph node-derived cells were cultured with 
BALB/c stimulators for 18 hours and IFN-! spot-forming cells detected by 
ELISPOT. The results for the three mice are shown separately in Figure 48. 
Expressed as frequencies, the responses of the three mice were very similar: 
mean 3.15, range 3.06 - 3.21 IFN-! spot-forming cells per 1000 PLN –derived 
cells. !!!
Figure 47. Injection of BALB/c splenocytes into single footpads of C57BL/6 mice 
resulted in higher cellularity of the draining lateral than contralateral popliteal lymph 
nodes.  
Five C57BL/6 mice were each injected with 5x106 BALB/c splenocytes into their left hind 
footpad. Six days later the mice were euthanased and the lateral and contralateral popliteal 
lymph nodes removed. The nodes were disrupted and the freed cells counted using a 
haemocytometer. Points represent individual mice; horizontal lines the means. 
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To confirm that the increase in frequency of IFN-! spot-forming cells was a 
consequence of a specific alloimmune response, and not a consequence of 
non-specific inflammation, a further experiment was performed. Three mice had 
allogeneic cells injected into a footpad, and a control mouse received syngeneic 
cells. After six days, the mice were killed and draining popliteal nodes, 
mesenteric nodes, spleens and blood samples taken. ELISPOT was used as 
before to detect IFN-! spot-forming cells resulting from the mixed leukocyte 
reaction. The data are now expressed as frequencies to aid comparison 
between experiments. The frequencies of IFN-! spot-forming cells were higher, 
in all compartments examined, in the allosensitised mice than in the mouse that 
Figure 48. The number of popliteal lymph node -derived cells that produced IFN-!  on 
recall stimulation was determined by ELISPOT.  
Three C57BL/6 mice (Ms 1 – 3) were each injected with 5x106 BALB/c splenocytes into their 
left hind footpad. After six days the mice were killed and the lateral popliteal nodes removed. 
The popliteal lymph node-derived cells were either seeded alone (100 000 per well) or co-
cultured with BALB/c splenocytes (200 000 per well) in a mixed leukocyte reaction. In some 
cases stimulators were cultured alone or with 5 µg/ml concanavalin A (ConA). After 18 hours 
the cells were removed and the number of IFN-! -producing cells that had been present in 
each well determined by ELISPOT. Graph shows means ± s.e.m. (triplicate determinations). 
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received syngeneic cells (Figure 49). Interestingly, the frequencies of 
responding cells were similar in the draining popliteal nodes, spleens and blood, 
but lower in the mesenteric nodes. This probably indicates that alloactivated T 
cells have emigrated from the popliteal lymph nodes into the blood 
compartment. 
!
!!
Figure 49. Injection of allogeneic cells into the footpad resulted in a higher 
frequency of IFN-!  spot-forming alloreactive cells in several immune compartments 
than sensitisation with syngeneic cells.  
Three C57BL/6 mice were each injected with 5x106 BALB/c splenocytes into their left hind 
footpad. One mouse was injected with 5x106 C57BL/6 splenocytes. Six days later the 
mice were killed and the draining popliteal lymph node (PLN), mesenteric nodes (MLN), 
spleen (SPL) and sample of peripheral blood (BLO) taken from each animal. 10 000 of the 
spleen, lymph node or peripheral blood-derived cells were co-cultured with 200 000 
BALB/c splenocytes in mixed leukocyte reactions. After 18 hours of culture the number of 
IFN-! spot-forming cells per well was measured by ELISPOT. The data are expressed 
here, and in similar subsequent figures, as frequencies. Graph shows means ± s.e.m. 
(triplicate determinations). 
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In this study, the phosphorylated derivative of FTY720 – which is the bioactive 
compound - was administered directly to the mice in order to modulate cell 
trafficking. Before use in this model, the activity of the drug was tested. FTY720-
P was administered i.p. or i.v. to mice each day for two days and the T cell 
count in peripheral blood measured on the third day. As expected, and 
irrespective of the route of administration, FTY720-P caused a very large 
decrease in the number of T cells in the peripheral blood (Figure 50). In one 
experiment, the absolute CD3+ cell counts were: no drug, 8.14x106 per ml; i.p. 
FTY720-P, 0.46x106 per ml; i.v. FTY720-P, 0.36 x106 per ml. In further 
experiments, the drug was administered via the i.p. route. !
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Figure 50. Treatment of mice with FTY720-P either i.v. or i.p. resulted in almost 
complete depletion of T cells from peripheral blood.  
Three C57BL/6 mice were treated as follows. One was left untreated; the second 
injected i.p. with 100 µl of 100 µg/ml FTY720-P each day for two days; the third 
injected i.v. with 100 µl of 100 µg/ml FTY720-P each day for two days. On the third 
day 50 µl blood samples were taken from the mice via the tail vein. The blood 
samples were stained with a fluorescently conjugated anti-mouse CD3 monoclonal 
antibody. CD3-positive cells were enumerated by flow cytometry. Numbers shown in 
the figure are the percentage of cells derived from peripheral blood staining positive 
for CD3. Data is from one experiment. 
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Adaptive immune responses begin with the transport of antigen to a lymph node 
where it is presented by specialised antigen-presenting cells to T cells. As there 
is some evidence to suggest that FTY720-P may interfere with the early steps in 
this process, in our protocol administration of the drug was delayed for two days 
after footpad injection. So, to see whether FTY720-P could block egress of 
activated alloreactive cells from the popliteal node, C57BL/6 mice were first 
sensitised by footpad injection with BALB/c splenocytes, as before, on day zero. 
The mice received i.p. injections either with FTY720-P or control each day from 
day two to day five and were killed on day six. The draining popliteal lymph 
nodes were removed, and the cells derived from them reacted with BALB/c 
splenocytes to determine the number of alloreactive cells by IFN-! ELISPOT. 
Interestingly, while FTY720-P had no effect on the total number of cells within 
the activated popliteal lymph nodes (Figure 51, upper panel), it did cause a 
significant increase in the frequency of alloreactive cells there (mean 
frequencies of 15.0 (drug-treated) and 7.9 (control treated) per 1000 PLN-
derived cells respectively; Figure 51, lower panel).  
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Figure 51. FTY720-P treatment increased the frequency of alloreactive cells in the 
popliteal lymph node.  
Day 0: 5x106 BALB/c splenocytes were injected into the hind left footpads of C57BL/6 mice. 
Days 2-5: mice were injected daily i.p. with 100 µl of 100 µg/ml FTY720-P or vehicle. Day 6: 
Mice were killed, and the draining popliteal nodes removed. Upper panel; the total number of 
cells derived from each node was measured using a haemocytometer. Lower panel; popliteal 
node-derived cells were co-cultured with BALB/c splenocytes. The frequency of IFN-! spot-
forming cells was determined by ELISPOT. Points represent individual mice; 6 mice treated with 
vehicle, 7 with FTY720-P. Horizontal lines are means. 
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These results indicated that FTY720 could sequester activated, alloreactive, 
cells within the draining lymph node. To confirm that these cells were activated 
T cells, cells from the draining popliteal nodes of FTY720-P and control–treated 
animals were stained with a CXCR3-specific monoclonal antibody. As expected, 
FTY720-P treatment resulted in an almost doubling of the percentage of 
CXCR3-positive cells in the draining lymph node (Figure 52; FTY720-P -treated: 
18.9 %, SEM: 2.56; control-treated: 9.83 %, SEM: 0.491). !!!!!!!!!!!!!!!!
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Figure 52. FTY720-P treatment of allosensitised mice caused the retention of 
CXCR3-positive cells within the draining popliteal node.  
Popliteal lymph node -derived cells were taken from three vehicle-treated and three 
FTY720-P -treated mice used in the previous experiment. The cells were stained with a 
fluorescently conjugated anti-mouse CXCR3 monoclonal antibody, and analysed by 
flow cytometry. Upper panel; representative staining of cells from one control mouse 
and one drug-treated mouse. Numbers are the percentage of CXCR3-positive cells. 
Lower panel; percentages of cells derived from the draining popliteal lymph nodes of 
three control and three drug-treated mice that were CXCR3-positive. Data points are 
individual mice, horizontal lines are means of each group. 
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5.4 Discussion 
Here, an in vivo model of alloimmunity has been used to address several 
outstanding questions over the control of egress of antigen-activated T cells 
from lymphoid tissue. An alloantigen challenge model was used to test for 
dependence of activated T cells on S1P receptor signalling for egress from an 
activated lymph node. The findings support a model in which recently activated 
T cells are able to leave an inflamed lymph node while non-specific cells remain 
sequestered there. This presumably allows for early trafficking of effector T cells 
to the periphery and immune protection, whilst maintaining capacity inside the 
lymph node for further immune priming and maturation of the adaptive immune 
response. 
Cultured ELISPOT specific for IFN-! was used in this study to estimate the 
frequency of alloreactive cells in various compartments. This was because 
alloimmune responses are commonly associated with a dominance of Th1 type 
immunity, associated with high levels of IFN-! production (Strom et al., 1996). 
The finding here that approximately 0.1 % of splenic T cells from ‘naïve’ 
C57BL/6 mice reacted with BALB/c splenocytes by production of IFN-! is 
broadly similar with results reported by others (Felix et al., 2007). Nevertheless, 
it is probable that the frequencies reported here are an underestimate of the 
true numbers of alloreactive cells in vivo, either because of the existence of 
alloreactive cells that did not produce IFN-!, or those producing levels that were 
below the limit of detection of the assay.  
In the first set of in vivo experiments, mice were primed with BALB/c 
splenocytes injected into one hind footpad. After six days, the cellularity of the 
draining popliteal lymph node and contralateral node from each mouse were 
measured. As expected, there was a significant difference between them. There 
was a mean of approximately 2x106 cells in the draining node, four times that in 
the contralateral one. In a similar study, in which the same number of BALB/c 
splenocytes were injected into the footpads of C57BL/6 mice, the authors 
reported slightly higher counts in the popliteal node than those recorded here 
(mean cell counts of about 3x106 in the draining node), although they looked 
seven days after footpad injection (Funeshima-Fuji et al., 2008). Whether the 
disparity can be attributed to the different experiment endpoint, or other factors, 
could be resolved by further study of the dynamics of node inflammation after 
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footpad injection. Nevertheless, the results here are consistent with 
inflammation of the draining node, and an accumulation of lymphocytes caused 
by a non-specific block in lymphocyte egress. Direct presentation of intact allo-
MHC on BALB/c splenocytes to C57BL/6 T cells within the node itself was 
probably the most important method of immune priming in this situation. This is 
because there is a much higher frequency of precursor T cells that will be 
activated by intact MHC complexes on allogeneic cells than processed peptides 
derived from allo-MHC (indirect presentation by host antigen-presenting cells). 
High levels of IFN-" produced by T cells (and probably also by NK cells) will 
then trigger upregulation of CD69 on ingressing T cells, resulting in a block in 
their egress (Shiow et al., 2006).  
Priming with BALB/c splenocytes resulted in an increase in the frequency of 
alloresponders (measured six days after injection) in not just the draining 
popliteal lymph node, but also the spleen, mesenteric nodes and blood. This 
implies the release of alloreactive T cells, originally activated in the popliteal 
node, throughout the mice. Interestingly, the number of alloreactive cells in the 
mesenteric nodes was much lower than the spleen and blood. This probably 
reflects the low number of specific central memory cells able to enter that 
compartment, whereas the blood and spleen probably contained a mixture of 
memory and effector T cells. In a study in which mice were challenged with 
OVA antigen intradermally in the neck and ear, antigen-specific cells were 
observed in distal lymph nodes as early as day five (Miller et al., 2004). These 
data therefore suggest that by day six after injection of alloimmune cells into the 
footpad, specific cells are egressing the draining node, whilst inflammation there 
is still ongoing. 
Published work has shown that FTY720 can influence the earliest stages 
involved in the generation of adaptive immune responses. Using an antigen 
challenge model, Xie et al. showed that if FTY720 is administered prior to 
injection of antigen into the footpad, then the number of activated T cells in the 
draining lymph node, measured three days after priming, was significantly 
reduced (Xie et al., 2003). They suggest that this effect is mediated, in part, by 
a defective recirculation of naïve T cells triggered by drug treatment. This 
attenuates the accumulation of potentially reactive naïve T cells in the local 
lymph node, thereby impairing the efficiency of the adaptive response. 
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Therefore, to minimise the influence of FTY720 on immune priming in this 
model, FTY720-P treatment was delayed for two days after footpad injection. By 
this time, it would be expected that direct presentation will have occurred and T 
cells will be proliferating in the node. Few T cells would be expected to be 
leaving however at this stage. 
FTY720-P treatment increased the frequency of alloactivated cells in the 
draining lymph node six days after footpad injection. This clearly implies that at 
least some of the alloactivated T cells capable of leaving up to that time point 
were dependent on S1P receptor signalling for egress. The results of our study 
bolster the conclusions of Habicht et al. who showed that effector memory T 
cells could be trapped in regional lymphoid tissue by FTY720 treatment. They 
also used an alloimmune model, although they adoptively transferred TCR-
transgenic allospecific T cells along with the allograft, and then followed how the 
distribution of those cells was affected by FTY720 (Habicht et al., 2006). Here, 
ELISPOT has been used to show that activated alloreactive cells (originating 
from the recipient animal) are similarly retained in lymph nodes by FTY720-P 
treatment. 
Other groups have suggested that antigen-activated T cells are not dependent 
on S1P receptor signalling for cell egress from lymph nodes. It has been known 
for some time that whereas FTY720 treatment efficiently depletes naïve T cells 
from peripheral sites, and sequesters them in LN, antigen-experienced cells are 
not so affected (Hofmann et al., 2006). Furthermore, using an in vivo model of 
contact hypersensitivity, Nakashima et al. showed that FTY720 did not 
significantly suppress the delayed-type hypersensitivity reaction if administered 
during the elicitation phase (Nakashima et al., 2008). It is possible however to 
reconcile these apparently contradictory sets of results. Regarding the delayed 
type hypersensitivity model, the generation of effector memory cells in the 
sensitisation phase probably explains their results. Pre-existing effector memory 
T cells do not efficiently enter lymph nodes, and are not therefore sequestered 
there by FTY720 treatment delivered during the elicitation stage.  
That antigen-activated T cells were indeed being retained by FTY720-P 
treatment was confirmed by CXCR3 staining. However, as both effector 
memory and central memory T cells express this receptor (Groom and Luster, 
2011), it is not possible to be certain whether there was any bias in retention of 
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one of these subsets. Central memory cells do express CCR7 and it seems 
reasonable to suppose that this may confer a stronger requirement for S1PR1 
signalling to facilitate their egress (compared with effector memory and effector 
cells). T cells genetically deficient in CCR7 are less efficiently retained in lymph 
nodes by FTY720 treatment than wild type cells (Pham et al., 2008). Analysis of 
the retained lymphocytes for effector and central memory markers (including 
CD45RA, CD45RO and CCR7) is clearly needed to resolve this question. 
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General Discussion 
6.1 Summary 
Effective T cell-mediated adaptive immunity depends on the orchestration of a 
complex series of cell movements. Chemokines produced either constitutively, 
or induced for example in response to inflammation, play an important role in 
many cases. Recent work has indicated that the endogeneous lipid sphingosine 
1-phosphate and the chemokine ligands for CCR7, CCL19 and 21, act in a 
complementary way to direct T cell recirculation under homeostatic conditions. 
In this thesis, the role of S1P in control of T cell trafficking was explored in 
further detail. At the start of the investigation, one objective was to look for 
potential cross-talk between the S1P signalling axis and that of a prototypical 
chemokine. Secondary to this, the aim was to understand mechanistically any 
observed effects on chemokine function. Another objective was to observe and 
explain the regulation of S1P signalling after T cell activation, and to test in vivo 
the dependence on S1P for the egress of antigen-activated T cells from 
lymphoid tissue. 
The data presented in this thesis show cross-talk between the S1P and 
chemokine signalling pathways. They show that S1P can potently affect the 
ability of both resting and activated T cells to migrate towards homeostatic and 
inflammatory chemokines. This furthers our understanding of the ways in which 
T cell migration can be cross-regulated by multiple factors that they may 
encounter in vivo. It was also shown here that T cell activation is followed by 
changes in the capacity of S1P to signal through its receptor S1PR1. This was 
demonstrated to be a result of changes both in S1PR1 gene expression and in 
expression of the transmembrane protein CD69. This is biologically significant 
as the egress of activated T cells from lymph nodes is dependent on S1P 
receptor signalling. These results contribute to our understanding of a 
fundamental aspect of adaptive immunity: how the egress of activated T cells, 
primed in lymph nodes during adaptive immune responses, is regulated. 
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6.2 Cross-talk between S1P and Chemokines 
Changes in the expression of chemokines in various immune compartments, 
and in the expression of chemokine receptors on T cells, can only partly explain 
the fine control of cell migration in vivo. It has become clear that there is much 
cross-regulation and integration of different signals that allows the migration of 
cells to be precisely controlled depending on the immune status at any 
particular time and at any specific site in the body. Foxman et al. have 
described a ‘chemotactic field’ in which cells receive multiple inputs at each 
stage as they migrate (for example from vascular endothelium to their final 
destination at some site in peripheral tissues (Foxman et al., 1997)). 
Cross-regulation of chemokine responses is extensively described in the 
literature. An example of this is the cross-inhibition of migration and adhesion 
responses induced by CXCL12 and CCL5 (Vaday et al., 2001; Hecht et al., 
2003). This occurs via a process known as heterologous desensitisation, in 
which G protein-coupled receptors (other than the type directly stimulated) are 
internalised. Cross-phosphorylation of chemokine receptors by protein kinase 
C, and a pathway involving phospholipase C activity (Didsbury et al., 1991; Ali 
et al., 1999) are involved in the process. Evidence has been found that points to 
a specific role for the protein kinase C -epsilon (PKC&) isoform in the ability of 
CXCR1 and CCR5 to cross-desensitise each other on receptor signalling 
(Nasser et al., 2005). fMLP (a bacterial product and end-stage chemoattractant) 
can stimulate the cross-phosphorylation of the C5aR and the IL-8 receptor 
CXCR1, but is itself resistant to this regulation (Richardson et al., 1995). It is 
thought that this kind of regulation is necessary for the prioritisation of 
chemotactic cues. Responses to chemokines are also affected by the non-
chemotactic factors. TNF-" augments the pro-adhesive action of CXCL12, but 
suppresses the migratory response to the chemokine (Franitza et al., 2000). It 
has been suggested that this might be important for anchoring T cells at 
inflamed sites where they may then execute their effector function. 
A drive to understand the mechanism of action of the immunosuppressive drug 
FTY720 led to the discovery that the lysophospholipid S1P plays, at the least, 
an important role in the homeostatic trafficking of T cells. Pham et al. showed 
that S1P functions specifically in T cells at egress sites in lymph nodes. S1PR1 
signalling was shown to inhibit G"i signalling, predominantly that of CCR7, to 
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promote cell entry into cortical sinuses (Pham et al., 2008). Thus the S1P / 
S1PR1 signalling axis was demonstrated to interact directly with that of 
chemokines in the control of T cell recirculation. The ubiquity of chemokines 
and S1P in many different compartments in vivo means that there are other 
opportunities for crosstalk between the two signalling pathways. These include 
S1PR1 and the other prominent homeostatic chemokine CXCL12, and also 
inflammatory chemokines such as CXCL10. 
A number of preliminary studies showed that S1P could indeed modulate 
responses to chemokines other than the CCR7 ligands (Graeler et al., 2002; 
Yopp et al., 2005). They did not however offer any mechanistic insight into how 
this was mediated. In Chapter 3 the ability of S1P to modulate T cell chemotaxis 
towards the homeostatic chemokine CXCL12 was tested using the Jurkat 
human T cell line. A systematic approach was then applied to address the 
question of a potential mechanism for any observed effect. Pre-treatment with 1 
µM S1P for one hour enhanced the migration of Jurkat T cells towards CXCL12. 
Use of a receptor-specific agonist showed that the effect was mediated through 
S1PR1. The enhancement of migration could not be explained simply with 
reference to heterologous desensitisation of the chemokine receptor, as this 
typically results in the suppression rather than enhancement of chemokine 
responses. Investigation into the mechanism behind the effect ruled out S1P -
driven changes in levels of CXCR4, coupling to adenylate cyclase via the G"i G 
protein, or other pathways including the phosphorylation of ERK 1 / 2 as 
possible explanations. 
In Chapter 4, S1P was shown to potently suppress the migration of resting 
primary T cells towards CXCL12. This is opposite to the effect of S1P on the 
migration of Jurkat T cells towards the same chemokine, pointing to the 
unsuitability of this, and perhaps all cell lines, for studies of this kind. Although 
the mechanism for the effect on primary cells was not sought here, the 
phenomenon is analogous to that caused by other GPCR agonists and might be 
a result of heterologous desensitisation of CXCR4 (Hecht et al., 2003). 
Differences in the complement of proteins involved in chemokine receptor 
signalling, S1P receptor signalling, or both presumably account for the disparity 
in the effects seen in Jurkat versus primary T cells.  
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The inhibition of migration of resting primary T cells towards CXCL12 fits with 
the report of Pham et al. which stated that S1P signalling inhibited that of G"i- 
coupled chemokine receptors (Pham et al., 2008). Both CCR7, to which they 
refer, and CXCR4 (a receptor for CXCL12), are G"i coupled receptors that 
direct entry of T cells into lymph nodes (Bai et al., 2009). CXCL12 is produced 
constitutively at a significant level by endothelial cells and stromal cells in the 
parafollicular areas of lymph nodes, is presented on high endothelial venules 
(Karin, 2010), and probably functions alongside CCL19 and CCL21 as a 
retention signal in lymph nodes. 
S1P pre-treatment enhanced, rather than suppressed, T cell migration towards 
the inflammatory chemokine CXCL10. A subset of activated T cells begin 
expressing the receptor for this chemokine, CXCR3, after priming in lymph 
nodes (Groom and Luster, 2011). CXCL10 is important for the trafficking of 
effector T cells into many inflamed tissues including the CNS (Zhang et al., 
2008), allografts (Agostini et al., 2001) and inflamed liver (Zeremski et al., 
2007). The high level of S1P in blood may therefore act to ‘sensitise’ activated T 
cells that have recently left the lymph node to CXCL10. This would promote 
adaptive immunity by increasing the efficiency of migration of effector T cells to 
inflamed sites. Increased levels of sphingosine 1-phosphate in inflamed tissues, 
caused by vascular leakage (Dvorak, 2010) and increased export from cells 
(such as mast cells; Mitra et al., 2006), may conceivably also enhance cell 
migration along interstitial gradients of inflammatory chemokines. 
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6.3 Regulation of S1PR1 Signalling After T Cell Activation 
An adaptive immune response begins with the presentation of processed 
antigen by mature specialised antigen-presenting cells to lymphocytes. This 
occurs within the specialised microenvironment of lymphoid tissue. Activation of 
the innate immune system precedes the adaptive response, and prepares 
lymphoid tissue to increase the probability of a productive adaptive immune 
response. One way this is achieved is via simultaneously increasing recruitment 
of lymphocytes to inflamed lymph nodes and also blocking their egress, 
sequestering them there. This block in egress is known as lymph node 
shutdown. Early work implicated prostaglandin E2 and complement activation 
as important mediators of the effect (Hay and Hobbs, 1977; Hopkins et al., 
1981). However, without a complete model to describe lymphocyte, particularly 
T cell, recirculation under normal conditions their data could not be placed in 
adequate context. 
As has been previously detailed, a crucial role for S1PR1 signalling in control of 
egress of resting T cells from lymph nodes under normal conditions has been 
demonstrated (Matloubian et al., 2004). Subsequently, Pham et al. explained 
the role of S1PR1, showing that CCR7 and S1PR1 form an antagonistic axis, 
promoting entry and retention, and the exit of T cells respectively (Pham et al., 
2008). By inference, lymph node shutdown was presumably therefore 
dependent on a loss in the capacity for S1P to signal through S1PR1 
(expressed on T cells) and permit cell egress. A potential regulator of S1PR1 
was identified by Chu et al., who performed a genetic screen in Jurkat T cells 
and identified a negative regulatory interaction between CD69 and S1PR1 (Chu 
et al., 2003). It was then shown that interferon "/# signalling is crucial for the 
block in egress of T cells from lymph nodes, providing the link between the 
innate response and lymph node shutdown (Shiow et al., 2006). They 
demonstrated that the phenomenon was T cell intrinsic and was caused by IFN-
"/# dependent upregulation of CD69, resulting in downregulation and 
inactivation of surface S1PR1. CD69 was found to interact directly with S1PR1 
protein, perhaps altering the conformation of the receptor, and utilising existing 
regulatory pathways of S1PR1 expression to downregulate the protein 
(Bankovich et al., 2010). Experiments using in vivo imaging techniques showed 
that T cell entry into inflamed nodes was associated with very rapid upregulation 
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of CD69, to a level sufficient to block entry into lymphatic sinuses (Grigorova et 
al., 2010). 
In productive adaptive immune responses, a small number of sequestered T 
cells are primed through interaction with mature antigen-presenting cells 
bearing cognate antigen. These cells, and their daughters that result from cell 
division, are known to be temporarily retained in lymph nodes as they 
differentiate into effector and memory cells. Until now it has been unclear 
whether S1PR1 signalling in, and by extension egress capability of, antigen-
activated T cells is regulated differently to that of non-specific cells in inflamed 
lymph nodes. In Chapter 4, the regulation of S1PR1 signalling in activated T 
cells in vitro was investigated. T cells were stimulated with CD3 / CD28 beads 
to mimic activation by a mature professional antigen-presenting cell presenting 
peptide specific for the T cell receptor. The S1PR1-specific agonist SEW2871 
was then used to probe for the capacity of S1PR1 to signal in the cells at 
various time points after activation.  
Using SEW2871, resting T cells were shown to respond to stimulation of 
S1PR1. T cell activation through CD3 and CD28 resulted in a complete loss in 
the capacity of S1PR1 to signal 24 hours after activation. By day 3, receptor 
signalling was restored. These changes in the capacity of T cells to receive 
signals through S1PR1 mirror the in vivo migration of T cells before and after 
activation. Resting T cells can enter and exit lymph nodes quickly under 
homeostatic conditions. T cell activation results in complete arrest of T cells 
within lymph nodes, and it is not until approximately three days after the initial 
activation event that activated T cells begin leaving the node and enter the 
circulation (Matloubian et al., 2004).  
Graeler and Goetzl showed that activation of mouse splenic T cells was 
associated with a significant decrease in S1PR1 gene expression (Graeler and 
Goetzl, 2002). Similarly, here it is shown that stimulation through CD3 and 
CD28 resulted in a significant decrease in S1PR1 gene expression in human T 
cells, measured 24 hours later. This decrease was sustained for three days. 
Reasoning that this did not adequately explain the rapid and complete loss of 
S1PR1 signalling one day after activation, the dynamics of CD69 expression 
were also investigated. CD69 was upregulated to the cell surface very rapidly 
and to a high level after stimulation through CD3 and CD28. Levels were 
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highest approximately 24 hours after activation when ability of S1PR1 to signal 
was completely lost. Between one and six days after activation CD69 protein 
was progressively downregulated with cell division. These results showed a 
strong negative correlation between CD69 expression and S1PR1 signalling 
capacity in T cells. To confirm whether CD69 did indeed regulate S1PR1 
signalling in activated T cells, siRNA was used to attenuate the upregulation of 
CD69 following T cell activation. Preloading T cells with CD69-specific siRNA, 
but not non-specific siRNA, restored S1PR1 signalling in 24 hour-activated T 
cells. This confirmed CD69 as an important regulator of this receptor in the 
context of T cell activation. 
This work supports a model in which CD69 expression plays an important role 
in the regulation of S1PR1 signalling in antigen-activated T cells. It seems that 
the upregulation of CD69 is necessary for the rapid loss in S1PR1 signalling 
following activation, which cannot be achieved through the reduction in gene 
expression alone. The CFSE dilution experiment showed that in proliferating T 
cells, surface CD69 decreased by approximately one half with each cell 
division. This would be consistent with transient burst of neosynthesis of CD69 
protein following T cell activation, followed by splitting of existing protein 
between daughter cells as the cells divide. This means that, on average, cells 
that have divided more times express lower levels of CD69. In vivo, this 
probably translates into an increase in the probability of egress of a particular 
cell from a lymph node the more times that it has divided. 
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6.4 S1P Receptor-dependent Egress of Activated T Cells 
from Lymph Nodes 
In Chapter Four, it was shown that S1PR1 signalling is modulated after T cell 
activation. Changes in both the expression of the receptor and in surface 
expression of the known interaction partner CD69 were demonstrated to be 
important. As this work was performed entirely in vitro however, the 
physiological significance remained open to doubt. Specifically, an outstanding 
controversy in the literature is the extent to which, in vivo, the egress of 
activated T cells is dependent on S1PR1 signalling in T cells. T cell activation 
consists of a complex array of cellular events and produces daughter cells 
expressing a different complement of proteins including those involved in 
adhesion and migration. This raises the possibility that the egress of activated T 
cells is regulated differently to that of resting T cells.  
The work detailed in Chapter Five complements that in the previous chapter by 
showing that S1P receptor signalling is indeed necessary for the egress of 
activated T cells from lymph nodes. An alloimmune response was generated in 
the popliteal lymph node of a mouse by transfer of fully MHC-mismatched 
splenocytes into the footpad. Cultured ELISPOT was used to determine the 
frequency of alloactivated cells within the popliteal node six days after footpad 
injection. Treatment with the S1P receptor superagonist FTY720-P (which 
downregulates S1P receptors and abrogates receptor signalling) following 
footpad injection resulted in an increase in the frequency of alloactivated cells 
within the draining lymph node. The fraction of cells that were CXCR3+ 
(indicative of activated T cells) in the node at day six was also increased by 
FTY720-P treatment. Alloactivated cells were thus found to be sequestered in a 
lymph node by FTY720-P, suggesting that their egress was dependent on S1P 
receptor signalling. These data are consistent with those of another report 
showing that the release of antigen-activated CD4 T cells into the blood was 
S1P-dependent (Xie et al., 2003). In their study however, adoptively transferred 
antigen-specific cells were used and they counted activated T cells once they 
had exited into the peripheral blood. Here, natively produced alloactivated cells 
have been enumerated in the local lymph node.  
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6.5 Future Work 
There are a number of questions arising from this work that provide a sound 
basis for further investigation. 
A number of different approaches were used to try, unsuccessfully, to identify 
the mechanism by which S1P enhanced chemotaxis of Jurkat T cells towards 
CXCL12. Subsequently, experimentation with primary cells showed that S1P 
suppressed the migration of resting T cells towards the same chemokine. As 
has been already stated, heterologous desensitisation of CXCR4 resulting from 
prior S1PR1 signalling might account for this effect. The mechanism of 
desensitisation usually entails phosphorylation of the intracellular tail of the 
receptor, and internalisation of the protein from the plasma membrane. 
Immunofluorescence flow cytometry could be used to detect any change in the 
abundance of surface CXCR4 following S1P treatment. If a reduction in surface 
receptor is seen, this work could be followed up by examination of 
phosphorylation of the receptor tail by western blotting. Hecht et al. showed that 
CCL5 inhibited CXCR4 signalling independently of receptor levels, but that Ca2+ 
mobilisation, and ERK and Protein tyrosine kinase 2 phosphorylation triggered 
by receptor stimulation were suppressed (Hecht et al., 2003). These pathways 
could also be examined. Chemokines do not simply trigger chemotaxis, but also 
signal changes in the conformation of integrins (Laudanna et al., 2002) and 
affect cell adhesion to matrix or other cells. A flow cytometry-based adhesion 
assay could be used to determine the effect of S1P pre-treatment on the ability 
of CXCL12 to trigger changes in integrin conformation and capacity for high 
affinity binding to their ligand (for example VLA-4 on activated T cells and 
VCAM-1 (O’Boyle et al., 2009)). This could also be investigated using 
microfluidic apparatus that can be used to create a more accurate model of cell 
flow within capillaries. 
Cross-talk between S1P and chemokines in vivo could be better modelled using 
transendothelial migration assays. The bare transwell assays used here simply 
rely upon cell squeezing through pores in a plastic membrane. Transendothelial 
work allows one to assess the capacity of cells to respond to presented 
chemokine and form the required adhesive interactions for paracellular 
migration. These experiments could be done by coating the transwell 
membrane with suitable cells such as the human endothelial cell line EA.hy926 
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(Edgell et al., 1983). These can be cultured on the membrane till confluent, and 
then migration assays performed as before (Newton et al., 2009). By including 
S1P in the upper compartment and combining this with T cell pre-treatment, this 
would constitute a better representation of the in vivo situation of cellular 
migration from the vascular compartment across an endothelial barrier into 
tissue. 
The reasons behind the different effects of S1P on migration towards 
homeostatic and inflammatory chemokines (CXCL12 and CXCL10 respectively) 
were not addressed. Hints at a potential mechanism have emerged from studies 
examining the precise G"i subunit usage of these chemokine receptors. 
CXCR3-mediated signalling is G"i2-dependent and enhanced in the absence of 
G"i3, indicating a potential antagonistic role for the latter (Thompson et al., 
2007). Chemotaxis towards CXCL12 shows dependence on both G"i subunits. 
Interestingly, although the total magnitude of the response is reduced, in G"i3 
knockout cells the effect of S1P is to enhance rather than suppress chemotaxis 
towards CXCL12 (Jin et al., 2008). These data therefore indicate that 
differences in G"i subunit usage might underpin the different effects of S1P on 
responses to different chemokines. The work of Jin et al. (which used mouse T 
cells and a slightly different experimental protocol) could be followed up with 
primary human resting T cells using the protocol outlined in this thesis. siRNA 
could be used to downmodulate the G"i3 protein. The effect of S1P pre-
treatment (with 1 µM ligand for 1 hour) on migration of these cells towards 
CXCL12 could then be tested. 
While strong staining of HEK 293 S1PR1 transfectants (data not shown) could 
be achieved with mouse monoclonal 218713 (R&D Systems) against S1PR1, 
primary T cells stained very weakly with the same antibody. Another group has 
been able to achieve significant staining of S1PR1 using a self-produced 
affinity-purified anti-serum (Lo et al., 2005). With a highly specific antibody for 
the receptor, it would be possible to expand on the work in Chapter Four, and 
study the change in the abundance of surface S1PR1 after T cell activation. 
Shiow et al. showed that not only does CD69 inhibit S1PR1 signalling, but that it 
results in downregulation of the protein from the cell surface (Shiow et al., 
2006). The very high levels of CD69 induced by T cell activation may even drive 
significant degradation of S1PR1 (seen in CD69 S1PR1 double transfectants 
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(Bankovich et al., 2010)) and thus contribute to the significant reduction in total 
protein seen 24 hours after cell activation (Graeler and Goetzl, 2002). This 
could be tested by blocking the upregulation of CD69 on T cell activation with 
specific siRNA, using the method detailed in Chapter Four. 
There is scope to expand work with the in vivo model described in Chapter Five. 
The limitation of the work here is that the ELISPOT assay does not allow the 
phenotype of the alloactivated cells to be studied in any detail. This is a 
significant deficiency as adaptive immune responses typically result in the 
generation of a heterogeneous population of activated T cells. There are short-
lived effectors and longer-lived memory cells, and the latter can be further 
categorised as central memory or effector memory cells. An outstanding 
question in the literature concerns whether these different types of T cell have 
differential lymph node egress requirements. Like CD69, CCR7 expression is 
progressively downregulated with T cell division, and this is correlated with 
simultaneous upregulation of S1PR1 (Pham et al., 2008). Central memory cells, 
which have a shorter division history, express higher levels of CCR7 than 
effector T cells (Sallusto and Lanzavecchia, 2009). Because of this, central 
memory cells might be expected to exhibit relatively stronger dependence on 
S1P signalling for egress from lymph nodes – and might leave on average later 
in the response. This question could be addressed using an IFN-! cytokine 
secretion assay (Miltenyi Biotech) instead of ELISPOT to identify alloactivated 
cells inside lymph nodes. This would allow simultaneous phenotyping of the 
cytokine-secreting cells, such as distinguishing central memory (CCR7+ 
CD62L+ CD44+) from effector memory and short-lived effector cells (CCR7- 
CD62L- CD44+). The end-point of the experiment could also be varied from day 
three to day six, so that the dynamics of cell egress over that period could be 
studied. 
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